{"matching_results": 17250, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 878, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 696}, {"key": "negative", "matching_results": 178}, {"key": "neutral", "matching_results": 4}]}]}, {"key": "freelancer.com.co", "matching_results": 790, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 735}, {"key": "negative", "matching_results": 52}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "theolympiareport.com", "matching_results": 747, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 545}, {"key": "negative", "matching_results": 202}]}]}, {"key": "watchlistnews.com", "matching_results": 687, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 520}, {"key": "negative", "matching_results": 167}]}]}, {"key": "wkrb13.com", "matching_results": 676, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 542}, {"key": "negative", "matching_results": 134}]}]}, {"key": "tickerreport.com", "matching_results": 668, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 554}, {"key": "negative", "matching_results": 111}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "thelincolnianonline.com", "matching_results": 624, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 461}, {"key": "negative", "matching_results": 163}]}]}, {"key": "zolmax.com", "matching_results": 587, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 446}, {"key": "negative", "matching_results": 140}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "dailypolitical.com", "matching_results": 558, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 420}, {"key": "negative", "matching_results": 136}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "financialbuzz.com", "matching_results": 545, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 349}, {"key": "negative", "matching_results": 190}, {"key": "neutral", "matching_results": 5}]}]}]}], "results": [{"id": "KKPfLoVxddskjhoCc3ndulSyS8tj2C_A8GEw81HOuxiNd-p0L5FSASaH5N2VsBXf", "result_metadata": {"score": 36.227047}, "author": "BioCentury", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Adcetris", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "FDA", "relevance": 0.33, "type": "Organization"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Adcetris", "keywords": [{"text": "Adcetris"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "sentence": "Adcetris gets speedy label expansion under FDA real-time pilot", "object": {"text": "speedy label expansion", "keywords": [{"text": "speedy label"}, {"text": "expansion"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "gets", "normalized": "get"}}], "concepts": [], "categories": [{"score": 0.725085, "label": "/health and fitness/drugs"}, {"score": 0.690664, "label": "/food and drink"}, {"score": 0.617568, "label": "/health and fitness/weight loss"}], "relations": [], "keywords": [{"text": "speedy label expansion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.751055, "count": 1}, {"text": "Adcetris", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437158, "count": 1}, {"text": "FDA real-time pilot", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.299109, "count": 1}]}, "crawl_date": "2018-11-17T18:09:22Z", "url": "https://www.biocentury.com/bc-extra/company-news/2018-11-16/adcetris-gets-speedy-label-expansion-under-fda-real-time-pilot", "host": "biocentury.com", "text": "Seattle Genetics and partner Takeda Pharmaceutical Co.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-17T17:37:00Z", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": 0, "label": "neutral"}, "text": "FDA", "relevance": 0.893808, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 7, "sentiment": {"score": -0.582319, "label": "negative"}, "text": "Adcetris", "relevance": 0.58685, "type": "Person"}, {"count": 3, "sentiment": {"score": 0.516205, "label": "positive"}, "text": "RTOR", "relevance": 0.447422, "type": "Organization"}, {"count": 5, "sentiment": {"score": -0.587273, "label": "negative"}, "text": "Seattle", "relevance": 0.443875, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seattle Genetics Inc.", "relevance": 0.409686, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.582319, "label": "negative"}, "text": "peripheral T-cell lymphoma", "relevance": 0.403781, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Peripheral T-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Peripheral_T-cell_lymphoma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Adcetris brentuximab vedotin", "relevance": 0.315968, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "large cell lymphoma", "relevance": 0.303547, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}, {"count": 1, "sentiment": {"score": -0.250468, "label": "negative"}, "text": "classical Hodgkin lymphoma", "relevance": 0.29426, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "sBLA", "relevance": 0.274069, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PTCL", "relevance": 0.2581, "type": "Organization", "disambiguation": {"subtype": ["Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.227527, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PTCL", "relevance": 0.225287, "type": "Company", "disambiguation": {"subtype": [], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and CEO", "relevance": 0.215157, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "cancer", "relevance": 0.211219, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clay Siegall", "relevance": 0.210902, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Priority Review", "relevance": 0.210699, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "American Society of Hematology", "relevance": 0.209401, "type": "Organization", "disambiguation": {"subtype": [], "name": "American Society of Hematology", "dbpedia_resource": "http://dbpedia.org/resource/American_Society_of_Hematology"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.200022, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "San Diego", "relevance": 0.197563, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "San Diego", "dbpedia_resource": "http://dbpedia.org/resource/San_Diego"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Siegall", "relevance": 0.195665, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.19153, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "official", "relevance": 0.187757, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "partner", "relevance": 0.179084, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.383592, "label": "positive"}, "text": "Tokyo", "relevance": 0.167812, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.166809, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "three weeks", "relevance": 0.166809, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "two weeks", "relevance": 0.166809, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$125,000", "relevance": 0.166809, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$95,000", "relevance": 0.166809, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$57.43", "relevance": 0.166809, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.04", "relevance": 0.166809, "type": "Quantity"}], "sentiment": {"document": {"score": 0.271642, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Print PDF FDA", "keywords": [{"text": "Print PDF FDA"}], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": "Print PDF FDA approved a label expansion for Adcetris brentuximab vedotin less than two weeks after Seattle Genetics Inc. (NASDAQ:SGEN) submitted the sBLA.", "object": {"text": "a label expansion for Adcetris brentuximab vedotin less than two weeks after Seattle Genetics Inc. (NASDAQ:SGEN) submitted the sBLA", "keywords": [{"text": "Adcetris brentuximab vedotin"}, {"text": "Seattle Genetics Inc."}, {"text": "expansion"}, {"text": "label"}], "entities": [{"type": "Location", "text": "Adcetris brentuximab vedotin", "disambiguation": {"subtype": ["City"]}}, {"type": "Company", "text": "Seattle Genetics Inc."}, {"type": "Company", "text": "sBLA"}, {"type": "Quantity", "text": "two weeks"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "The agency", "keywords": [{"text": "agency"}]}, "sentence": " The agency said Adcetris is the first U.S.-approved treatment for newly diagnosed peripheral T-cell lymphoma (PTCL), and the second drug approved through FDA's Real-Time Oncology Review (RTOR) program.", "object": {"text": "Adcetris is the first U.S.-approved treatment for newly diagnosed peripheral T-cell lymphoma (PTCL), and the second drug approved through FDA's Real-Time Oncology Review (RTOR) program", "keywords": [{"text": "peripheral T-cell lymphoma"}, {"text": "Real-Time Oncology Review"}, {"text": "U.S.-approved treatment"}, {"text": "RTOR"}], "entities": [{"type": "Person", "text": "Adcetris"}, {"type": "Person", "text": "Adcetris"}, {"type": "HealthCondition", "text": "peripheral T-cell lymphoma", "disambiguation": {"subtype": [], "name": "Peripheral T-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Peripheral_T-cell_lymphoma"}}, {"type": "Organization", "text": "PTCL", "disambiguation": {"subtype": ["Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}, {"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"type": "Organization", "text": "RTOR"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "The RTOR pilot program", "keywords": [{"text": "pilot program"}], "entities": [{"type": "Organization", "text": "RTOR"}]}, "sentence": " The RTOR pilot program allows FDA to access key data and begin reviewing supplemental indications of approved cancer drugs before a sponsor's official submission.", "object": {"text": "FDA to access key data", "keywords": [{"text": "key data"}, {"text": "FDA"}], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allows", "normalized": "allow"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " The RTOR pilot program allows FDA to access key data and begin reviewing supplemental indications of approved cancer drugs before a sponsor's official submission.", "object": {"text": "reviewing supplemental indications of approved cancer drugs", "keywords": [{"text": "supplemental indications"}, {"text": "cancer drugs"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "begin", "tense": "present"}, "text": "begin", "normalized": "begin"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " The RTOR pilot program allows FDA to access key data and begin reviewing supplemental indications of approved cancer drugs before a sponsor's official submission.", "object": {"text": "supplemental indications of approved cancer drugs", "keywords": [{"text": "supplemental indications"}, {"text": "cancer drugs"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "review", "tense": "present"}, "text": "begin reviewing", "normalized": "begin review"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " In time, FDA intends to roll out the program to NDAs and BLAs (see \u201cGetting Flatter\u201d ).", "object": {"text": "to roll out the program to NDAs and BLAs", "keywords": [{"text": "NDAs"}, {"text": "BLAs"}, {"text": "program"}]}, "action": {"verb": {"text": "intend", "tense": "present"}, "text": "intends", "normalized": "intend"}}, {"subject": {"text": "President and CEO Clay Siegall", "keywords": [{"text": "CEO Clay Siegall"}, {"text": "President"}], "entities": [{"type": "JobTitle", "text": "President and CEO"}, {"type": "Person", "text": "Clay Siegall"}]}, "sentence": " President and CEO Clay Siegall told BioCentury Seattle Genetics didn't receive a PDUFA date for the sBLA, which FDA reviewed under Priority Review.", "object": {"text": "didn't receive a PDUFA date for the sBLA, which FDA reviewed under Priority Review", "keywords": [{"text": "Priority Review"}, {"text": "PDUFA date"}, {"text": "FDA"}, {"text": "sBLA"}], "entities": [{"type": "Company", "text": "sBLA"}, {"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"type": "PrintMedia", "text": "Priority Review"}]}, "action": {"verb": {"text": "tell", "tense": "past"}, "text": "told", "normalized": "tell"}}, {"subject": {"text": "BioCentury Seattle Genetics", "keywords": [{"text": "BioCentury Seattle"}, {"text": "Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " President and CEO Clay Siegall told BioCentury Seattle Genetics didn't receive a PDUFA date for the sBLA, which FDA reviewed under Priority Review.", "object": {"text": "n't receive a PDUFA date for the sBLA, which FDA reviewed under Priority Review", "keywords": [{"text": "Priority Review"}, {"text": "PDUFA date"}, {"text": "FDA"}, {"text": "sBLA"}], "entities": [{"type": "Company", "text": "sBLA"}, {"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"type": "PrintMedia", "text": "Priority Review"}]}, "action": {"verb": {"text": "do", "tense": "past"}, "text": "did", "normalized": "do"}}, {"subject": {"text": "BioCentury Seattle Genetics", "keywords": [{"text": "BioCentury Seattle"}, {"text": "Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " President and CEO Clay Siegall told BioCentury Seattle Genetics didn't receive a PDUFA date for the sBLA, which FDA reviewed under Priority Review.", "object": {"text": "a PDUFA date", "keywords": [{"text": "PDUFA date"}], "entities": []}, "action": {"verb": {"text": "receive", "tense": "past", "negated": true}, "text": "receive", "normalized": "receive"}}, {"subject": {"text": "Adcetris", "keywords": [{"text": "Adcetris"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "sentence": " Adcetris is now available for the indication, he said, with a net price for a full course of therapy ranging from $95,000 to $125,000, based on duration of treatment on the trial.", "object": {"text": "available for the indication", "keywords": [{"text": "indication"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Adcetris"}]}, "sentence": " Adcetris is now available for the indication, he said, with a net price for a full course of therapy ranging from $95,000 to $125,000, based on duration of treatment on the trial.", "object": {"text": "Adcetris is now available for the indication", "keywords": [{"text": "indication"}, {"text": "Adcetris"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "combinations with chemotherapy for previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma", "keywords": [{"text": "angioimmunoblastic T-cell lymphoma"}, {"text": "large cell lymphoma"}, {"text": "CD30-expressing PTCL"}], "entities": [{"type": "HealthCondition", "text": "large cell lymphoma", "disambiguation": {"subtype": [], "name": "Large-cell lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Large-cell_lymphoma"}}]}, "sentence": " Adcetris' updated label covers combinations with chemotherapy for previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma.", "object": {"text": "Adcetris' updated label", "keywords": [{"text": "Adcetris"}, {"text": "label"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " FDA approved the PTCL indication based on the Phase III ECHELON-2 trial, in which Adcetris plus chemotherapy improved progression-free survival (PFS) vs. chemotherapy alone.", "object": {"text": "the PTCL indication based on the Phase III ECHELON-2 trial, in which Adcetris plus chemotherapy improved progression-free survival (PFS) vs. chemotherapy alone", "keywords": [{"text": "PTCL indication"}, {"text": "Phase III ECHELON-2"}, {"text": "progression-free survival"}, {"text": "chemotherapy"}], "entities": [{"type": "Company", "text": "PTCL", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Pakistan Telecommunication Company Ltd", "dbpedia_resource": "http://dbpedia.org/resource/Pakistan_Telecommunication_Company_Ltd"}}, {"type": "Person", "text": "Adcetris"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)", "keywords": [{"text": "partner Takeda Pharmaceutical"}, {"text": "Seattle Genetics"}, {"text": "Co. Ltd."}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd."}, {"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3.", "object": {"text": "ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3", "keywords": [{"text": "Hematology meeting"}, {"text": "American Society"}, {"text": "San Diego"}, {"text": "data"}], "entities": [{"type": "Organization", "text": "American Society of Hematology", "disambiguation": {"subtype": ["Organization"], "name": "American Society of Hematology", "dbpedia_resource": "http://dbpedia.org/resource/American_Society_of_Hematology"}}, {"type": "Location", "text": "San Diego", "disambiguation": {"subtype": ["City"], "name": "San Diego", "dbpedia_resource": "http://dbpedia.org/resource/San_Diego"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "ECHELON-2 data", "keywords": [{"text": "ECHELON-2 data"}]}, "sentence": " Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3.", "object": {"text": "presented at the American Society of Hematology meeting in San Diego", "keywords": [{"text": "Hematology meeting"}, {"text": "American Society"}, {"text": "San Diego"}], "entities": [{"type": "Organization", "text": "American Society of Hematology", "disambiguation": {"subtype": ["Organization"], "name": "American Society of Hematology", "dbpedia_resource": "http://dbpedia.org/resource/American_Society_of_Hematology"}}, {"type": "Location", "text": "San Diego", "disambiguation": {"subtype": ["City"], "name": "San Diego", "dbpedia_resource": "http://dbpedia.org/resource/San_Diego"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "ECHELON-2 data", "keywords": [{"text": "ECHELON-2 data"}]}, "sentence": " Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3.", "action": {"verb": {"text": "present", "tense": "future"}, "text": "will be presented", "normalized": "will be present"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " In October, Seattle Genetics guided to relatively flat 4Q18 Adcetris sales; Siegall declined to disclose whether the rapid approval changes that prediction.", "object": {"text": "to relatively flat 4Q18 Adcetris sales", "keywords": [{"text": "Adcetris sales"}]}, "action": {"verb": {"text": "guide", "tense": "past"}, "text": "guided", "normalized": "guide"}}, {"subject": {"text": "Siegall", "keywords": [{"text": "Siegall"}], "entities": [{"type": "Company", "text": "Siegall"}]}, "sentence": " In October, Seattle Genetics guided to relatively flat 4Q18 Adcetris sales; Siegall declined to disclose whether the rapid approval changes that prediction.", "object": {"text": "whether the rapid approval changes that prediction", "keywords": [{"text": "rapid approval changes"}, {"text": "prediction"}]}, "action": {"verb": {"text": "decline", "tense": "past"}, "text": "declined", "normalized": "decline"}}, {"subject": {"text": "Siegall", "keywords": [{"text": "Siegall"}], "entities": [{"type": "Company", "text": "Siegall"}]}, "sentence": " In October, Seattle Genetics guided to relatively flat 4Q18 Adcetris sales; Siegall declined to disclose whether the rapid approval changes that prediction.", "object": {"text": "whether the rapid approval changes that prediction", "keywords": [{"text": "rapid approval changes"}, {"text": "prediction"}]}, "action": {"verb": {"text": "disclose", "tense": "future"}, "text": "declined to disclose", "normalized": "decline to disclose"}}, {"subject": {"text": "3Q18 Adcetris sales", "keywords": [{"text": "Adcetris sales"}]}, "sentence": " 3Q18 Adcetris sales fell short of expectations (see \"Seattle Genetics Sags as Adcetris Sales Miss Target\" ).", "object": {"text": "Seattle Genetics Sags as Adcetris Sales Miss Target\" )", "keywords": [{"text": "Seattle Genetics Sags"}, {"text": "Sales Miss Target"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "action": {"verb": {"text": "see", "tense": "present"}, "text": "see", "normalized": "see"}}, {"subject": {"text": "Adcetris", "keywords": [{"text": "Adcetris"}], "entities": [{"type": "Person", "text": "Adcetris"}]}, "sentence": " Adcetris has U.S. approval for five other indications, including previously untreated stage III or IV classical Hodgkin lymphoma.", "object": {"text": "U.S. approval for five other indications, including previously untreated stage III or IV classical Hodgkin lymphoma", "keywords": [{"text": "classical Hodgkin lymphoma"}, {"text": "untreated stage"}, {"text": "U.S. approval"}, {"text": "indications"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "previously untreated stage III or IV classical Hodgkin lymphoma", "keywords": [{"text": "classical Hodgkin lymphoma"}, {"text": "untreated stage"}], "entities": [{"type": "HealthCondition", "text": "classical Hodgkin lymphoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Hodgkin's lymphoma", "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}}]}, "sentence": " Adcetris has U.S. approval for five other indications, including previously untreated stage III or IV classical Hodgkin lymphoma.", "object": {"text": "five other indications", "keywords": [{"text": "indications"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "The antibody-drug conjugate (ADC)", "keywords": [{"text": "antibody-drug conjugate"}, {"text": "ADC"}]}, "sentence": " The antibody-drug conjugate (ADC) comprises an anti-CD30 mAb and monomethyl auristatin E (MMAE).", "object": {"text": "an anti-CD30 mAb and monomethyl auristatin E (MMAE)", "keywords": [{"text": "anti-CD30 mAb"}, {"text": "monomethyl auristatin"}, {"text": "MMAE"}]}, "action": {"verb": {"text": "comprise", "tense": "present"}, "text": "comprises", "normalized": "comprise"}}, {"subject": {"text": "Seattle Genetics", "keywords": [{"text": "Seattle Genetics"}], "entities": [{"type": "Location", "text": "Seattle", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}]}, "sentence": " Seattle Genetics gained $3.04 to $57.43 Friday.", "object": {"text": "$3.04", "entities": [{"type": "Quantity", "text": "$3.04"}]}, "action": {"verb": {"text": "gain", "tense": "past"}, "text": "gained", "normalized": "gain"}}], "concepts": [{"text": "Lymphoma", "relevance": 0.948559, "dbpedia_resource": "http://dbpedia.org/resource/Lymphoma"}, {"text": "Anaplastic large cell lymphoma", "relevance": 0.693088, "dbpedia_resource": "http://dbpedia.org/resource/Anaplastic_large_cell_lymphoma"}, {"text": "Hodgkin's lymphoma", "relevance": 0.595404, "dbpedia_resource": "http://dbpedia.org/resource/Hodgkin's_lymphoma"}, {"text": "Non-Hodgkin lymphoma", "relevance": 0.586845, "dbpedia_resource": "http://dbpedia.org/resource/Non-Hodgkin_lymphoma"}, {"text": "Chemotherapy", "relevance": 0.554858, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Cancer", "relevance": 0.457962, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Doxorubicin", "relevance": 0.453998, "dbpedia_resource": "http://dbpedia.org/resource/Doxorubicin"}, {"text": "Blood disorders", "relevance": 0.445941, "dbpedia_resource": "http://dbpedia.org/resource/Blood_disorders"}, {"text": "Oncology", "relevance": 0.414798, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Hematology", "relevance": 0.413795, "dbpedia_resource": "http://dbpedia.org/resource/Hematology"}, {"text": "Vincristine", "relevance": 0.392023, "dbpedia_resource": "http://dbpedia.org/resource/Vincristine"}, {"text": "Sign", "relevance": 0.36469, "dbpedia_resource": "http://dbpedia.org/resource/Sign"}, {"text": "Thomas Hodgkin", "relevance": 0.359997, "dbpedia_resource": "http://dbpedia.org/resource/Thomas_Hodgkin"}, {"text": "Food and Drug Administration", "relevance": 0.354708, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Ann Arbor staging", "relevance": 0.323772, "dbpedia_resource": "http://dbpedia.org/resource/Ann_Arbor_staging"}, {"text": "Indication", "relevance": 0.321086, "dbpedia_resource": "http://dbpedia.org/resource/Indication"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.320568, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Novartis", "relevance": 0.320466, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Types of cancer", "relevance": 0.319168, "dbpedia_resource": "http://dbpedia.org/resource/Types_of_cancer"}, {"text": "DNA", "relevance": 0.310667, "dbpedia_resource": "http://dbpedia.org/resource/DNA"}, {"text": "Large cell lymphoma", "relevance": 0.307453, "dbpedia_resource": "http://dbpedia.org/resource/Large_cell_lymphoma"}], "categories": [{"score": 0.955879, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.885243, "label": "/health and fitness/therapy"}, {"score": 0.549415, "label": "/health and fitness/weight loss"}], "relations": [{"type": "hasAttribute", "sentence": "Print PDF FDA approved a label expansion for Adcetris brentuximab vedotin less than two weeks after Seattle Genetics Inc. (NASDAQ:SGEN) submitted the sBLA.", "score": 0.93216, "arguments": [{"text": "Seattle Genetics Inc.", "location": [100, 121], "entities": [{"type": "Organization", "text": "Seattle Genetics Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "SGEN", "location": [130, 134], "entities": [{"type": "Ticker", "text": "SGEN"}]}]}, {"type": "affectedBy", "sentence": "Adcetris' updated label covers combinations with chemotherapy for previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma.", "score": 0.485425, "arguments": [{"text": "PTCL", "location": [1303, 1307], "entities": [{"type": "Organization", "text": "PTCL"}]}, {"text": "expressing", "location": [1292, 1302], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}, {"type": "agentOf", "sentence": "FDA approved the PTCL indication based on the Phase III ECHELON-2 trial, in which Adcetris plus chemotherapy improved progression-free survival (PFS) vs. chemotherapy alone.", "score": 0.953914, "arguments": [{"text": "FDA", "location": [1355, 1358], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "approved", "location": [1359, 1367], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "timeOf", "sentence": "FDA approved the PTCL indication based on the Phase III ECHELON-2 trial, in which Adcetris plus chemotherapy improved progression-free survival (PFS) vs. chemotherapy alone.", "score": 0.917463, "arguments": [{"text": "ECHELON-2", "location": [1411, 1420], "entities": [{"type": "Date", "text": "ECHELON-2"}]}, {"text": "trial", "location": [1421, 1426], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "managerOf", "sentence": "Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3.", "score": 0.618837, "arguments": [{"text": "partner", "location": [1550, 1557], "entities": [{"type": "Person", "text": "partner"}]}, {"text": "Takeda Pharmaceutical Co. Ltd.", "location": [1558, 1588], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3.", "score": 0.61297, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [1558, 1588], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Tokyo", "location": [1590, 1595], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}]}, {"type": "timeOf", "sentence": "Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3.", "score": 0.813725, "arguments": [{"text": "ECHELON-2", "location": [1607, 1616], "entities": [{"type": "Date", "text": "ECHELON-2"}]}, {"text": "said", "location": [1602, 1606], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "partOf", "sentence": "Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3.", "score": 0.497227, "arguments": [{"text": "said", "location": [1602, 1606], "entities": [{"type": "EventCommunication", "text": "said"}]}, {"text": "meeting", "location": [1678, 1685], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3.", "score": 0.615716, "arguments": [{"text": "American Society of Hematology", "location": [1647, 1677], "entities": [{"type": "Organization", "text": "American Society of Hematology"}]}, {"text": "meeting", "location": [1678, 1685], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "locatedAt", "sentence": "Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3.", "score": 0.978365, "arguments": [{"text": "meeting", "location": [1678, 1685], "entities": [{"type": "EventMeeting", "text": "meeting"}]}, {"text": "San Diego", "location": [1689, 1698], "entities": [{"type": "GeopoliticalEntity", "text": "San Diego"}]}]}, {"type": "timeOf", "sentence": "Seattle Genetics and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said ECHELON-2 data will be presented at the American Society of Hematology meeting in San Diego on Dec. 3.", "score": 0.951045, "arguments": [{"text": "Dec. 3", "location": [1702, 1708], "entities": [{"type": "Date", "text": "Dec. 3"}]}, {"text": "meeting", "location": [1678, 1685], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "The agency said Adcetris is the first U.S.-approved treatment for newly diagnosed peripheral T-cell lymphoma (PTCL), and the second drug approved through FDA's Real-Time Oncology Review (RTOR) program.", "score": 0.798237, "arguments": [{"text": "agency", "location": [160, 166], "entities": [{"type": "Organization", "text": "Real-Time Oncology Review"}]}, {"text": "said", "location": [167, 171], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "locatedAt", "sentence": "Adcetris has U.S. approval for five other indications, including previously untreated stage III or IV classical Hodgkin lymphoma.", "score": 0.618545, "arguments": [{"text": "Adcetris", "location": [1976, 1984], "entities": [{"type": "Person", "text": "Adcetris"}]}, {"text": "U.S.", "location": [1989, 1993], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Seattle Genetics gained $3.04 to $57.43 Friday.", "score": 0.525234, "arguments": [{"text": "Seattle Genetics", "location": [2203, 2219], "entities": [{"type": "Organization", "text": "Seattle Genetics Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$3.04", "location": [2227, 2232], "entities": [{"type": "Money", "text": "$3.04"}]}]}, {"type": "hasAttribute", "sentence": "Seattle Genetics gained $3.04 to $57.43 Friday.", "score": 0.63734, "arguments": [{"text": "Seattle Genetics", "location": [2203, 2219], "entities": [{"type": "Organization", "text": "Seattle Genetics Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$57.43", "location": [2236, 2242], "entities": [{"type": "Money", "text": "$57.43"}]}]}, {"type": "partOf", "sentence": "The agency said Adcetris is the first U.S.-approved treatment for newly diagnosed peripheral T-cell lymphoma (PTCL), and the second drug approved through FDA's Real-Time Oncology Review (RTOR) program.", "score": 0.609663, "arguments": [{"text": "Real-Time Oncology Review", "location": [316, 341], "entities": [{"type": "Organization", "text": "Real-Time Oncology Review"}]}, {"text": "FDA", "location": [310, 313], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "employedBy", "sentence": "The RTOR pilot program allows FDA to access key data and begin reviewing supplemental indications of approved cancer drugs before a sponsor's official submission.", "score": 0.712024, "arguments": [{"text": "pilot", "location": [367, 372], "entities": [{"type": "Person", "text": "Clay Siegall"}]}, {"text": "RTOR", "location": [362, 366], "entities": [{"type": "Organization", "text": "Real-Time Oncology Review"}]}]}, {"type": "hasAttribute", "sentence": "The RTOR pilot program allows FDA to access key data and begin reviewing supplemental indications of approved cancer drugs before a sponsor's official submission.", "score": 0.922382, "arguments": [{"text": "sponsor", "location": [490, 497], "entities": [{"type": "Person", "text": "sponsor"}]}, {"text": "cancer", "location": [468, 474], "entities": [{"type": "HealthCondition", "text": "cancer"}]}]}, {"type": "partOf", "sentence": "The agency's first approval via RTOR, a label expansion for Kisqali ribociclib from Novartis AG (NYSE:NVS; SIX:NOVN), took less than three weeks (see \"FDA Real-Time Pilot Speeds Kisqali Label Expansion\" ).", "score": 0.836876, "arguments": [{"text": "Real-Time Pilot Speeds Kisqali Label Expansion", "location": [676, 722], "entities": [{"type": "Organization", "text": "Real-Time Pilot Speeds Kisqali Label Expansion"}]}, {"text": "FDA", "location": [672, 675], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "agentOf", "sentence": "President and CEO Clay Siegall told BioCentury Seattle Genetics didn't receive a PDUFA date for the sBLA, which FDA reviewed under Priority Review.", "score": 0.994217, "arguments": [{"text": "Clay Siegall", "location": [833, 845], "entities": [{"type": "Person", "text": "Clay Siegall"}]}, {"text": "told", "location": [846, 850], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Adcetris is now available for the indication, he said, with a net price for a full course of therapy ranging from $95,000 to $125,000, based on duration of treatment on the trial.", "score": 0.989493, "arguments": [{"text": "he", "location": [1009, 1011], "entities": [{"type": "Person", "text": "Clay Siegall"}]}, {"text": "said", "location": [1012, 1016], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "affectedBy", "sentence": "President and CEO Clay Siegall told BioCentury Seattle Genetics didn't receive a PDUFA date for the sBLA, which FDA reviewed under Priority Review.", "score": 0.840504, "arguments": [{"text": "BioCentury Seattle Genetics", "location": [851, 878], "entities": [{"type": "Organization", "text": "BioCentury Seattle Genetics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "told", "location": [846, 850], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Adcetris' updated label covers combinations with chemotherapy for previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma.", "score": 0.947449, "arguments": [{"text": "CD30", "location": [1287, 1291], "entities": [{"type": "Person", "text": "CD30 mAb"}]}, {"text": "expressing", "location": [1292, 1302], "entities": [{"type": "EventCommunication", "text": "expressing"}]}]}], "keywords": [{"text": "Adcetris brentuximab vedotin", "sentiment": {"score": 0.867303, "label": "positive"}, "relevance": 0.786458, "count": 1}, {"text": "Seattle Genetics Inc.", "sentiment": {"score": 0.867303, "label": "positive"}, "relevance": 0.710815, "count": 1}, {"text": "PDF FDA", "sentiment": {"score": 0.867303, "label": "positive"}, "relevance": 0.661253, "count": 1}, {"text": "Adcetris", "sentiment": {"score": 0.448216, "label": "positive"}, "relevance": 0.626681, "count": 5}, {"text": "FDA's Real-Time Oncology Review", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624622, "count": 1}, {"text": "flat 4Q18 Adcetris sales", "sentiment": {"score": -0.913628, "label": "negative"}, "relevance": 0.596008, "count": 1}, {"text": "label expansion", "sentiment": {"score": 0.867303, "label": "positive"}, "relevance": 0.593236, "count": 2}, {"text": "BioCentury Seattle Genetics", "sentiment": {"score": -0.642186, "label": "negative"}, "relevance": 0.588818, "count": 1}, {"text": "supplemental indications", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575717, "count": 1}, {"text": "FDA", "sentiment": {"score": 0, "mixed": "1", "label": "neutral"}, "relevance": 0.573918, "count": 4}, {"text": "antibody-drug conjugate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565805, "count": 1}, {"text": "indication", "sentiment": {"score": 0.294741, "label": "positive"}, "relevance": 0.564757, "count": 1}, {"text": "agency", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554032, "count": 1}, {"text": "CEO Clay Siegall", "sentiment": {"score": -0.642186, "label": "negative"}, "relevance": 0.553103, "count": 1}, {"text": "President", "sentiment": {"score": -0.642186, "label": "negative"}, "relevance": 0.55301, "count": 1}, {"text": "peripheral T-cell lymphoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550282, "count": 1}, {"text": "second drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540666, "count": 1}, {"text": "Phase III ECHELON-2 trial", "sentiment": {"score": 0.575298, "label": "positive"}, "relevance": 0.540398, "count": 1}, {"text": "progression-free survival", "sentiment": {"score": 0.575298, "label": "positive"}, "relevance": 0.540278, "count": 1}, {"text": "weeks", "sentiment": {"score": 0.867303, "label": "positive"}, "relevance": 0.539674, "count": 2}, {"text": "time", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535998, "count": 1}, {"text": "agency's first approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535799, "count": 1}, {"text": "Seattle Genetics", "sentiment": {"score": -0.913628, "label": "negative"}, "relevance": 0.534512, "count": 3}, {"text": "program", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533512, "count": 2}, {"text": "October", "sentiment": {"score": -0.913628, "label": "negative"}, "relevance": 0.533169, "count": 1}, {"text": "indications", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532516, "count": 1}, {"text": "first U.S.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531776, "count": 1}, {"text": "RTOR pilot program", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530646, "count": 1}, {"text": "chemotherapy", "sentiment": {"score": 0.575298, "label": "positive"}, "relevance": 0.528223, "count": 2}, {"text": "Tokyo", "sentiment": {"score": 0.571879, "label": "positive"}, "relevance": 0.525632, "count": 1}, {"text": "expectations", "sentiment": {"score": -0.913628, "label": "negative"}, "relevance": 0.52451, "count": 1}, {"text": "3Q18 Adcetris sales", "sentiment": {"score": -0.913628, "label": "negative"}, "relevance": 0.524131, "count": 1}, {"text": "NYSE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52318, "count": 1}, {"text": "Kisqali ribociclib", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521113, "count": 1}, {"text": "trial", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520923, "count": 1}, {"text": "San Diego", "sentiment": {"score": -0.524018, "mixed": "1", "label": "negative"}, "relevance": 0.518256, "count": 1}, {"text": "treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51808, "count": 1}, {"text": "ADC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515277, "count": 1}, {"text": "systemic anaplastic large cell lymphoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51352, "count": 1}, {"text": "BLAs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510769, "count": 1}, {"text": "key data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50943, "count": 1}, {"text": "NASDAQ", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509311, "count": 1}, {"text": "User", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508865, "count": 1}, {"text": "Seattle Genetics Sags", "sentiment": {"score": -0.913628, "label": "negative"}, "relevance": 0.508291, "count": 1}, {"text": "PFS", "sentiment": {"score": 0.575298, "label": "positive"}, "relevance": 0.508237, "count": 1}, {"text": "Novartis AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507799, "count": 1}, {"text": "untreated stage III", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506681, "count": 1}, {"text": "prediction", "sentiment": {"score": -0.913628, "label": "negative"}, "relevance": 0.504792, "count": 1}, {"text": "Adcetris Sales Miss Target", "sentiment": {"score": -0.913628, "label": "negative"}, "relevance": 0.496798, "count": 1}, {"text": "label covers combinations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.495694, "count": 1}]}, "extracted_metadata": {"sha1": "e1b8eff84a5eb59cb917d85cb9c2351cf807d108", "filename": "1542478162294.zip-e54f7293f2ccfd01463ecb7e5b81f561.xml", "file_type": "json"}, "external_links": ["http://xmlns.com/foaf/0.1/", "http://purl.org/rss/1.0/modules/content/", "http://purl.org/dc/terms/", "http://rdfs.org/sioc/types#", "http://rdfs.org/sioc/ns#"], "title": "Adcetris gets speedy label expansion under FDA real-time pilot", "forum_title": "Latest Headlines from Cafepharma"}, {"id": "tWcQnWB1I5GhjjlpTPB4Kr8hll8NmhitGV6qdiq9mX-KVV8Fa1jatW1yu0f5Zb6F", "result_metadata": {"score": 36.113686}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Cardiovascular Drugs Market Augmented Expansion", "keywords": [{"text": "Cardiovascular Drugs"}, {"text": "Expansion"}, {"text": "Market"}]}, "sentence": "Cardiovascular Drugs Market Augmented Expansion to be Registered by 2024", "object": {"text": "Registered by 2024"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}], "concepts": [{"text": "Trademark", "relevance": 0.86306, "dbpedia_resource": "http://dbpedia.org/resource/Trademark"}, {"text": "Economics", "relevance": 0.854444, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}], "categories": [{"score": 0.967704, "label": "/health and fitness"}, {"score": 0.799545, "label": "/health and fitness/disease/heart disease"}, {"score": 0.743599, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Cardiovascular Drugs Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997442, "count": 1}, {"text": "Expansion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.801703, "count": 1}]}, "crawl_date": "2018-11-18T10:11:30Z", "url": "http://www.webnewswire.com/2018/11/18/cardiovascular-drugs-market-augmented-expansion-to-be-registered-by-2024/", "host": "webnewswire.com", "text": "., Johnson & Johnson, United Therapeutics Corporation, Actelion Pharmaceuticals Ltd //www.researchreportinsights.com/report/upcomming/120124597/Cardiovascular-Drugs-Market About Us trends Contact Us:", "main_image_url": "https://s0.wp.com/i/blank.jpg", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-18T10:10:00Z", "enriched_text": {"entities": [{"count": 8, "sentiment": {"score": -0.821483, "label": "negative"}, "text": "Inflammatory heart disease", "relevance": 0.864111, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}, {"count": 1, "sentiment": {"score": -0.884723, "label": "negative"}, "text": "hypertensive heart disease", "relevance": 0.475902, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}, {"count": 3, "sentiment": {"score": -0.689291, "label": "negative"}, "text": "rheumatic fever", "relevance": 0.422832, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"count": 1, "sentiment": {"score": -0.832524, "label": "negative"}, "text": "Kawasaki disease", "relevance": 0.228441, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}, {"count": 1, "sentiment": {"score": -0.579322, "label": "negative"}, "text": "subarachnoid hemorrhage", "relevance": 0.220934, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Subarachnoid hemorrhage", "dbpedia_resource": "http://dbpedia.org/resource/Subarachnoid_hemorrhage"}}, {"count": 1, "sentiment": {"score": -0.497833, "label": "negative"}, "text": "Group A streptococcal infection", "relevance": 0.209334, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.179335, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.176992, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": -0.745426, "label": "negative"}, "text": "obesity", "relevance": 0.176761, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.169145, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lovenox", "relevance": 0.167662, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.167557, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.166705, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": -0.227112, "label": "negative"}, "text": "Bayer AG", "relevance": 0.166479, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Company Limited", "relevance": 0.166456, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.243362, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.166436, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Xarelto", "relevance": 0.159988, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma Inc.", "relevance": 0.159732, "type": "Company", "disambiguation": {"subtype": [], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"count": 1, "sentiment": {"score": -0.745426, "label": "negative"}, "text": "diabetes", "relevance": 0.159617, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 1, "sentiment": {"score": -0.52748, "label": "negative"}, "text": "Actelion Pharmaceuticals Ltd", "relevance": 0.157943, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United Therapeutics Corporation", "relevance": 0.138793, "type": "Company"}], "sentiment": {"document": {"score": -0.733057, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Cardiovascular disorders or heart disorders", "keywords": [{"text": "Cardiovascular disorders"}, {"text": "heart disorders"}], "entities": [{"type": "HealthCondition", "text": "cardiovascular disorders", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "sentence": " Cardiovascular disorders or heart disorders are disorders of circulatory systems and heart.", "object": {"text": "disorders of circulatory systems and heart", "keywords": [{"text": "circulatory systems"}, {"text": "disorders"}, {"text": "heart"}], "entities": [{"type": "HealthCondition", "text": "cardiovascular disorders", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the occurrence of high blood pressure", "keywords": [{"text": "high blood pressure"}, {"text": "occurrence"}], "entities": []}, "sentence": " In most cases, the occurrence of high blood pressure leads to hypertensive heart ailments.", "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leads", "normalized": "lead"}}, {"subject": {"text": "hypertrophy, angina, coronary heart disease and heart failure", "keywords": [{"text": "coronary heart disease"}, {"text": "heart failure"}, {"text": "hypertrophy"}, {"text": "angina"}]}, "sentence": " Major effects of hypertensive heart ailments include hypertrophy, angina, coronary heart disease and heart failure.", "object": {"text": "Major effects of hypertensive heart ailments", "keywords": [{"text": "hypertensive heart ailments"}, {"text": "Major effects"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Rheumatic heart disorders", "keywords": [{"text": "Rheumatic heart disorders"}]}, "sentence": " Similarly, Rheumatic heart disorders are caused by frequent rheumatic fever.", "object": {"text": "by frequent rheumatic fever", "keywords": [{"text": "frequent rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are caused", "normalized": "be cause"}}, {"subject": {"text": "by frequent rheumatic fever", "keywords": [{"text": "frequent rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "sentence": " Similarly, Rheumatic heart disorders are caused by frequent rheumatic fever.", "object": {"text": "Rheumatic heart disorders", "keywords": [{"text": "Rheumatic heart disorders"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "are caused", "normalized": "be cause"}}, {"subject": {"text": "The disorder", "keywords": [{"text": "disorder"}], "entities": [{"type": "HealthCondition", "text": "cardiovascular disorders", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "sentence": " The disorder is mostly identified in children across the globe, especially in developing economies.", "object": {"text": "mostly identified in children across the globe", "keywords": [{"text": "globe"}, {"text": "children"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The disorder", "keywords": [{"text": "disorder"}], "entities": [{"type": "HealthCondition", "text": "cardiovascular disorders", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "sentence": " The disorder is mostly identified in children across the globe, especially in developing economies.", "object": {"text": "in children across the globe, especially in developing economies", "keywords": [{"text": "economies"}, {"text": "globe"}, {"text": "children"}]}, "action": {"verb": {"text": "identify", "tense": "past"}, "text": "is mostly identified", "normalized": "be mostly identify"}}, {"subject": {"text": "Cerebrovascular ailment", "keywords": [{"text": "Cerebrovascular ailment"}]}, "sentence": " Cerebrovascular ailment affects neurones and blood vessels of the brain.", "object": {"text": "neurones and blood vessels of the brain", "keywords": [{"text": "blood vessels"}, {"text": "neurones"}, {"text": "brain"}], "entities": []}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "stroke, transient ischemic attack (TIA), vascular dementia, and subarachnoid hemorrhage", "keywords": [{"text": "transient ischemic attack"}, {"text": "subarachnoid hemorrhage"}, {"text": "vascular dementia"}, {"text": "stroke"}], "entities": [{"type": "HealthCondition", "text": "subarachnoid hemorrhage", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Subarachnoid hemorrhage", "dbpedia_resource": "http://dbpedia.org/resource/Subarachnoid_hemorrhage"}}]}, "sentence": " Most commonly occurring cerebrovascular disorders include stroke, transient ischemic attack (TIA), vascular dementia, and subarachnoid hemorrhage.", "object": {"text": "Most commonly occurring cerebrovascular disorders", "keywords": [{"text": "cerebrovascular disorders"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Reduced supply of blood to the heart", "keywords": [{"text": "supply"}, {"text": "blood"}, {"text": "heart"}]}, "sentence": " Reduced supply of blood to the heart is a major characteristic of Ischemic heart disorders.", "object": {"text": "a major characteristic of Ischemic heart disorders", "keywords": [{"text": "Ischemic heart disorders"}, {"text": "major characteristic"}], "entities": [{"type": "HealthCondition", "text": "cardiovascular disorders"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "High death rates", "keywords": [{"text": "High death rates"}]}, "sentence": " High death rates have been registered due to ischemic heart disorders, especially in western parts of the globe.", "object": {"text": "registered due to ischemic heart disorders", "keywords": [{"text": "ischemic heart disorders"}], "entities": [{"type": "HealthCondition", "text": "cardiovascular disorders", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Such type of disorders", "keywords": [{"text": "type"}, {"text": "disorders"}], "entities": [{"type": "HealthCondition", "text": "cardiovascular disorders", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "sentence": " Such type of disorders is linked with a history of Kawasaki disease or rheumatic fever.", "object": {"text": "with a history of Kawasaki disease or rheumatic fever", "keywords": [{"text": "rheumatic fever"}, {"text": "Kawasaki disease"}, {"text": "history"}], "entities": [{"type": "HealthCondition", "text": "Kawasaki disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}, {"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is linked", "normalized": "be link"}}, {"subject": {"text": "Factors such as the arrival of newer and advanced drugs and growing prevalence of heart diseases", "keywords": [{"text": "heart diseases"}, {"text": "prevalence"}, {"text": "arrival"}, {"text": "Factors"}]}, "sentence": " Factors such as the arrival of newer and advanced drugs and growing prevalence of heart diseases are expected to drive the global cardiovascular drugs market in near future.", "object": {"text": "the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "are expected to drive", "normalized": "be expect to drive"}}, {"subject": {"text": "higher occurrence of life-style diseases and rise in the global geriatric population", "keywords": [{"text": "global geriatric population"}, {"text": "higher occurrence"}, {"text": "life-style diseases"}]}, "sentence": " In addition, higher occurrence of life-style diseases and rise in the global geriatric population is further contributing to the market growth.", "object": {"text": "further contributing to the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "increasing prevalence of chronic diseases such as obesity and diabetes", "keywords": [{"text": "chronic diseases"}, {"text": "prevalence"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "sentence": " Moreover, increasing prevalence of chronic diseases such as obesity and diabetes are fueling the demand for cardiovascular drugs.", "object": {"text": "fueling the demand for cardiovascular drugs", "keywords": [{"text": "cardiovascular drugs"}, {"text": "demand"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "side-effects from cardiovascular drugs and stern regulatory norms", "keywords": [{"text": "stern regulatory norms"}, {"text": "cardiovascular drugs"}, {"text": "side-effects"}]}, "sentence": " In contrast, risk of side-effects from cardiovascular drugs and stern regulatory norms are expected to pose challenges for the market growth.", "object": {"text": "challenges", "keywords": [{"text": "challenges"}]}, "action": {"verb": {"text": "pose", "tense": "future"}, "text": "are expected to pose", "normalized": "be expect to pose"}}, {"subject": {"text": "the expiration of the patent for several blockbuster drugs", "keywords": [{"text": "blockbuster drugs"}, {"text": "expiration"}, {"text": "patent"}]}, "sentence": " Likewise, the expiration of the patent for several blockbuster drugs is an additional factor anticipated to inhibit the growth of global cardiovascular market.", "object": {"text": "an additional factor anticipated to inhibit the growth of global cardiovascular market", "keywords": [{"text": "global cardiovascular market"}, {"text": "additional factor"}, {"text": "growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "key trends governing the global cardiovascular drug market", "keywords": [{"text": "global cardiovascular drug"}, {"text": "key trends"}, {"text": "market"}]}, "sentence": " Introduction of improved drug combinations and increasing in acquisition and mergers between pharmaceutical companies are key trends governing the global cardiovascular drug market.", "object": {"text": "Introduction of improved drug combinations and increasing in acquisition and mergers between pharmaceutical companies", "keywords": [{"text": "drug combinations"}, {"text": "pharmaceutical companies"}, {"text": "mergers"}, {"text": "acquisition"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "key trends", "keywords": [{"text": "key trends"}]}, "sentence": " Introduction of improved drug combinations and increasing in acquisition and mergers between pharmaceutical companies are key trends governing the global cardiovascular drug market.", "object": {"text": "the global cardiovascular drug market", "keywords": [{"text": "global cardiovascular drug"}, {"text": "market"}]}, "action": {"verb": {"text": "govern", "tense": "present"}, "text": "governing", "normalized": "govern"}}, {"subject": {"text": "the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}]}, "sentence": " On the basis of drugs, the global cardiovascular drugs market is segmented into anti-dyslipidemics drugs, anti-thrombotics drugs and anti-hypertensive drugs.", "object": {"text": "segmented into anti-dyslipidemics drugs, anti-thrombotics drugs and anti-hypertensive drugs", "keywords": [{"text": "anti-dyslipidemics drugs"}, {"text": "anti-thrombotics drugs"}, {"text": "anti-hypertensive drugs"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}]}, "sentence": " On the basis of drugs, the global cardiovascular drugs market is segmented into anti-dyslipidemics drugs, anti-thrombotics drugs and anti-hypertensive drugs.", "object": {"text": "into anti-dyslipidemics drugs, anti-thrombotics drugs and anti-hypertensive drugs", "keywords": [{"text": "anti-dyslipidemics drugs"}, {"text": "anti-thrombotics drugs"}, {"text": "anti-hypertensive drugs"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The Anti-dyslipidemics drug segment", "keywords": [{"text": "Anti-dyslipidemics drug segment"}]}, "sentence": " The Anti-dyslipidemics drug segment is further sub-segment into Tredaptive, Lipitor, Niaspan, Zetia/Vytorin, Crestor, and TriCor/Trilipix.", "object": {"text": "further sub-segment into Tredaptive, Lipitor, Niaspan, Zetia/Vytorin, Crestor, and TriCor/Trilipix", "keywords": [{"text": "Niaspan"}, {"text": "Lipitor"}, {"text": "Crestor"}, {"text": "sub-segment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Anti-hypertensive drug segment", "keywords": [{"text": "Anti-hypertensive drug segment"}]}, "sentence": " The Anti-hypertensive drug segment is also sub-segmented into Seloken/Toprol-XL, Diovan/Co-Diovan, Benicar/Benicar HCT, Blopress, Aprovel/CoAprovel, Edarbi, Exforge/Exforge HCT, Coversyl, Micardis/Micardis HCT, Tekturna/Rasilez, Cozaar/Hyzaar, and Norvasc.", "object": {"text": "sub-segmented"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Lovenox, Plavix, Brilique/Brilinta, Pradaxa, Eliquis and Xarelto", "keywords": [{"text": "Plavix"}, {"text": "Lovenox"}, {"text": "Brilique/Brilinta"}, {"text": "Pradaxa"}], "entities": [{"type": "Company", "text": "Lovenox"}, {"type": "Location", "text": "Xarelto", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " The Anti-thrombotics drug segment includes Lovenox, Plavix, Brilique/Brilinta, Pradaxa, Eliquis and Xarelto.", "object": {"text": "The Anti-thrombotics drug segment", "keywords": [{"text": "Anti-thrombotics drug segment"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "the key players", "keywords": [{"text": "key players"}]}, "sentence": " Some of the key players operating in the cardiovascular disease drug market are AstraZeneca plc, Pfizer, Inc., Sanofi S.A., Merck & Co., Daiichi Sankyo Company Limited, Novartis AG, Bayer AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Johnson & Johnson, United Therapeutics Corporation, Actelion Pharmaceuticals Ltd", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Some of the key players operating in the cardiovascular disease drug market", "keywords": [{"text": "cardiovascular disease drug"}, {"text": "key players"}, {"text": "market"}]}, "sentence": " Some of the key players operating in the cardiovascular disease drug market are AstraZeneca plc, Pfizer, Inc., Sanofi S.A., Merck & Co., Daiichi Sankyo Company Limited, Novartis AG, Bayer AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Johnson & Johnson, United Therapeutics Corporation, Actelion Pharmaceuticals Ltd", "object": {"text": "AstraZeneca plc, Pfizer, Inc., Sanofi S.A., Merck & Co., Daiichi Sankyo Company Limited, Novartis AG, Bayer AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Johnson & Johnson, United Therapeutics Corporation, Actelion Pharmaceuticals Ltd", "keywords": [{"text": "Daiichi Sankyo Company"}, {"text": "Boehringer Ingelheim GmbH"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Bayer AG"}], "entities": [{"type": "Company", "text": "Pfizer, Inc."}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Daiichi Sankyo Company Limited"}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"type": "Company", "text": "Astellas Pharma Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "United Therapeutics Corporation"}, {"type": "Company", "text": "Actelion Pharmaceuticals Ltd"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Hypertension", "relevance": 0.971207, "dbpedia_resource": "http://dbpedia.org/resource/Hypertension"}, {"text": "Heart disease", "relevance": 0.825892, "dbpedia_resource": "http://dbpedia.org/resource/Heart_disease"}, {"text": "Cardiology", "relevance": 0.708007, "dbpedia_resource": "http://dbpedia.org/resource/Cardiology"}, {"text": "Heart", "relevance": 0.678162, "dbpedia_resource": "http://dbpedia.org/resource/Heart"}, {"text": "Diseases and disorders", "relevance": 0.647746, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}, {"text": "Disease", "relevance": 0.639635, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Medicine", "relevance": 0.603969, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Ischemia", "relevance": 0.567038, "dbpedia_resource": "http://dbpedia.org/resource/Ischemia"}, {"text": "Genetic disorder", "relevance": 0.563693, "dbpedia_resource": "http://dbpedia.org/resource/Genetic_disorder"}, {"text": "Myocardial infarction", "relevance": 0.550213, "dbpedia_resource": "http://dbpedia.org/resource/Myocardial_infarction"}, {"text": "Blood vessel", "relevance": 0.499072, "dbpedia_resource": "http://dbpedia.org/resource/Blood_vessel"}, {"text": "Stroke", "relevance": 0.498601, "dbpedia_resource": "http://dbpedia.org/resource/Stroke"}, {"text": "Aspirin", "relevance": 0.475509, "dbpedia_resource": "http://dbpedia.org/resource/Aspirin"}, {"text": "Blood", "relevance": 0.47279, "dbpedia_resource": "http://dbpedia.org/resource/Blood"}, {"text": "Cardiovascular diseases", "relevance": 0.468779, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_diseases"}, {"text": "Cardiovascular system", "relevance": 0.462998, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_system"}, {"text": "Coronary artery disease", "relevance": 0.457361, "dbpedia_resource": "http://dbpedia.org/resource/Coronary_artery_disease"}, {"text": "Pharmaceutical drug", "relevance": 0.432933, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pharmacology", "relevance": 0.423311, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical industry", "relevance": 0.396012, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Heart failure", "relevance": 0.392534, "dbpedia_resource": "http://dbpedia.org/resource/Heart_failure"}, {"text": "Ischaemic heart disease", "relevance": 0.390994, "dbpedia_resource": "http://dbpedia.org/resource/Ischaemic_heart_disease"}, {"text": "Infection", "relevance": 0.386243, "dbpedia_resource": "http://dbpedia.org/resource/Infection"}, {"text": "Streptococcus", "relevance": 0.385454, "dbpedia_resource": "http://dbpedia.org/resource/Streptococcus"}, {"text": "Infectious disease", "relevance": 0.384024, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Non-infectious disease", "relevance": 0.372842, "dbpedia_resource": "http://dbpedia.org/resource/Non-infectious_disease"}, {"text": "Circulatory system", "relevance": 0.36843, "dbpedia_resource": "http://dbpedia.org/resource/Circulatory_system"}, {"text": "Rheumatic fever", "relevance": 0.365747, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}, {"text": "AstraZeneca", "relevance": 0.360319, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Cardiovascular disease", "relevance": 0.358296, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}, {"text": "Atherosclerosis", "relevance": 0.354984, "dbpedia_resource": "http://dbpedia.org/resource/Atherosclerosis"}, {"text": "Boehringer Ingelheim", "relevance": 0.351485, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Blood pressure", "relevance": 0.325902, "dbpedia_resource": "http://dbpedia.org/resource/Blood_pressure"}, {"text": "Pfizer", "relevance": 0.320256, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Inflammation", "relevance": 0.313645, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Amlodipine", "relevance": 0.304293, "dbpedia_resource": "http://dbpedia.org/resource/Amlodipine"}, {"text": "Hypercholesterolemia", "relevance": 0.301887, "dbpedia_resource": "http://dbpedia.org/resource/Hypercholesterolemia"}, {"text": "Obesity", "relevance": 0.300871, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.300043, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.999876, "label": "/health and fitness/disease/heart disease"}], "relations": [{"type": "hasAttribute", "sentence": "Most commonly occurring cerebrovascular disorders include stroke, transient ischemic attack (TIA), vascular dementia, and subarachnoid hemorrhage.", "score": 0.711322, "arguments": [{"text": "TIA", "location": [1006, 1009], "entities": [{"type": "Person", "text": "TIA"}]}, {"text": "stroke", "location": [971, 977], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "locatedAt", "sentence": "The Anti-dyslipidemics drug segment is further sub-segment into Tredaptive, Lipitor, Niaspan, Zetia/Vytorin, Crestor, and TriCor/Trilipix.", "score": 0.49647, "arguments": [{"text": "Zetia", "location": [2716, 2721], "entities": [{"type": "GeopoliticalEntity", "text": "Zetia"}]}, {"text": "Crestor", "location": [2731, 2738], "entities": [{"type": "GeopoliticalEntity", "text": "Crestor"}]}]}, {"type": "locatedAt", "sentence": "The Anti-hypertensive drug segment is also sub-segmented into Seloken/Toprol-XL, Diovan/Co-Diovan, Benicar/Benicar HCT, Blopress, Aprovel/CoAprovel, Edarbi, Exforge/Exforge HCT, Coversyl, Micardis/Micardis HCT, Tekturna/Rasilez, Cozaar/Hyzaar, and Norvasc.", "score": 0.550017, "arguments": [{"text": "Co-Diovan", "location": [2849, 2858], "entities": [{"type": "GeopoliticalEntity", "text": "Co-Diovan"}]}, {"text": "Benicar", "location": [2860, 2867], "entities": [{"type": "GeopoliticalEntity", "text": "Benicar HCT"}]}]}, {"type": "locatedAt", "sentence": "The Anti-hypertensive drug segment is also sub-segmented into Seloken/Toprol-XL, Diovan/Co-Diovan, Benicar/Benicar HCT, Blopress, Aprovel/CoAprovel, Edarbi, Exforge/Exforge HCT, Coversyl, Micardis/Micardis HCT, Tekturna/Rasilez, Cozaar/Hyzaar, and Norvasc.", "score": 0.62814, "arguments": [{"text": "Benicar HCT", "location": [2868, 2879], "entities": [{"type": "GeopoliticalEntity", "text": "Benicar HCT"}]}, {"text": "Blopress", "location": [2881, 2889], "entities": [{"type": "GeopoliticalEntity", "text": "Blopress"}]}]}, {"type": "locatedAt", "sentence": "The Anti-hypertensive drug segment is also sub-segmented into Seloken/Toprol-XL, Diovan/Co-Diovan, Benicar/Benicar HCT, Blopress, Aprovel/CoAprovel, Edarbi, Exforge/Exforge HCT, Coversyl, Micardis/Micardis HCT, Tekturna/Rasilez, Cozaar/Hyzaar, and Norvasc.", "score": 0.944401, "arguments": [{"text": "CoAprovel", "location": [2899, 2908], "entities": [{"type": "GeopoliticalEntity", "text": "CoAprovel"}]}, {"text": "Edarbi", "location": [2910, 2916], "entities": [{"type": "GeopoliticalEntity", "text": "Edarbi"}]}]}, {"type": "employedBy", "sentence": "The Anti-hypertensive drug segment is also sub-segmented into Seloken/Toprol-XL, Diovan/Co-Diovan, Benicar/Benicar HCT, Blopress, Aprovel/CoAprovel, Edarbi, Exforge/Exforge HCT, Coversyl, Micardis/Micardis HCT, Tekturna/Rasilez, Cozaar/Hyzaar, and Norvasc.", "score": 0.491725, "arguments": [{"text": "Rasilez", "location": [2981, 2988], "entities": [{"type": "Person", "text": "Rasilez"}]}, {"text": "Norvasc", "location": [3009, 3016], "entities": [{"type": "Organization", "text": "Norvasc", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Request For Report TOC : https://www.researchreportinsights.com/report/TOC/120124597/Cardiovascular-Drugs-Market Key Players: Some of the key players operating in the cardiovascular disease drug market are AstraZeneca plc, Pfizer, Inc., Sanofi S.A., Merck & Co., Daiichi Sankyo Company Limited, Novartis AG, Bayer AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Johnson & Johnson, United Therapeutics Corporation, Actelion Pharmaceuticals Ltd  //www.researchreportinsights.com/report/upcomming/120124597/Cardiovascular-Drugs-Market About Us  trends Contact Us:", "score": 0.54587, "arguments": [{"text": "players", "location": [3269, 3276], "entities": [{"type": "Person", "text": "players"}]}, {"text": "cardiovascular disease", "location": [3294, 3316], "entities": [{"type": "HealthCondition", "text": "cardiovascular disorders"}]}]}, {"type": "hasAttribute", "sentence": "Request For Report TOC : https://www.researchreportinsights.com/report/TOC/120124597/Cardiovascular-Drugs-Market Key Players: Some of the key players operating in the cardiovascular disease drug market are AstraZeneca plc, Pfizer, Inc., Sanofi S.A., Merck & Co., Daiichi Sankyo Company Limited, Novartis AG, Bayer AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Johnson & Johnson, United Therapeutics Corporation, Actelion Pharmaceuticals Ltd  //www.researchreportinsights.com/report/upcomming/120124597/Cardiovascular-Drugs-Market About Us  trends Contact Us:", "score": 0.441803, "arguments": [{"text": "Actelion Pharmaceuticals Ltd\n //", "location": [3585, 3617], "entities": [{"type": "Organization", "text": "Actelion Pharmaceuticals Ltd\n //", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "www.researchreportinsights.com/report/upcomming/120124597/Cardiovascular", "location": [3617, 3689], "entities": [{"type": "Web", "text": "www.researchreportinsights.com/report/upcomming/120124597/Cardiovascular"}]}]}, {"type": "agentOf", "sentence": "Most commonly occurring cerebrovascular disorders include stroke, transient ischemic attack (TIA), vascular dementia, and subarachnoid hemorrhage.", "score": 0.549114, "arguments": [{"text": "TIA", "location": [1006, 1009], "entities": [{"type": "Person", "text": "TIA"}]}, {"text": "attack", "location": [998, 1004], "entities": [{"type": "EventViolence", "text": "attack"}]}]}, {"type": "locatedAt", "sentence": "Factors such as the arrival of newer and advanced drugs and growing prevalence of heart diseases are expected to drive the global cardiovascular drugs market in near future.", "score": 0.386369, "arguments": [{"text": "drugs", "location": [1589, 1594], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "market", "location": [1595, 1601], "entities": [{"type": "Facility", "text": "market"}]}]}, {"type": "hasAttribute", "sentence": "In addition, higher occurrence of life-style diseases and rise in the global geriatric population is further contributing to the market growth.", "score": 0.650279, "arguments": [{"text": "population", "location": [1705, 1715], "entities": [{"type": "Person", "text": "population"}]}, {"text": "diseases", "location": [1663, 1671], "entities": [{"type": "HealthCondition", "text": "heart diseases"}]}]}, {"type": "partOfMany", "sentence": "Moreover, increasing prevalence of chronic diseases such as obesity and diabetes are fueling the demand for cardiovascular drugs.", "score": 0.751335, "arguments": [{"text": "diabetes", "location": [1834, 1842], "entities": [{"type": "HealthCondition", "text": "diabetes"}]}, {"text": "chronic diseases", "location": [1797, 1813], "entities": [{"type": "HealthCondition", "text": "chronic diseases"}]}]}, {"type": "partOfMany", "sentence": "Moreover, increasing prevalence of chronic diseases such as obesity and diabetes are fueling the demand for cardiovascular drugs.", "score": 0.348067, "arguments": [{"text": "cardiovascular", "location": [1870, 1884], "entities": [{"type": "HealthCondition", "text": "cardiovascular disorders"}]}, {"text": "diabetes", "location": [1834, 1842], "entities": [{"type": "HealthCondition", "text": "diabetes"}]}]}, {"type": "locatedAt", "sentence": "Likewise, the expiration of the patent for several blockbuster drugs is an additional factor anticipated to inhibit the growth of global cardiovascular market.", "score": 0.401658, "arguments": [{"text": "drugs", "location": [2185, 2190], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "blockbuster", "location": [2173, 2184], "entities": [{"type": "Facility", "text": "blockbuster"}]}]}, {"type": "locatedAt", "sentence": "The Anti-dyslipidemics drug segment is further sub-segment into Tredaptive, Lipitor, Niaspan, Zetia/Vytorin, Crestor, and TriCor/Trilipix.", "score": 0.68216, "arguments": [{"text": "Tredaptive", "location": [2686, 2696], "entities": [{"type": "GeopoliticalEntity", "text": "Tredaptive"}]}, {"text": "Lipitor", "location": [2698, 2705], "entities": [{"type": "GeopoliticalEntity", "text": "Lipitor"}]}]}, {"type": "locatedAt", "sentence": "The Anti-dyslipidemics drug segment is further sub-segment into Tredaptive, Lipitor, Niaspan, Zetia/Vytorin, Crestor, and TriCor/Trilipix.", "score": 0.570139, "arguments": [{"text": "Niaspan", "location": [2707, 2714], "entities": [{"type": "GeopoliticalEntity", "text": "Niaspan"}]}, {"text": "Zetia", "location": [2716, 2721], "entities": [{"type": "GeopoliticalEntity", "text": "Zetia"}]}]}], "keywords": [{"text": "Cardiovascular Drugs Market", "sentiment": {"score": -0.967728, "label": "negative"}, "relevance": 0.804174, "count": 1}, {"text": "heart disorders", "sentiment": {"score": -0.967728, "label": "negative"}, "relevance": 0.663684, "count": 1}, {"text": "Inflammatory heart disease", "sentiment": {"score": -0.98664, "label": "negative"}, "relevance": 0.648425, "count": 1}, {"text": "advanced drugs", "sentiment": {"score": -0.629164, "label": "negative"}, "relevance": 0.635424, "count": 1}, {"text": "hypertensive heart disease", "sentiment": {"score": -0.98664, "label": "negative"}, "relevance": 0.631231, "count": 1}, {"text": "anti-dyslipidemics drugs", "sentiment": {"score": -0.68813, "label": "negative"}, "relevance": 0.630898, "count": 1}, {"text": "Anti-dyslipidemics drug segment", "sentiment": {"score": -0.804087, "label": "negative"}, "relevance": 0.624399, "count": 1}, {"text": "global cardiovascular drugs market", "sentiment": {"score": -0.660968, "label": "negative"}, "relevance": 0.601485, "count": 2}, {"text": "heart", "sentiment": {"score": -0.923845, "label": "negative"}, "relevance": 0.600982, "count": 2}, {"text": "Cardiovascular disorders", "sentiment": {"score": -0.967728, "label": "negative"}, "relevance": 0.600844, "count": 1}, {"text": "pharmaceutical companies", "sentiment": {"score": 0.871973, "label": "positive"}, "relevance": 0.596588, "count": 1}, {"text": "segment", "sentiment": {"score": -0.804087, "label": "negative"}, "relevance": 0.580266, "count": 1}, {"text": "occurrence of high blood pressure leads", "sentiment": {"score": -0.723141, "label": "negative"}, "relevance": 0.578797, "count": 1}, {"text": "rheumatic heart disease", "sentiment": {"score": -0.98664, "label": "negative"}, "relevance": 0.566713, "count": 1}, {"text": "Such type of disorders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55985, "count": 1}, {"text": "anti-thrombotics drugs", "sentiment": {"score": -0.68813, "label": "negative"}, "relevance": 0.558229, "count": 1}, {"text": "expiration of the patent", "sentiment": {"score": -0.731439, "label": "negative"}, "relevance": 0.557644, "count": 1}, {"text": "cerebrovascular heart disease", "sentiment": {"score": -0.98664, "label": "negative"}, "relevance": 0.550655, "count": 1}, {"text": "cardiovascular drugs", "sentiment": {"score": -0.869278, "label": "negative"}, "relevance": 0.549684, "count": 2}, {"text": "additional factor", "sentiment": {"score": -0.731439, "label": "negative"}, "relevance": 0.548683, "count": 1}, {"text": "Introduction", "sentiment": {"score": 0.871973, "label": "positive"}, "relevance": 0.548638, "count": 1}, {"text": "Daiichi Sankyo Company Limited", "sentiment": {"score": -0.575069, "label": "negative"}, "relevance": 0.546713, "count": 1}, {"text": "www", "sentiment": {"score": -0.716307, "label": "negative"}, "relevance": 0.544513, "count": 2}, {"text": "coronary heart disease", "sentiment": {"score": -0.768031, "label": "negative"}, "relevance": 0.541779, "count": 1}, {"text": "Factors", "sentiment": {"score": -0.629164, "label": "negative"}, "relevance": 0.536004, "count": 1}, {"text": "Cardiovascular-Drugs-Market", "sentiment": {"score": -0.716307, "label": "negative"}, "relevance": 0.534388, "count": 2}, {"text": "contrast", "sentiment": {"score": -0.826795, "label": "negative"}, "relevance": 0.53353, "count": 1}, {"text": "Major effects of hypertensive heart ailments", "sentiment": {"score": -0.768031, "label": "negative"}, "relevance": 0.531127, "count": 1}, {"text": "ischemic heart disease fall", "sentiment": {"score": -0.98664, "label": "negative"}, "relevance": 0.530272, "count": 1}, {"text": "prevalence of heart diseases", "sentiment": {"score": -0.629164, "label": "negative"}, "relevance": 0.526667, "count": 1}, {"text": "drug combinations", "sentiment": {"score": 0.871973, "label": "positive"}, "relevance": 0.526222, "count": 1}, {"text": "key trends", "sentiment": {"score": 0.871973, "label": "positive"}, "relevance": 0.525789, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525114, "count": 1}, {"text": "cases", "sentiment": {"score": -0.723141, "label": "negative"}, "relevance": 0.524617, "count": 1}, {"text": "Benicar HCT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524489, "count": 1}, {"text": "Anti-hypertensive drug segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524464, "count": 1}, {"text": "hypertensive heart ailments", "sentiment": {"score": -0.745978, "label": "negative"}, "relevance": 0.52388, "count": 1}, {"text": "acquisition", "sentiment": {"score": 0.871973, "label": "positive"}, "relevance": 0.523029, "count": 1}, {"text": "report", "sentiment": {"score": -0.716307, "label": "negative"}, "relevance": 0.521798, "count": 2}, {"text": "com", "sentiment": {"score": -0.716307, "label": "negative"}, "relevance": 0.521592, "count": 2}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": -0.575069, "label": "negative"}, "relevance": 0.521449, "count": 1}, {"text": "disorder", "sentiment": {"score": -0.727765, "label": "negative"}, "relevance": 0.521425, "count": 1}, {"text": "Johnson", "sentiment": {"score": -0.575069, "label": "negative"}, "relevance": 0.521156, "count": 2}, {"text": "mergers", "sentiment": {"score": 0.871973, "label": "positive"}, "relevance": 0.521115, "count": 1}, {"text": "Novartis AG", "sentiment": {"score": -0.575069, "label": "negative"}, "relevance": 0.521017, "count": 1}, {"text": "blockbuster drugs", "sentiment": {"score": -0.731439, "label": "negative"}, "relevance": 0.520459, "count": 1}, {"text": "heart failure", "sentiment": {"score": -0.768031, "label": "negative"}, "relevance": 0.520438, "count": 1}, {"text": "Pfizer", "sentiment": {"score": -0.575069, "label": "negative"}, "relevance": 0.519811, "count": 1}, {"text": "vascular dementia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519544, "count": 1}, {"text": "anti-hypertensive drugs", "sentiment": {"score": -0.747652, "label": "negative"}, "relevance": 0.519375, "count": 1}]}, "extracted_metadata": {"sha1": "635a6d282f6de73ef9b42d6a76ba15114238eae7", "filename": "1542535890308.zip-73caf0ce95815a80bff7668370fb8839.xml", "file_type": "json"}, "external_links": ["https://www.researchreportinsights.com/report/upsample/120124597/Cardiovascular-Drugs-Market", "https://www.researchreportinsights.com/report/TOC/120124597/Cardiovascular-Drugs-Market", "https://www.researchreportinsights.com/", "https://www.researchreportinsights.com/report/upcomming/120124597/Cardiovascular-Drugs-Market"], "title": "Cardiovascular Drugs Market Augmented Expansion to be Registered by 2024", "forum_title": "Webnewswire"}, {"id": "fwn1PylGmtBWelbqPssL3eXJZ7wjwOSKcCBwrTqAGS6ldTbcMGVK6LjCO1glNTDu", "result_metadata": {"score": 32.642307}, "author": "ann.castro", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.448332, "label": "negative"}, "text": "Ironwood Pharmaceuticals Inc", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Opioid", "relevance": 0.921398, "dbpedia_resource": "http://dbpedia.org/resource/Opioid"}, {"text": "Drug", "relevance": 0.837479, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Daiichi Sankyo", "relevance": 0.712, "dbpedia_resource": "http://dbpedia.org/resource/Daiichi_Sankyo"}], "categories": [{"score": 0.836107, "label": "/health and fitness"}, {"score": 0.814329, "label": "/health and fitness/disease/chronic pain"}, {"score": 0.76786, "label": "/health and fitness/addiction"}], "relations": [], "keywords": [{"text": "Global Opioid", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.978606, "count": 1}, {"text": "Constipation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.763598, "count": 1}, {"text": "Drugs Market Insights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.652189, "count": 1}, {"text": "Ironwood Pharmaceuticals Inc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459646, "count": 1}, {"text": "Daiichi Sankyo Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262858, "count": 1}, {"text": "OIC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.159834, "count": 1}]}, "crawl_date": "2018-11-17T23:13:35Z", "url": "http://blamfluie.com/global-opioid-induced-constipation-oic-drugs-market-insights-2018-2025-ironwood-pharmaceuticals-inc-daiichi-sankyo-co-ltd/", "host": "blamfluie.com", "text": "Pharma AG, Mundipharma International Limited, Ono Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Limited, Theravance Biopharma Inc, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, C.B.", "main_image_url": "http://blamfluie.com/wp-content/uploads/2018/07/Global-Opioid-Induced-Constipation-Drugs-Market.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-17T23:10:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": -0.480703, "label": "negative"}, "text": "Ironwood Pharmaceuticals Inc", "relevance": 0.707931, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Co Ltd", "relevance": 0.673481, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lubiprostone", "relevance": 0.508268, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alvimopan", "relevance": 0.508023, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.503623, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Naltrexone", "relevance": 0.501984, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.498417, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.497341, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Application Hospital Pharmacies", "relevance": 0.458976, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.39059, "label": "negative"}, "text": "Hospital Pharmacies", "relevance": 0.444732, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.48333, "label": "negative"}, "text": "Valeant Pharmaceuticals International", "relevance": 0.428133, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd", "relevance": 0.424081, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.392847, "label": "negative"}, "text": "Progenics Pharmaceuticals Inc", "relevance": 0.412361, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.301968, "label": "negative"}, "text": "Porters Five Forces", "relevance": 0.408364, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.543458, "label": "negative"}, "text": "Sucampo Pharmaceuticals", "relevance": 0.408046, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.40256, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.576011, "label": "negative"}, "text": "Cosmo Pharmaceuticals SA", "relevance": 0.40113, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.385558, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Purdue Pharma", "relevance": 0.369031, "type": "Company", "disambiguation": {"subtype": [], "name": "Purdue Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Purdue_Pharma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.362365, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.354324, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.351733, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "East Africa", "relevance": 0.348953, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.344358, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Theravance Biopharma Inc", "relevance": 0.343969, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ono Pharmaceutical Co.", "relevance": 0.341664, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shionogi & Co.", "relevance": 0.341222, "type": "Company", "disambiguation": {"subtype": [], "name": "Shionogi", "dbpedia_resource": "http://dbpedia.org/resource/Shionogi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharma AG", "relevance": 0.339029, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daewoong Pharmaceutical", "relevance": 0.338616, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nektar Therapeutics", "relevance": 0.333265, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan Plc", "relevance": 0.329951, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mundipharma International Limited", "relevance": 0.3282, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "C.B. Fleet Company", "relevance": 0.310894, "type": "Company"}], "sentiment": {"document": {"score": -0.568027, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "The global \u201c Opioid Induced Constipation (OIC) Drugs market \u201d research report", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "Drugs market"}, {"text": "OIC"}, {"text": "research report"}], "entities": []}, "sentence": " The global \u201c Opioid Induced Constipation (OIC) Drugs market \u201d research report offers a comprehensive analysis and forecasts of the Opioid Induced Constipation (OIC) Drugs market at both the global and regional level.", "object": {"text": "a comprehensive analysis and forecasts of the Opioid Induced Constipation (OIC) Drugs market at both the global and regional level", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "Drugs market"}, {"text": "comprehensive analysis"}, {"text": "regional level"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "It"}, "sentence": " It offers an in-depth and unbiased market review.", "object": {"text": "an in-depth and unbiased market review", "keywords": [{"text": "unbiased market review"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report highlights the main inclinations and services that play a key role in the development of the global Opioid Induced Constipation (OIC) Drugs market for the estimated period.", "object": {"text": "the main inclinations and services that play a key role in the development of the global Opioid Induced Constipation (OIC) Drugs market for the estimated period", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "main inclinations"}, {"text": "estimated period"}, {"text": "Drugs market"}]}, "action": {"verb": {"text": "highlight", "tense": "present"}, "text": "highlights", "normalized": "highlight"}}, {"subject": {"text": "the main inclinations and services", "keywords": [{"text": "main inclinations"}, {"text": "services"}]}, "sentence": " The report highlights the main inclinations and services that play a key role in the development of the global Opioid Induced Constipation (OIC) Drugs market for the estimated period.", "object": {"text": "a key role", "keywords": [{"text": "key role"}]}, "action": {"verb": {"text": "play", "tense": "present"}, "text": "play", "normalized": "play"}}, {"subject": {"text": "It"}, "sentence": " It also emphasizes on the market drivers and opportunities of the global Opioid Induced Constipation (OIC) Drugs market for the upcoming period.", "object": {"text": "on the market drivers and opportunities of the global Opioid Induced Constipation (OIC) Drugs market for the upcoming period", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "Drugs market"}, {"text": "upcoming period"}, {"text": "market drivers"}]}, "action": {"verb": {"text": "emphasize", "tense": "present"}, "text": "emphasizes", "normalized": "emphasize"}}, {"subject": {"text": "The research report", "keywords": [{"text": "research report"}]}, "sentence": " The research report encompasses an in-depth value chain analysis by giving an extensive vision of the global Opioid Induced Constipation (OIC) Drugs market.", "object": {"text": "an in-depth value chain analysis", "keywords": [{"text": "in-depth value chain"}, {"text": "analysis"}]}, "action": {"verb": {"text": "encompass", "tense": "present"}, "text": "encompasses", "normalized": "encompass"}}, {"subject": {"text": "an in-depth value chain analysis", "keywords": [{"text": "in-depth value chain"}, {"text": "analysis"}]}, "sentence": " The research report encompasses an in-depth value chain analysis by giving an extensive vision of the global Opioid Induced Constipation (OIC) Drugs market.", "object": {"text": "an extensive vision of the global Opioid Induced Constipation (OIC) Drugs market", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "OIC"}, {"text": "extensive vision"}, {"text": "Drugs"}]}, "action": {"verb": {"text": "give", "tense": "present"}, "text": "giving", "normalized": "give"}}, {"subject": {"text": "Porters Five Forces analysis", "keywords": [{"text": "Porters"}, {"text": "Forces analysis"}], "entities": [{"type": "Company", "text": "Porters Five Forces"}]}, "sentence": " It uses Porters Five Forces analysis to understand the competitive scenario of the global Opioid Induced Constipation (OIC) Drugs market.", "object": {"text": "the competitive scenario of the global Opioid Induced Constipation (OIC) Drugs market", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "competitive scenario"}, {"text": "OIC"}, {"text": "Drugs"}]}, "action": {"verb": {"text": "understand", "tense": "future"}, "text": "to understand", "normalized": "to understand"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report describes the market dynamics and market trends, limiting factors, drivers, and opportunities for the current and future global Opioid Induced Constipation (OIC) Drugs market.", "object": {"text": "the market dynamics and market trends, limiting factors, drivers, and opportunities", "keywords": [{"text": "market dynamics"}, {"text": "market trends"}, {"text": "factors"}, {"text": "drivers"}]}, "action": {"verb": {"text": "describe", "tense": "present"}, "text": "describes", "normalized": "describe"}}, {"subject": {"text": "the major product categories and segments By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs along with their sub-segments Hospital Pharmacies, Retail Pharmacies, Online Pharmacies in detail", "keywords": [{"text": "Methyl Naltrexone Bromide"}, {"text": "sub-segments Hospital Pharmacies"}, {"text": "Branded Prescribed Drugs"}, {"text": "Retail Pharmacies"}], "entities": [{"type": "Drug", "text": "Lubiprostone"}, {"type": "Drug", "text": "Naltrexone"}, {"type": "Drug", "text": "Alvimopan"}, {"type": "Company", "text": "Hospital Pharmacies"}]}, "sentence": " Additionally, the global Opioid Induced Constipation (OIC) Drugs market report covers the major product categories and segments By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs along with their sub-segments Hospital Pharmacies, Retail Pharmacies, Online Pharmacies in detail.", "object": {"text": "the global Opioid Induced Constipation (OIC) Drugs market report", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "Drugs market report"}, {"text": "OIC"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "the global Opioid Induced Constipation (OIC) Drugs market research report", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "Drugs market research"}, {"text": "OIC"}]}, "sentence": " In addition, the global Opioid Induced Constipation (OIC) Drugs market research report demonstrates an analysis of varied business strategies implemented by leading players in the global Opioid Induced Constipation (OIC) Drugs market that help for the development and expansion of their businesses.", "object": {"text": "an analysis of varied business strategies implemented by leading players in the global Opioid Induced Constipation (OIC) Drugs market that help for the development and expansion of their businesses", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "varied business strategies"}, {"text": "Drugs market"}, {"text": "OIC"}]}, "action": {"verb": {"text": "demonstrate", "tense": "present"}, "text": "demonstrates", "normalized": "demonstrate"}}, {"subject": {"text": "OIC) Drugs market", "keywords": [{"text": ") Drugs market"}, {"text": "market"}]}, "sentence": " In addition, the global Opioid Induced Constipation (OIC) Drugs market research report demonstrates an analysis of varied business strategies implemented by leading players in the global Opioid Induced Constipation (OIC) Drugs market that help for the development and expansion of their businesses.", "object": {"text": "for the development and expansion of their businesses", "keywords": [{"text": "expansion"}, {"text": "development"}, {"text": "businesses"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "The study", "keywords": [{"text": "study"}]}, "sentence": " The study offers an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market in terms of revenue (USD Million) across numerous regions including the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America.", "object": {"text": "an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "entire outlook"}, {"text": "OIC"}, {"text": "Drugs"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America", "keywords": [{"text": "Middle East"}, {"text": "Asia Pacific"}, {"text": "North America"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " The study offers an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market in terms of revenue (USD Million) across numerous regions including the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America.", "object": {"text": "numerous regions", "keywords": [{"text": "numerous regions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the decisive analysis of the global Opioid Induced Constipation (OIC) Drugs market by classifying it on the basis of product type, end user, and application segments", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "decisive analysis"}, {"text": "application segments"}, {"text": "Drugs market"}], "entities": []}, "sentence": " The global Opioid Induced Constipation (OIC) Drugs market research includes the decisive analysis of the global Opioid Induced Constipation (OIC) Drugs market by classifying it on the basis of product type, end user, and application segments.", "object": {"text": "The global Opioid Induced Constipation (OIC) Drugs market research", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "Drugs market research"}, {"text": "OIC"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "The development of every segment", "keywords": [{"text": "segment"}, {"text": "development"}]}, "sentence": " The development of every segment is assessed along with the forecast of their expansion in the near future.", "object": {"text": "along with the forecast of their expansion in the near future", "keywords": [{"text": "forecast"}, {"text": "expansion"}, {"text": "future"}]}, "action": {"verb": {"text": "assess", "tense": "past"}, "text": "is assessed", "normalized": "be assess"}}, {"subject": {"text": "The pertinent facts and figures", "keywords": [{"text": "pertinent facts"}, {"text": "figures"}]}, "sentence": " The pertinent facts and figures gathered from the regulatory authorities are presented in the global Opioid Induced Constipation (OIC) Drugs research report to review the expansion of each segment.", "object": {"text": "from the regulatory authorities", "keywords": [{"text": "regulatory authorities"}]}, "action": {"verb": {"text": "gather", "tense": "past"}, "text": "gathered", "normalized": "gather"}}, {"subject": {"text": "The pertinent facts and figures gathered from the regulatory authorities", "keywords": [{"text": "pertinent facts"}, {"text": "regulatory authorities"}, {"text": "figures"}]}, "sentence": " The pertinent facts and figures gathered from the regulatory authorities are presented in the global Opioid Induced Constipation (OIC) Drugs research report to review the expansion of each segment.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "are presented", "normalized": "be present"}}, {"subject": {"text": "the global Opioid Induced Constipation (OIC) Drugs market", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "OIC"}, {"text": "Drugs"}]}, "sentence": " Furthermore, the global Opioid Induced Constipation (OIC) Drugs market is bifurcated on the basis of geographical regions such as Latin America, North America, Middle & East Africa, Europe, and the Asia Pacific.", "object": {"text": "on the basis of geographical regions such as Latin America, North America, Middle & East Africa, Europe, and the Asia Pacific", "keywords": [{"text": "geographical regions"}, {"text": "East Africa"}, {"text": "Asia Pacific"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "East Africa", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Facility", "text": "Asia Pacific"}]}, "action": {"verb": {"text": "bifurcate", "tense": "past"}, "text": "is bifurcated", "normalized": "be bifurcate"}}, {"subject": {"text": "Numerous analytical techniques", "keywords": [{"text": "Numerous analytical techniques"}]}, "sentence": " Numerous analytical techniques are used to study the expansion of the global Opioid Induced Constipation (OIC) Drugs market.", "object": {"text": "to study the expansion of the global Opioid Induced Constipation (OIC) Drugs market", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "OIC"}, {"text": "expansion"}, {"text": "Drugs"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "are used", "normalized": "be use"}}, {"subject": {"text": "Numerous analytical techniques", "keywords": [{"text": "Numerous analytical techniques"}]}, "sentence": " Numerous analytical techniques are used to study the expansion of the global Opioid Induced Constipation (OIC) Drugs market.", "object": {"text": "the expansion of the global Opioid Induced Constipation (OIC) Drugs market", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "OIC"}]}, "action": {"verb": {"text": "study", "tense": "future"}, "text": "to study", "normalized": "to study"}}, {"subject": {"text": "It"}, "sentence": " It also highlights key parameters of the dominating market players influencing the growth of the global Opioid Induced Constipation (OIC) Drugs market along with their position in the global market.", "object": {"text": "key parameters of the dominating market players influencing the growth of the global Opioid Induced Constipation (OIC) Drugs market along with their position in the global market", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "dominating market players"}, {"text": "key parameters"}, {"text": "Drugs market"}], "entities": []}, "action": {"verb": {"text": "highlight", "tense": "present"}, "text": "highlights", "normalized": "highlight"}}, {"subject": {"text": "15 Chapters", "keywords": [{"text": "Chapters"}]}, "sentence": " There are 15 Chapters to display the Global Opioid Induced Constipation (OIC) Drugs market", "object": {"text": "the Global Opioid Induced Constipation (OIC) Drugs market", "keywords": [{"text": "Opioid Induced Constipation"}, {"text": "OIC"}, {"text": "Drugs"}], "entities": []}, "action": {"verb": {"text": "display", "tense": "future"}, "text": "to display", "normalized": "to display"}}], "concepts": [{"text": "Pharmacology", "relevance": 0.970404, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical drug", "relevance": 0.736907, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pharmacy", "relevance": 0.716651, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Opioid", "relevance": 0.656971, "dbpedia_resource": "http://dbpedia.org/resource/Opioid"}, {"text": "Drug", "relevance": 0.631554, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Bankruptcy in the United States", "relevance": 0.620034, "dbpedia_resource": "http://dbpedia.org/resource/Bankruptcy_in_the_United_States"}, {"text": "Market trend", "relevance": 0.610029, "dbpedia_resource": "http://dbpedia.org/resource/Market_trend"}, {"text": "Ribavirin", "relevance": 0.563353, "dbpedia_resource": "http://dbpedia.org/resource/Ribavirin"}, {"text": "Market trends", "relevance": 0.545775, "dbpedia_resource": "http://dbpedia.org/resource/Market_trends"}, {"text": "Dow Jones Industrial Average", "relevance": 0.543462, "dbpedia_resource": "http://dbpedia.org/resource/Dow_Jones_Industrial_Average"}, {"text": "Wall Street Crash of 1929", "relevance": 0.542903, "dbpedia_resource": "http://dbpedia.org/resource/Wall_Street_Crash_of_1929"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.528039, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.956759, "label": "/health and fitness"}, {"score": 0.931566, "label": "/health and fitness/addiction"}, {"score": 0.897503, "label": "/health and fitness/drugs"}], "relations": [{"type": "partOfMany", "sentence": "Additionally, the global Opioid Induced Constipation (OIC) Drugs market report covers the major product categories and segments By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs along with their sub-segments Hospital Pharmacies, Retail Pharmacies, Online Pharmacies in detail.", "score": 0.654157, "arguments": [{"text": "Lubiprostone", "location": [1915, 1927], "entities": [{"type": "Person", "text": "Lubiprostone"}]}, {"text": "their", "location": [2081, 2086], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "locatedAt", "sentence": "The study offers an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market in terms of revenue (USD Million) across numerous regions including the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America.", "score": 0.698386, "arguments": [{"text": "regions", "location": [2621, 2628], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Pacific", "location": [2670, 2677], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "The study offers an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market in terms of revenue (USD Million) across numerous regions including the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America.", "score": 0.842296, "arguments": [{"text": "regions", "location": [2621, 2628], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Europe", "location": [2679, 2685], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The study offers an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market in terms of revenue (USD Million) across numerous regions including the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America.", "score": 0.909574, "arguments": [{"text": "regions", "location": [2621, 2628], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "North America", "location": [2687, 2700], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The study offers an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market in terms of revenue (USD Million) across numerous regions including the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America.", "score": 0.894129, "arguments": [{"text": "regions", "location": [2621, 2628], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [2706, 2719], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The study offers an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market in terms of revenue (USD Million) across numerous regions including the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America.", "score": 0.612492, "arguments": [{"text": "Asia", "location": [2665, 2669], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2670, 2677], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Furthermore, the global Opioid Induced Constipation (OIC) Drugs market is bifurcated on the basis of geographical regions such as Latin America, North America, Middle & East Africa, Europe, and the Asia Pacific.", "score": 0.694702, "arguments": [{"text": "Asia", "location": [3603, 3607], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3608, 3615], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Furthermore, the global Opioid Induced Constipation (OIC) Drugs market is bifurcated on the basis of geographical regions such as Latin America, North America, Middle & East Africa, Europe, and the Asia Pacific.", "score": 0.910186, "arguments": [{"text": "regions", "location": [3519, 3526], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [3535, 3548], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Furthermore, the global Opioid Induced Constipation (OIC) Drugs market is bifurcated on the basis of geographical regions such as Latin America, North America, Middle & East Africa, Europe, and the Asia Pacific.", "score": 0.85446, "arguments": [{"text": "regions", "location": [3519, 3526], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "North America", "location": [3550, 3563], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Furthermore, the global Opioid Induced Constipation (OIC) Drugs market is bifurcated on the basis of geographical regions such as Latin America, North America, Middle & East Africa, Europe, and the Asia Pacific.", "score": 0.909308, "arguments": [{"text": "regions", "location": [3519, 3526], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Europe", "location": [3587, 3593], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Furthermore, the global Opioid Induced Constipation (OIC) Drugs market is bifurcated on the basis of geographical regions such as Latin America, North America, Middle & East Africa, Europe, and the Asia Pacific.", "score": 0.840579, "arguments": [{"text": "regions", "location": [3519, 3526], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Asia", "location": [3603, 3607], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Furthermore, the global Opioid Induced Constipation (OIC) Drugs market is bifurcated on the basis of geographical regions such as Latin America, North America, Middle & East Africa, Europe, and the Asia Pacific.", "score": 0.623908, "arguments": [{"text": "regions", "location": [3519, 3526], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Pacific", "location": [3608, 3615], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOfMany", "sentence": "Additionally, the global Opioid Induced Constipation (OIC) Drugs market report covers the major product categories and segments By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs along with their sub-segments Hospital Pharmacies, Retail Pharmacies, Online Pharmacies in detail.", "score": 0.973698, "arguments": [{"text": "Methyl Naltrexone Bromide", "location": [1929, 1954], "entities": [{"type": "Person", "text": "Methyl Naltrexone Bromide"}]}, {"text": "their", "location": [2081, 2086], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "There are 15 Chapters to display the Global Opioid Induced Constipation (OIC) Drugs market Chapter 1 , Definition, Specifications and Classification of Opioid Induced Constipation (OIC) Drugs , Applications of Opioid Induced Constipation (OIC) Drugs Opioid Induced Constipation (OIC) Drugs , Capacity Opioid Induced Constipation (OIC) Drugs Segment Market Analysis (by Type); Chapter 7 and 8 , The Opioid Induced Constipation (OIC) Drugs Segment Market Analysis (by Application) Major Manufacturers Analysis of Opioid Induced Constipation (OIC) Drugs ; Chapter 9 , Market Trend Analysis, Regional Market Trend, Market Trend by Product Type By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs,", "score": 0.739102, "arguments": [{"text": "Classification", "location": [4075, 4089], "entities": [{"type": "Person", "text": "Classification"}]}, {"text": "Specifications", "location": [4056, 4070], "entities": [{"type": "Person", "text": "Specifications"}]}]}, {"type": "employedBy", "sentence": "There are 15 Chapters to display the Global Opioid Induced Constipation (OIC) Drugs market Chapter 1 , Definition, Specifications and Classification of Opioid Induced Constipation (OIC) Drugs , Applications of Opioid Induced Constipation (OIC) Drugs Opioid Induced Constipation (OIC) Drugs , Capacity Opioid Induced Constipation (OIC) Drugs Segment Market Analysis (by Type); Chapter 7 and 8 , The Opioid Induced Constipation (OIC) Drugs Segment Market Analysis (by Application) Major Manufacturers Analysis of Opioid Induced Constipation (OIC) Drugs ; Chapter 9 , Market Trend Analysis, Regional Market Trend, Market Trend by Product Type By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs,", "score": 0.554404, "arguments": [{"text": "Type", "location": [4310, 4314], "entities": [{"type": "Person", "text": "Drug Type"}]}, {"text": "Segment Market Analysis", "location": [4282, 4305], "entities": [{"type": "Organization", "text": "Application Hospital Pharmacies"}]}]}, {"type": "partOf", "sentence": "There are 15 Chapters to display the Global Opioid Induced Constipation (OIC) Drugs market Chapter 1 , Definition, Specifications and Classification of Opioid Induced Constipation (OIC) Drugs , Applications of Opioid Induced Constipation (OIC) Drugs Opioid Induced Constipation (OIC) Drugs , Capacity Opioid Induced Constipation (OIC) Drugs Segment Market Analysis (by Type); Chapter 7 and 8 , The Opioid Induced Constipation (OIC) Drugs Segment Market Analysis (by Application) Major Manufacturers Analysis of Opioid Induced Constipation (OIC) Drugs ; Chapter 9 , Market Trend Analysis, Regional Market Trend, Market Trend by Product Type By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs,", "score": 0.415938, "arguments": [{"text": "Manufacturers Analysis", "location": [4426, 4448], "entities": [{"type": "Organization", "text": "Manufacturers Analysis"}]}, {"text": "Opioid Induced Constipation", "location": [4452, 4479], "entities": [{"type": "Organization", "text": "Global Opioid Induced Constipation"}]}]}, {"type": "managerOf", "sentence": "Market Trend by Application Hospital Pharmacies, Retail Pharmacies, Online Pharmacies; Opioid Induced Constipation (OIC) Drugs ; Chapter 12 , Opioid Induced Constipation (OIC) Drugs Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15 , Opioid Induced Constipation (OIC) Drugs buying.html?repid=65996 Reasons for Buying Opioid Induced Constipation (OIC) Drugs", "score": 0.327848, "arguments": [{"text": "buying.html?repid=65996", "location": [5070, 5093], "entities": [{"type": "Person", "text": "buying.html?repid=65996"}]}, {"text": "Reasons", "location": [5094, 5101], "entities": [{"type": "Organization", "text": "Reasons"}]}]}, {"type": "partOfMany", "sentence": "Additionally, the global Opioid Induced Constipation (OIC) Drugs market report covers the major product categories and segments By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs along with their sub-segments Hospital Pharmacies, Retail Pharmacies, Online Pharmacies in detail.", "score": 0.985416, "arguments": [{"text": "Naldemedine", "location": [1956, 1967], "entities": [{"type": "Person", "text": "Naldemedine"}]}, {"text": "their", "location": [2081, 2086], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Additionally, the global Opioid Induced Constipation (OIC) Drugs market report covers the major product categories and segments By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs along with their sub-segments Hospital Pharmacies, Retail Pharmacies, Online Pharmacies in detail.", "score": 0.983793, "arguments": [{"text": "Alvimopan", "location": [1969, 1978], "entities": [{"type": "Person", "text": "Alvimopan"}]}, {"text": "their", "location": [2081, 2086], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Additionally, the global Opioid Induced Constipation (OIC) Drugs market report covers the major product categories and segments By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs along with their sub-segments Hospital Pharmacies, Retail Pharmacies, Online Pharmacies in detail.", "score": 0.907208, "arguments": [{"text": "Prescription Type", "location": [1990, 2007], "entities": [{"type": "Person", "text": "Prescription Type"}]}, {"text": "their", "location": [2081, 2086], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "partOfMany", "sentence": "Additionally, the global Opioid Induced Constipation (OIC) Drugs market report covers the major product categories and segments By Drug Type, Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other, By Prescription Type, Generic and Branded Prescribed Drugs, Over The Counter Drugs along with their sub-segments Hospital Pharmacies, Retail Pharmacies, Online Pharmacies in detail.", "score": 0.647945, "arguments": [{"text": "Generic", "location": [2009, 2016], "entities": [{"type": "Person", "text": "Generic"}]}, {"text": "their", "location": [2081, 2086], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "locatedAt", "sentence": "The study offers an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market in terms of revenue (USD Million) across numerous regions including the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America.", "score": 0.858533, "arguments": [{"text": "regions", "location": [2621, 2628], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Middle East", "location": [2643, 2654], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The study offers an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market in terms of revenue (USD Million) across numerous regions including the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America.", "score": 0.856189, "arguments": [{"text": "regions", "location": [2621, 2628], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Africa", "location": [2657, 2663], "entities": [{"type": "GeopoliticalEntity", "text": "Africa", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The study offers an entire outlook on the growth of the Opioid Induced Constipation (OIC) Drugs market in terms of revenue (USD Million) across numerous regions including the Middle East & Africa, Asia Pacific, Europe, North America, and Latin America.", "score": 0.875534, "arguments": [{"text": "regions", "location": [2621, 2628], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Asia", "location": [2665, 2669], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}], "keywords": [{"text": "Drugs Market Insights", "sentiment": {"score": -0.815332, "label": "negative"}, "relevance": 0.860421, "count": 1}, {"text": "Opioid Induced Constipation", "sentiment": {"score": -0.854821, "label": "negative"}, "relevance": 0.77239, "count": 4}, {"text": "Global Opioid", "sentiment": {"score": -0.815332, "label": "negative"}, "relevance": 0.758419, "count": 1}, {"text": "research report", "sentiment": {"score": -0.298351, "mixed": "1", "label": "negative"}, "relevance": 0.723825, "count": 2}, {"text": "Drugs market", "sentiment": {"score": -0.668731, "mixed": "1", "label": "negative"}, "relevance": 0.692194, "count": 13}, {"text": "Constipation", "sentiment": {"score": -0.606312, "mixed": "1", "label": "negative"}, "relevance": 0.649746, "count": 15}, {"text": "forecasts of the Opioid Induced Constipation", "sentiment": {"score": -0.815332, "label": "negative"}, "relevance": 0.647435, "count": 1}, {"text": "Ironwood Pharmaceuticals Inc", "sentiment": {"score": -0.815332, "label": "negative"}, "relevance": 0.620808, "count": 2}, {"text": "comprehensive analysis", "sentiment": {"score": -0.815332, "label": "negative"}, "relevance": 0.611595, "count": 1}, {"text": "OIC", "sentiment": {"score": -0.737956, "mixed": "1", "label": "negative"}, "relevance": 0.610179, "count": 28}, {"text": "report", "sentiment": {"score": -0.759377, "label": "negative"}, "relevance": 0.598014, "count": 3}, {"text": "development of the global Opioid", "sentiment": {"score": -0.600306, "label": "negative"}, "relevance": 0.570775, "count": 1}, {"text": "growth of the Opioid Induced Constipation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55599, "count": 1}, {"text": "Purdue Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555721, "count": 1}, {"text": "Drug Type", "sentiment": {"score": -0.824394, "label": "negative"}, "relevance": 0.551296, "count": 2}, {"text": "Daiichi Sankyo Co Ltd", "sentiment": {"score": -0.815332, "label": "negative"}, "relevance": 0.549345, "count": 2}, {"text": "Chapter", "sentiment": {"score": -0.866097, "label": "negative"}, "relevance": 0.542703, "count": 4}, {"text": "Chapters", "sentiment": {"score": -0.866097, "label": "negative"}, "relevance": 0.542703, "count": 1}, {"text": "numerous regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541439, "count": 1}, {"text": "opportunities of the global Opioid", "sentiment": {"score": -0.663237, "label": "negative"}, "relevance": 0.538531, "count": 1}, {"text": "Drugs", "sentiment": {"score": -0.852565, "label": "negative"}, "relevance": 0.535177, "count": 7}, {"text": "unbiased market review", "sentiment": {"score": 0.659169, "label": "positive"}, "relevance": 0.53255, "count": 1}, {"text": "segments", "sentiment": {"score": -0.779351, "label": "negative"}, "relevance": 0.531895, "count": 1}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531612, "count": 2}, {"text": "business strategies", "sentiment": {"score": -0.450111, "label": "negative"}, "relevance": 0.529718, "count": 1}, {"text": "Mundipharma International Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529642, "count": 1}, {"text": "Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529125, "count": 1}, {"text": "sub-segments Hospital Pharmacies", "sentiment": {"score": -0.779351, "label": "negative"}, "relevance": 0.528167, "count": 1}, {"text": "analysis", "sentiment": {"score": -0.450111, "label": "negative"}, "relevance": 0.528031, "count": 1}, {"text": "Global Opioid Induced Constipation", "sentiment": {"score": -0.866097, "label": "negative"}, "relevance": 0.526548, "count": 1}, {"text": "regulatory authorities", "sentiment": {"score": -0.345043, "label": "negative"}, "relevance": 0.526376, "count": 1}, {"text": "Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524805, "count": 2}, {"text": "Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523292, "count": 1}, {"text": "study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523183, "count": 1}, {"text": "Type", "sentiment": {"score": -0.866097, "label": "negative"}, "relevance": 0.523071, "count": 1}, {"text": "market trends", "sentiment": {"score": -0.881862, "label": "negative"}, "relevance": 0.521608, "count": 1}, {"text": "extensive vision of the global Opioid", "sentiment": {"score": 0.745452, "label": "positive"}, "relevance": 0.521198, "count": 1}, {"text": "Numerous analytical techniques", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519994, "count": 1}, {"text": "Asia Pacific", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519913, "count": 2}, {"text": "Latin America", "sentiment": {"score": -0.786665, "label": "negative"}, "relevance": 0.519745, "count": 2}, {"text": "regional level", "sentiment": {"score": -0.815332, "label": "negative"}, "relevance": 0.519485, "count": 1}, {"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518771, "count": 1}, {"text": "data source", "sentiment": {"score": -0.866097, "label": "negative"}, "relevance": 0.517386, "count": 1}, {"text": "global market", "sentiment": {"score": -0.866097, "label": "negative"}, "relevance": 0.517152, "count": 1}, {"text": "detail", "sentiment": {"score": -0.450111, "label": "negative"}, "relevance": 0.516957, "count": 1}, {"text": "depth value chain analysis", "sentiment": {"score": 0.745452, "label": "positive"}, "relevance": 0.516908, "count": 1}, {"text": "Drugs market research report", "sentiment": {"score": -0.450111, "label": "negative"}, "relevance": 0.516744, "count": 1}, {"text": "terms of revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516591, "count": 1}, {"text": "development", "sentiment": {"score": -0.450111, "label": "negative"}, "relevance": 0.516242, "count": 1}, {"text": "depth", "sentiment": {"score": 0.659169, "label": "positive"}, "relevance": 0.51523, "count": 1}]}, "extracted_metadata": {"sha1": "a490a6cce5512680d617ef6ea6ab9a8eea56d2a1", "filename": "1542496415100.zip-69afa6f33b637b2dbeb0f772b742a98c.xml", "file_type": "json"}, "external_links": ["http://www.reportsbuzz.com/request-for-sample.html?repid=65996", "http://www.reportsbuzz.com/65996/global-opioid-induced-constipation-oic-drugs-market-outlook/", "http://www.reportsbuzz.com/inquiry-for-buying.html?repid=65996"], "title": "Global Opioid Induced Constipation (OIC) Drugs Market Insights 2018-2025: Ironwood Pharmaceuticals Inc, Daiichi Sankyo Co Ltd", "forum_title": "Blamfluie"}, {"id": "LqfFuz1m8YCDRPqn9OvUEMJARWAgTJAKORXdMKGYMrCQo_TJjMRnFkdkpvIZymvw", "result_metadata": {"score": 31.053009}, "author": "Zehong (Marco) Zhou", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.691407, "label": "negative"}, "text": "Takeda", "relevance": 0.33, "type": "Person"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Deal or No Deal", "relevance": 0.838489, "dbpedia_resource": "http://dbpedia.org/resource/Deal_or_No_Deal"}], "categories": [{"score": 0.764016, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Valeant Drops", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999619, "count": 1}, {"text": "Deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.910005, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.858499, "count": 1}]}, "crawl_date": "2018-11-17T20:54:11Z", "url": "https://www.financialbuzz.com/valeant-drops-after-the-deal-with-takeda-broke-down-630392/", "host": "financialbuzz.com", "text": "(NYSE:VRX) has decided to keep its stomach-drug unit in house after talks to sell Salix to Japan\u2019s Takeda Pharmaceutical Co. broke down.", "main_image_url": "https://www.financialbuzz.com/wp-content/uploads/2018/08/1480542994_valeantt.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2016-11-30T16:56:00-06:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.563797, "label": "negative"}, "text": "Salix", "relevance": 0.956212, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.431286, "label": "negative"}, "text": "Salix Pharmaceuticals", "relevance": 0.616215, "type": "Company", "disambiguation": {"subtype": [], "name": "Salix Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Salix_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.454912, "label": "negative"}, "text": "Valeant Pharmaceuticals International, Inc.", "relevance": 0.42032, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.49773, "label": "negative"}, "text": "Takeda Pharmaceutical Co.", "relevance": 0.408315, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": -0.431286, "label": "negative"}, "text": "Valeant", "relevance": 0.40268, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.431286, "label": "negative"}, "text": "Takeda", "relevance": 0.339324, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.82431, "label": "negative"}, "text": "Valeant", "relevance": 0.320001, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dow Jones", "relevance": 0.282462, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.49773, "label": "negative"}, "text": "Japan", "relevance": 0.271845, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.20246, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$11.1 billion", "relevance": 0.20246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$10 billion", "relevance": 0.20246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$12 billion", "relevance": 0.20246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$30 billion", "relevance": 0.20246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "34 percent", "relevance": 0.20246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "90 percent", "relevance": 0.20246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "8 percent", "relevance": 0.20246, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.79", "relevance": 0.20246, "type": "Quantity"}], "sentiment": {"document": {"score": -0.597217, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Valeant Pharmaceuticals International, Inc. (NYSE:VRX)", "keywords": [{"text": "Valeant Pharmaceuticals"}, {"text": "VRX"}, {"text": "NYSE"}, {"text": "Inc."}], "entities": [{"type": "Company", "text": "Valeant Pharmaceuticals International, Inc."}, {"type": "Company", "text": "NYSE"}]}, "sentence": "Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has decided to keep its stomach-drug unit in house after talks to sell Salix to Japan\u2019s Takeda Pharmaceutical Co. broke down.", "object": {"text": "to keep its stomach-drug unit in house after talks to sell Salix to Japan\u2019s Takeda Pharmaceutical Co. broke down", "keywords": [{"text": "Takeda Pharmaceutical Co."}, {"text": "stomach-drug unit"}, {"text": "Salix"}, {"text": "talks"}], "entities": [{"type": "Company", "text": "Salix"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "decide", "tense": "past"}, "text": "decided", "normalized": "decide"}}, {"subject": {"text": "Valeant Pharmaceuticals International, Inc. (NYSE:VRX)", "keywords": [{"text": "Valeant Pharmaceuticals"}, {"text": "VRX"}, {"text": "NYSE"}, {"text": "Inc."}], "entities": [{"type": "Company", "text": "Valeant Pharmaceuticals International, Inc."}, {"type": "Company", "text": "NYSE"}]}, "sentence": "Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has decided to keep its stomach-drug unit in house after talks to sell Salix to Japan\u2019s Takeda Pharmaceutical Co. broke down.", "object": {"text": "its stomach-drug unit in house", "keywords": [{"text": "stomach-drug unit"}, {"text": "house"}]}, "action": {"verb": {"text": "keep", "tense": "future"}, "text": "has decided to keep", "normalized": "have decide to keep"}}, {"subject": {"text": "Salix", "keywords": [{"text": "Salix"}], "entities": [{"type": "Company", "text": "Salix"}]}, "sentence": "Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has decided to keep its stomach-drug unit in house after talks to sell Salix to Japan\u2019s Takeda Pharmaceutical Co. broke down.", "object": {"text": "to Japan\u2019s Takeda Pharmaceutical Co.", "keywords": [{"text": "Japan\u2019s Takeda"}, {"text": "Pharmaceutical"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "sell", "tense": "future"}, "text": "to sell", "normalized": "to sell"}}, {"subject": {"text": "Valeant", "keywords": [{"text": "Valeant"}], "entities": [{"type": "Person", "text": "Valeant"}]}, "sentence": " Earlier this month, Valeant was reported in talk with Japanese drug maker Takeda to sell Salix Pharmaceuticals for about $10 billion.", "action": {"verb": {"text": "report", "tense": "past"}, "text": "was reported", "normalized": "be report"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Earlier this month, Valeant was reported in talk with Japanese drug maker Takeda to sell Salix Pharmaceuticals for about $10 billion.", "object": {"text": "Salix Pharmaceuticals", "keywords": [{"text": "Salix Pharmaceuticals"}], "entities": [{"type": "Company", "text": "Salix Pharmaceuticals", "disambiguation": {"subtype": [], "name": "Salix Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Salix_Pharmaceuticals"}}]}, "action": {"verb": {"text": "sell", "tense": "future"}, "text": "to sell", "normalized": "to sell"}}, {"subject": {"text": "The rumor", "keywords": [{"text": "rumor"}]}, "sentence": " The rumor sent Valeant\u2019s stock up 34 percent.", "object": {"text": "Valeant\u2019s stock", "keywords": [{"text": "Valeant"}, {"text": "stock"}]}, "action": {"verb": {"text": "send", "tense": "past"}, "text": "sent", "normalized": "send"}}, {"subject": {"text": "The discussions broke down due to the last-minute disagreements over price", "keywords": [{"text": "last-minute disagreements"}, {"text": "discussions"}, {"text": "price"}]}, "sentence": " The discussions broke down due to the last-minute disagreements over price, according to people familiar with the matter.", "object": {"text": "to people familiar with the matter", "keywords": [{"text": "matter"}, {"text": "people"}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "Dow Jones", "keywords": [{"text": "Dow Jones"}], "entities": [{"type": "Person", "text": "Dow Jones"}]}, "sentence": " Dow Jones first reported the news.", "object": {"text": "the news", "keywords": [{"text": "news"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "the sales force for two Salix products, the irritable-bowel drug Xifaxan and constipation treatment Relistor", "keywords": [{"text": "irritable-bowel drug Xifaxan"}, {"text": "constipation treatment Relistor"}, {"text": "Salix products"}], "entities": [{"type": "Company", "text": "Salix"}]}, "sentence": " Valeant on Tuesday said in a news release that it would build the sales force for two Salix products, the irritable-bowel drug Xifaxan and constipation treatment Relistor.", "action": {"verb": {"text": "Valeant", "tense": "past"}, "text": "Valeant", "normalized": "Valeant"}}, {"subject": {"text": "Valeant", "keywords": [{"text": "Valeant"}]}, "sentence": " Valeant on Tuesday said in a news release that it would build the sales force for two Salix products, the irritable-bowel drug Xifaxan and constipation treatment Relistor.", "object": {"text": "that it would build the sales force for two Salix products, the irritable-bowel drug Xifaxan and constipation treatment Relistor", "keywords": [{"text": "irritable-bowel drug Xifaxan"}, {"text": "constipation treatment Relistor"}, {"text": "Salix products"}, {"text": "sales"}], "entities": [{"type": "Company", "text": "Salix"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Valeant shares", "keywords": [{"text": "Valeant shares"}], "entities": [{"type": "Company", "text": "Valeant", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}]}, "sentence": " Valeant shares dropped 8 percent to $15.79 in Wednesday.", "object": {"text": "8 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "8 percent"}]}, "action": {"verb": {"text": "drop", "tense": "past"}, "text": "dropped", "normalized": "drop"}}, {"subject": {"text": "Valeant", "keywords": [{"text": "Valeant"}], "entities": [{"type": "Person", "text": "Valeant"}]}, "sentence": " Valeant bought Salix for $11.1 billion in 2015.", "object": {"text": "Salix", "keywords": [{"text": "Salix"}], "entities": [{"type": "Company", "text": "Salix"}]}, "action": {"verb": {"text": "buy", "tense": "past"}, "text": "bought", "normalized": "buy"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " After that, the company has been suffered from regulatory investigations about its high prices and accounting issues.", "object": {"text": "been suffered from regulatory investigations about its high prices and accounting issues", "keywords": [{"text": "regulatory investigations"}, {"text": "high prices"}, {"text": "accounting issues"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " After that, the company has been suffered from regulatory investigations about its high prices and accounting issues.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " After that, the company has been suffered from regulatory investigations about its high prices and accounting issues.", "object": {"text": "from regulatory investigations about its high prices and accounting issues", "keywords": [{"text": "regulatory investigations"}, {"text": "high prices"}, {"text": "accounting issues"}]}, "action": {"verb": {"text": "suffer", "tense": "past"}, "text": "has been suffered", "normalized": "have be suffer"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock has lost more than 90 percent of its value since its peak in August 2015.", "object": {"text": "lost more than 90 percent of its value since its peak in August 2015", "keywords": [{"text": "percent"}, {"text": "peak"}, {"text": "value"}], "entities": [{"type": "Quantity", "text": "90 percent"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock has lost more than 90 percent of its value since its peak in August 2015.", "object": {"text": "more than 90 percent of its value", "keywords": [{"text": "percent"}, {"text": "value"}], "entities": [{"type": "Quantity", "text": "90 percent"}]}, "action": {"verb": {"text": "lose", "tense": "past"}, "text": "has lost", "normalized": "have lose"}}, {"subject": {"text": "The failure to sell Salix", "keywords": [{"text": "Salix"}, {"text": "failure"}], "entities": [{"type": "Company", "text": "Salix"}]}, "sentence": " The failure to sell Salix make the company under pressure again.", "object": {"text": "the company", "keywords": [{"text": "company"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "make", "normalized": "make"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company now has about $30 billion in debt and it has expected the sale would help pay off about $12 billion debt.", "object": {"text": "about $30 billion in debt", "keywords": [{"text": "debt"}], "entities": [{"type": "Quantity", "text": "$30 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "it"}, "sentence": " The company now has about $30 billion in debt and it has expected the sale would help pay off about $12 billion debt.", "object": {"text": "the sale", "keywords": [{"text": "sale"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has expected", "normalized": "have expect"}}, {"subject": {"text": "it"}, "sentence": " The company now has about $30 billion in debt and it has expected the sale would help pay off about $12 billion debt.", "object": {"text": "the sale would help pay off about $12 billion debt", "keywords": [{"text": "debt"}, {"text": "sale"}], "entities": [{"type": "Quantity", "text": "$12 billion"}]}, "action": {"verb": {"text": "expect", "tense": "past"}, "text": "has expected", "normalized": "have expect"}}, {"subject": {"text": "the sale", "keywords": [{"text": "sale"}]}, "sentence": " The company now has about $30 billion in debt and it has expected the sale would help pay off about $12 billion debt.", "object": {"text": "pay off about $12 billion debt", "keywords": [{"text": "pay"}, {"text": "debt"}], "entities": [{"type": "Quantity", "text": "$12 billion"}]}, "action": {"verb": {"text": "help", "tense": "future"}, "text": "help", "normalized": "help"}}], "concepts": [{"text": "Pharmacology", "relevance": 0.931319, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Valeant Pharmaceuticals International", "relevance": 0.81081, "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals_International"}, {"text": "Pharmaceutical drug", "relevance": 0.803946, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Stock", "relevance": 0.797631, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Ribavirin", "relevance": 0.76545, "dbpedia_resource": "http://dbpedia.org/resource/Ribavirin"}], "categories": [{"score": 0.750164, "label": "/health and fitness/drugs"}, {"score": 0.689851, "label": "/finance/investing/funds/hedge fund"}, {"score": 0.605615, "label": "/finance/financial news"}], "relations": [{"type": "basedIn", "sentence": "Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has decided to keep its stomach-drug unit in house after talks to sell Salix to Japan's Takeda Pharmaceutical Co. broke down.", "score": 0.912059, "arguments": [{"text": "Takeda Pharmaceutical Co.", "location": [143, 168], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [135, 140], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Valeant bought Salix for $11.1 billion in 2015.", "score": 0.548894, "arguments": [{"text": "Valeant", "location": [747, 754], "entities": [{"type": "Organization", "text": "Valeant Pharmaceuticals International, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$11.1 billion", "location": [772, 785], "entities": [{"type": "Money", "text": "$11.1 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Valeant bought Salix for $11.1 billion in 2015.", "score": 0.770523, "arguments": [{"text": "Salix", "location": [762, 767], "entities": [{"type": "Organization", "text": "Salix Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$11.1 billion", "location": [772, 785], "entities": [{"type": "Money", "text": "$11.1 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "The company now has about $30 billion in debt and it has expected the sale would help pay off about $12 billion debt.", "score": 0.845115, "arguments": [{"text": "company", "location": [1066, 1073], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "about $30 billion", "location": [1082, 1099], "entities": [{"type": "Money", "text": "about $30 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Earlier this month, Valeant was reported in talk with Japanese drug maker Takeda to sell Salix Pharmaceuticals for about $10 billion.", "score": 0.877289, "arguments": [{"text": "Valeant", "location": [201, 208], "entities": [{"type": "Organization", "text": "Valeant Pharmaceuticals International, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "reported", "location": [213, 221], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "participantIn", "sentence": "Earlier this month, Valeant was reported in talk with Japanese drug maker Takeda to sell Salix Pharmaceuticals for about $10 billion.", "score": 0.685024, "arguments": [{"text": "Japanese", "location": [235, 243], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "talk", "location": [225, 229], "entities": [{"type": "EventMeeting", "text": "discussions"}]}]}, {"type": "locatedAt", "sentence": "Earlier this month, Valeant was reported in talk with Japanese drug maker Takeda to sell Salix Pharmaceuticals for about $10 billion.", "score": 0.253977, "arguments": [{"text": "drug", "location": [244, 248], "entities": [{"type": "Substance", "text": "drug"}]}, {"text": "Japanese", "location": [235, 243], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "Earlier this month, Valeant was reported in talk with Japanese drug maker Takeda to sell Salix Pharmaceuticals for about $10 billion.", "score": 0.941219, "arguments": [{"text": "Salix Pharmaceuticals", "location": [270, 291], "entities": [{"type": "Organization", "text": "Salix Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "sell", "location": [265, 269], "entities": [{"type": "EventBusiness", "text": "sell"}]}]}, {"type": "hasAttribute", "sentence": "Earlier this month, Valeant was reported in talk with Japanese drug maker Takeda to sell Salix Pharmaceuticals for about $10 billion.", "score": 0.625714, "arguments": [{"text": "Salix Pharmaceuticals", "location": [270, 291], "entities": [{"type": "Organization", "text": "Salix Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "about $10 billion", "location": [296, 313], "entities": [{"type": "Money", "text": "about $10 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Dow Jones first reported the news.", "score": 0.803839, "arguments": [{"text": "Jones", "location": [487, 492], "entities": [{"type": "Organization", "text": "Jones", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "reported", "location": [499, 507], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "timeOf", "sentence": "Valeant on Tuesday said in a news release that it would build the sales force for two Salix products, the irritable-bowel drug Xifaxan and constipation treatment Relistor.", "score": 0.976603, "arguments": [{"text": "Tuesday", "location": [529, 536], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "said", "location": [537, 541], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "hasAttribute", "sentence": "Valeant shares dropped 8 percent to $15.79 in Wednesday.", "score": 0.573908, "arguments": [{"text": "Valeant", "location": [690, 697], "entities": [{"type": "Organization", "text": "Valeant Pharmaceuticals International, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$15.79", "location": [726, 732], "entities": [{"type": "Money", "text": "$15.79", "disambiguation": {"subtype": ["Gainloss"]}}]}]}], "keywords": [{"text": "Valeant Pharmaceuticals International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.879461, "count": 1}, {"text": "rumor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.695786, "count": 1}, {"text": "Valeant", "sentiment": {"score": -0.376382, "label": "negative"}, "relevance": 0.6665, "count": 2}, {"text": "sales force", "sentiment": {"score": -0.513009, "label": "negative"}, "relevance": 0.642272, "count": 1}, {"text": "stomach-drug unit", "sentiment": {"score": -0.893333, "label": "negative"}, "relevance": 0.639484, "count": 1}, {"text": "company", "sentiment": {"score": -0.621986, "label": "negative"}, "relevance": 0.630887, "count": 3}, {"text": "Dow Jones", "sentiment": {"score": 0.448643, "label": "positive"}, "relevance": 0.630601, "count": 1}, {"text": "Salix", "sentiment": {"score": -0.784354, "label": "negative"}, "relevance": 0.622297, "count": 3}, {"text": "Valeant\u2019s stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.614733, "count": 1}, {"text": "news release", "sentiment": {"score": -0.513009, "label": "negative"}, "relevance": 0.599422, "count": 1}, {"text": "talks", "sentiment": {"score": -0.893333, "label": "negative"}, "relevance": 0.577906, "count": 1}, {"text": "Japan\u2019s Takeda Pharmaceutical Co.", "sentiment": {"score": -0.893333, "label": "negative"}, "relevance": 0.572242, "count": 1}, {"text": "failure", "sentiment": {"score": -0.655093, "label": "negative"}, "relevance": 0.57071, "count": 1}, {"text": "Japanese drug maker Takeda", "sentiment": {"score": -0.376382, "label": "negative"}, "relevance": 0.569952, "count": 1}, {"text": "stock", "sentiment": {"score": -0.659453, "label": "negative"}, "relevance": 0.560985, "count": 1}, {"text": "sale", "sentiment": {"score": -0.313266, "label": "negative"}, "relevance": 0.558899, "count": 1}, {"text": "NYSE", "sentiment": {"score": -0.893333, "label": "negative"}, "relevance": 0.557359, "count": 1}, {"text": "high prices", "sentiment": {"score": -0.806507, "label": "negative"}, "relevance": 0.557271, "count": 1}, {"text": "discussions", "sentiment": {"score": -0.648784, "label": "negative"}, "relevance": 0.552181, "count": 1}, {"text": "house", "sentiment": {"score": -0.893333, "label": "negative"}, "relevance": 0.548244, "count": 1}, {"text": "news", "sentiment": {"score": -0.513009, "label": "negative"}, "relevance": 0.547166, "count": 1}, {"text": "Valeant shares", "sentiment": {"score": -0.695573, "label": "negative"}, "relevance": 0.542729, "count": 1}, {"text": "debt", "sentiment": {"score": -0.313266, "label": "negative"}, "relevance": 0.537504, "count": 2}, {"text": "price", "sentiment": {"score": -0.648784, "label": "negative"}, "relevance": 0.534517, "count": 1}, {"text": "Salix Pharmaceuticals", "sentiment": {"score": -0.376382, "label": "negative"}, "relevance": 0.533511, "count": 1}, {"text": "irritable-bowel drug Xifaxan", "sentiment": {"score": -0.513009, "label": "negative"}, "relevance": 0.522316, "count": 1}, {"text": "value", "sentiment": {"score": -0.659453, "label": "negative"}, "relevance": 0.519304, "count": 1}, {"text": "month", "sentiment": {"score": -0.376382, "label": "negative"}, "relevance": 0.517635, "count": 1}, {"text": "peak", "sentiment": {"score": -0.659453, "label": "negative"}, "relevance": 0.515924, "count": 1}, {"text": "pressure", "sentiment": {"score": -0.5082, "label": "negative"}, "relevance": 0.513134, "count": 1}, {"text": "matter", "sentiment": {"score": -0.403049, "mixed": "1", "label": "negative"}, "relevance": 0.513134, "count": 1}, {"text": "Salix products", "sentiment": {"score": -0.513009, "label": "negative"}, "relevance": 0.509547, "count": 1}, {"text": "last-minute disagreements", "sentiment": {"score": -0.648784, "label": "negative"}, "relevance": 0.508282, "count": 1}, {"text": "regulatory investigations", "sentiment": {"score": -0.806507, "label": "negative"}, "relevance": 0.480364, "count": 1}, {"text": "talk", "sentiment": {"score": -0.376382, "label": "negative"}, "relevance": 0.47257, "count": 1}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453186, "count": 1}, {"text": "Tuesday", "sentiment": {"score": -0.513009, "label": "negative"}, "relevance": 0.451796, "count": 1}, {"text": "constipation treatment Relistor", "sentiment": {"score": -0.613563, "label": "negative"}, "relevance": 0.450703, "count": 1}, {"text": "VRX", "sentiment": {"score": -0.893333, "label": "negative"}, "relevance": 0.447679, "count": 1}, {"text": "accounting issues", "sentiment": {"score": -0.738359, "label": "negative"}, "relevance": 0.43565, "count": 1}, {"text": "Wednesday", "sentiment": {"score": -0.695573, "label": "negative"}, "relevance": 0.408187, "count": 1}, {"text": "August", "sentiment": {"score": -0.657071, "label": "negative"}, "relevance": 0.408187, "count": 1}]}, "extracted_metadata": {"sha1": "5e055a842d40609ad474f1e9fd3decb890235854", "filename": "1542488051966.zip-17d615411769d51b293296cf3094102b.xml", "file_type": "json"}, "title": "Valeant Drops after the Deal with Takeda Broke Down", "forum_title": "Market News | Financial Buzz - Part 303"}, {"id": "zAXCHhjU7Ms1BSaKiNFHOeatG9ZlO6jMIyphm7iXa6ejt4cRbZjrtvnCmwlnbd8W", "result_metadata": {"score": 29.73062}, "author": "Stocks News Feed", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostics Markets", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Others", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.869997, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Strategic management", "relevance": 0.853464, "dbpedia_resource": "http://dbpedia.org/resource/Strategic_management"}, {"text": "Trade", "relevance": 0.745527, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "Greek loanwords", "relevance": 0.682598, "dbpedia_resource": "http://dbpedia.org/resource/Greek_loanwords"}], "categories": [{"score": 0.999977, "label": "/science/medicine/oncology"}], "relations": [], "keywords": [{"text": "Companion Diagnostics Markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.996141, "count": 1}, {"text": "Oncology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.783985, "count": 1}, {"text": "Neurology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.769966, "count": 1}, {"text": "Others", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.75324, "count": 1}, {"text": "Global Strategic Business Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.744645, "count": 1}, {"text": "com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594538, "count": 1}, {"text": "\u2013 ResearchAndMarkets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277505, "count": 1}]}, "crawl_date": "2018-11-17T20:47:52Z", "url": "https://stocksnewsfeed.com/companion-diagnostics-markets-2015-2022-oncology-neurology-others-global-strategic-business-report-2018-researchandmarkets-com/", "host": "stocksnewsfeed.com", "text": "Hoffmann-La Roche Ltd.", "main_image_url": "https://i1.wp.com/stocksnewsfeed.com/wp-content/uploads/2018/11/companion-diagnostics-markets-2015-2022-oncology-neurology-others-global-strategic-business-report-2018-researchandmarkets-com.jpg?fit=1200%2C627&amp;ssl=1", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T11:58:00-06:00", "enriched_text": {"entities": [{"count": 23, "sentiment": {"score": -0.42484, "label": "negative"}, "text": "Companion Diagnostics", "relevance": 0.922111, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostics in Oncology", "relevance": 0.308943, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.643894, "label": "negative"}, "text": "CDx Market", "relevance": 0.308817, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostics in Clinical Trials", "relevance": 0.302018, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oncology CDx Testing", "relevance": 0.259588, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Quest Diagnostics, Inc.", "relevance": 0.212509, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.609676, "label": "negative"}, "text": "Cancer", "relevance": 0.1926, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 4, "sentiment": {"score": 0.0904137, "label": "positive"}, "text": "Personalized Medicine", "relevance": 0.186074, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Companion Diagnostic Manufacturer", "relevance": 0.183401, "type": "JobTitle"}, {"count": 5, "sentiment": {"score": -0.464862, "label": "negative"}, "text": "Europe", "relevance": 0.180219, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 4, "sentiment": {"score": 0.452379, "label": "positive"}, "text": "US", "relevance": 0.171813, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 6, "sentiment": {"score": 0.633936, "label": "positive"}, "text": "FDA", "relevance": 0.171441, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb", "relevance": 0.170894, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Laboratory Corporation of America Holdings", "relevance": 0.165172, "type": "Company", "disambiguation": {"subtype": [], "name": "LabCorp", "dbpedia_resource": "http://dbpedia.org/resource/LabCorp"}}, {"count": 3, "sentiment": {"score": 0.619776, "label": "positive"}, "text": "Thermo Fisher Scientific", "relevance": 0.161448, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Thermo Fisher Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}}, {"count": 3, "sentiment": {"score": -0.651164, "label": "negative"}, "text": "Canada", "relevance": 0.15606, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 2, "sentiment": {"score": -0.411196, "label": "negative"}, "text": "Foundation Medicine", "relevance": 0.154411, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.740065, "label": "negative"}, "text": "Breast Cancer", "relevance": 0.147924, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Breast cancer", "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}}, {"count": 1, "sentiment": {"score": 0.256271, "label": "positive"}, "text": "Streamlined Drug Discovery & Development", "relevance": 0.1444, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Aid Cancer Treatment", "relevance": 0.14408, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.317013, "label": "negative"}, "text": "Major Market Driver", "relevance": 0.14276, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.14193, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 2, "sentiment": {"score": -0.411196, "label": "negative"}, "text": "Merck & Co. Inc.", "relevance": 0.140417, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Foundation Medicine, Inc.", "relevance": 0.13532, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.131901, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Danaher Corporation", "relevance": 0.13107, "type": "Company", "disambiguation": {"subtype": [], "name": "Danaher Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Danaher_Corporation"}}, {"count": 1, "sentiment": {"score": 0.329022, "label": "positive"}, "text": "Thermo Fisher Scientific, Inc.", "relevance": 0.128805, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Agilent Technologies, Inc.", "relevance": 0.127697, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Foundation Medicine Inks", "relevance": 0.12725, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.619776, "label": "positive"}, "text": "NeoGenomics", "relevance": 0.126774, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Fully Acquire Foundation Medicine", "relevance": 0.126723, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.125891, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.125545, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche", "relevance": 0.125332, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.125049, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Germany", "dbpedia_resource": "http://dbpedia.org/resource/Germany"}}, {"count": 1, "sentiment": {"score": -0.734861, "label": "negative"}, "text": "Irritable Bowel Disease", "relevance": 0.12504, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Irritable bowel syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Irritable_bowel_syndrome"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Qiagen", "relevance": 0.124804, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cepheid", "relevance": 0.124514, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche", "relevance": 0.122803, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Hoffmann-La Roche", "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.121788, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.121785, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NeoGenomics, Inc.", "relevance": 0.121526, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Adjuvant Treatment Decision", "relevance": 0.121317, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HIV", "relevance": 0.120205, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause", "RiskFactor"], "name": "Virus", "dbpedia_resource": "http://dbpedia.org/resource/Virus"}}, {"count": 1, "sentiment": {"score": 0.673325, "label": "positive"}, "text": "Myriad Bags Manufacturing", "relevance": 0.120155, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Agilent", "relevance": 0.11935, "type": "Company", "disambiguation": {"subtype": [], "name": "Agilent Technologies", "dbpedia_resource": "http://dbpedia.org/resource/Agilent_Technologies"}}, {"count": 1, "sentiment": {"score": 0.528544, "label": "positive"}, "text": "Breakthrough Innovation", "relevance": 0.117385, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Leica Biosystems Nussloch GmbH", "relevance": 0.11503, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Molecular Grade Index", "relevance": 0.114675, "type": "PrintMedia"}], "sentiment": {"document": {"score": 0.872819, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Companion Diagnostics \u2013 Global Strategic Business Report\u201d report", "keywords": [{"text": "Global Strategic Business"}, {"text": "Companion Diagnostics"}, {"text": "report"}]}, "sentence": "DUBLIN\u2013( BUSINESS WIRE )\u2013The \u201cCompanion Diagnostics \u2013 Global Strategic Business Report\u201d report has been added to ResearchAndMarkets.com \u2018s offering.", "object": {"text": "added to ResearchAndMarkets.com \u2018s offering", "keywords": [{"text": "ResearchAndMarkets.com \u2018s offering"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "DUBLIN\u2013( BUSINESS WIRE )\u2013The \u201cCompanion Diagnostics \u2013 Global Strategic Business Report\u201d report", "keywords": [{"text": "Global Strategic Business"}, {"text": "Companion Diagnostics"}, {"text": "BUSINESS WIRE"}, {"text": "DUBLIN\u2013"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}]}, "sentence": "DUBLIN\u2013( BUSINESS WIRE )\u2013The \u201cCompanion Diagnostics \u2013 Global Strategic Business Report\u201d report has been added to ResearchAndMarkets.com \u2018s offering.", "object": {"text": "to ResearchAndMarkets.com \u2018s offering", "keywords": [{"text": "ResearchAndMarkets.com \u2018s offering"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "has been added", "normalized": "have be add"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "object": {"text": "separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World", "keywords": [{"text": "separate comprehensive analytics"}, {"text": "Latin America"}, {"text": "Asia-Pacific"}, {"text": "Rest"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "Annual estimates and forecasts", "keywords": [{"text": "Annual estimates"}, {"text": "forecasts"}]}, "sentence": " Annual estimates and forecasts are provided for the period 2015 through 2022.", "object": {"text": "provided"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Annual estimates and forecasts", "keywords": [{"text": "Annual estimates"}, {"text": "forecasts"}]}, "sentence": " Annual estimates and forecasts are provided for the period 2015 through 2022.", "action": {"verb": {"text": "provide", "tense": "past"}, "text": "are provided", "normalized": "be provide"}}, {"subject": {"text": "a six-year historic analysis", "keywords": [{"text": "six-year historic analysis"}], "entities": [{"type": "Quantity", "text": "six-year"}]}, "sentence": " Also, a six-year historic analysis is provided for these markets.", "object": {"text": "provided for these markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a six-year historic analysis", "keywords": [{"text": "six-year historic analysis"}], "entities": [{"type": "Quantity", "text": "six-year"}]}, "sentence": " Also, a six-year historic analysis is provided for these markets.", "object": {"text": "for these markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "is provided", "normalized": "be provide"}}, {"subject": {"text": "Market data and analytics", "keywords": [{"text": "analytics"}, {"text": "Market data"}]}, "sentence": " Market data and analytics are derived from primary and secondary research.", "object": {"text": "from primary and secondary research", "keywords": [{"text": "secondary research"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "are derived", "normalized": "be derive"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report analyzes the worldwide markets for Companion Diagnostics in US$ Million.", "object": {"text": "the worldwide markets for Companion Diagnostics in US$ Million", "keywords": [{"text": "Companion Diagnostics"}, {"text": "worldwide markets"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}, {"type": "Company", "text": "Companion Diagnostics"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report profiles 80 companies including many key and niche players such as", "object": {"text": "80 companies including many key and niche players", "keywords": [{"text": "niche players"}, {"text": "companies"}]}, "action": {"verb": {"text": "profile", "tense": "present"}, "text": "profiles", "normalized": "profile"}}, {"subject": {"text": "many key and niche players such as", "keywords": [{"text": "niche players"}]}, "sentence": " The report profiles 80 companies including many key and niche players such as", "object": {"text": "80 companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "CDx", "keywords": [{"text": "CDx"}]}, "sentence": " Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development", "object": {"text": "the One-Size-Fits-All Approach", "keywords": [{"text": "One-Size-Fits-All Approach"}]}, "action": {"verb": {"text": "Quashing", "tense": "present"}, "text": "Quashing", "normalized": "Quashing"}}, {"subject": {"text": "Healthy Growth", "keywords": [{"text": "Healthy Growth"}]}, "sentence": " Healthy Growth Projected over the Next Few Years", "action": {"verb": {"text": "Projected", "tense": "past"}, "text": "Projected", "normalized": "Projected"}}, {"subject": {"text": "Northbound Trajectory in R&D Spending", "keywords": [{"text": "Northbound Trajectory"}, {"text": "R&D Spending"}]}, "sentence": " Northbound Trajectory in R&D Spending Creates Conducive Environment", "object": {"text": "Conducive Environment", "keywords": [{"text": "Conducive Environment"}]}, "action": {"verb": {"text": "Creates", "tense": "present"}, "text": "Creates", "normalized": "Creates"}}, {"subject": {"text": "Prevailing Economic Scenario", "keywords": [{"text": "Economic Scenario"}]}, "sentence": " Prevailing Economic Scenario Favors Funding Pattern", "object": {"text": "Funding Pattern", "keywords": [{"text": "Funding Pattern"}]}, "action": {"verb": {"text": "Favors", "tense": "present"}, "text": "Favors", "normalized": "Favors"}}, {"subject": {"text": "Herceptin", "keywords": [{"text": "Herceptin"}]}, "sentence": " Herceptin Lays the Road for Companion Diagnostics", "object": {"text": "the Road", "keywords": [{"text": "Road"}]}, "action": {"verb": {"text": "Lays", "tense": "present"}, "text": "Lays", "normalized": "Lays"}}, {"subject": {"text": "Regulatory Scenario", "keywords": [{"text": "Regulatory Scenario"}]}, "sentence": " Regulatory Scenario Favors CDx Market", "object": {"text": "CDx Market", "keywords": [{"text": "CDx Market"}], "entities": [{"type": "Company", "text": "CDx Market"}]}, "action": {"verb": {"text": "Favors", "tense": "present"}, "text": "Favors", "normalized": "Favors"}}, {"subject": {"text": "them"}, "sentence": " Companion Diagnostics: What Makes them Work", "object": {"text": "Work", "keywords": [{"text": "Work"}]}, "action": {"verb": {"text": "Makes", "tense": "present"}, "text": "Makes", "normalized": "Makes"}}, {"subject": {"text": "Techniques", "keywords": [{"text": "Techniques"}]}, "sentence": " Techniques Used in Companion Diagnostics", "action": {"verb": {"text": "Used", "tense": "past"}, "text": "Used", "normalized": "Used"}}, {"subject": {"text": "Companion Diagnostics", "keywords": [{"text": "Companion Diagnostics"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}]}, "sentence": " Select Companion Diagnostics in Cancer", "object": {"text": "in Cancer", "keywords": [{"text": "Cancer"}], "entities": [{"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "Select", "tense": "present"}, "text": "Select", "normalized": "Select"}}, {"subject": {"text": "Assay", "keywords": [{"text": "Assay"}]}, "sentence": " Trofile Assay to Aid in HIV Treatment", "object": {"text": "to Aid in HIV Treatment", "keywords": [{"text": "HIV Treatment"}, {"text": "Aid"}], "entities": [{"type": "HealthCondition", "text": "HIV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause", "RiskFactor"], "name": "Virus", "dbpedia_resource": "http://dbpedia.org/resource/Virus"}}]}, "action": {"verb": {"text": "Trofile", "tense": "present"}, "text": "Trofile", "normalized": "Trofile"}}, {"subject": {"text": "Players", "keywords": [{"text": "Players"}]}, "sentence": " Leading Players in the World Companion Diagnostics Market", "action": {"verb": {"text": "Leading", "tense": "present"}, "text": "Leading", "normalized": "Leading"}}, {"subject": {"text": "Vendors", "keywords": [{"text": "Vendors"}]}, "sentence": " Vendors Rely on Collaborations to Widen Market Footprint", "object": {"text": "on Collaborations", "keywords": [{"text": "Collaborations"}]}, "action": {"verb": {"text": "Rely", "tense": "present"}, "text": "Rely", "normalized": "Rely"}}, {"subject": {"text": "Foundation Medicine", "keywords": [{"text": "Foundation Medicine"}], "entities": [{"type": "Company", "text": "Foundation Medicine"}]}, "sentence": " Foundation Medicine Unveils FoundationOne CDx", "object": {"text": "FoundationOne CDx", "keywords": [{"text": "FoundationOne CDx"}]}, "action": {"verb": {"text": "Unveils", "tense": "present"}, "text": "Unveils", "normalized": "Unveils"}}, {"subject": {"text": "Roche", "keywords": [{"text": "Roche"}], "entities": [{"type": "Person", "text": "Roche"}]}, "sentence": " Roche to Fully Acquire Foundation Medicine", "object": {"text": "Foundation Medicine", "keywords": [{"text": "Foundation Medicine"}]}, "action": {"verb": {"text": "Acquire", "tense": "present"}, "text": "to Fully Acquire", "normalized": "to Fully Acquire"}}, {"subject": {"text": "Qiagen and Freenome", "keywords": [{"text": "Qiagen"}, {"text": "Freenome"}], "entities": [{"type": "Person", "text": "Qiagen"}]}, "sentence": " Qiagen and Freenome to Develop NGS-based Companion Diagnostics", "object": {"text": "NGS-based Companion Diagnostics", "keywords": [{"text": "NGS-based Companion Diagnostics"}], "entities": [{"type": "Company", "text": "Companion Diagnostics"}]}, "action": {"verb": {"text": "Develop", "tense": "future"}, "text": "to Develop", "normalized": "to Develop"}}, {"subject": {"text": "Foundation Medicine and Merck", "keywords": [{"text": "Merck"}, {"text": "Foundation Medicine"}], "entities": [{"type": "Company", "text": "Foundation Medicine"}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "sentence": " Foundation Medicine and Merck to Develop CDx Tests", "object": {"text": "CDx Tests", "keywords": [{"text": "CDx Tests"}]}, "action": {"verb": {"text": "Develop", "tense": "future"}, "text": "to Develop", "normalized": "to Develop"}}, {"subject": {"text": "NeoGenomics", "keywords": [{"text": "NeoGenomics"}], "entities": [{"type": "Company", "text": "NeoGenomics"}]}, "sentence": " NeoGenomics to Join Thermo Fisher\u2019s CDx Center of Excellence Program", "object": {"text": "Thermo Fisher\u2019s CDx Center of Excellence Program", "keywords": [{"text": "Thermo Fisher"}, {"text": "CDx Center"}, {"text": "Excellence"}, {"text": "Program"}], "entities": [{"type": "Company", "text": "Thermo Fisher Scientific", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Thermo Fisher Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}}, {"type": "Organization", "text": "Center of Excellence Program"}]}, "action": {"verb": {"text": "Join", "tense": "future"}, "text": "to Join", "normalized": "to Join"}}, {"subject": {"text": "Thermo Fisher", "keywords": [{"text": "Thermo Fisher"}], "entities": [{"type": "Company", "text": "Thermo Fisher Scientific", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Thermo Fisher Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}}]}, "sentence": " NeoGenomics to Join Thermo Fisher\u2019s CDx Center of Excellence Program", "object": {"text": "CDx Center of Excellence Program", "keywords": [{"text": "CDx Center"}, {"text": "Excellence"}, {"text": "Program"}], "entities": [{"type": "Organization", "text": "Center of Excellence Program"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Robust Personalized Medicine Market", "keywords": [{"text": "Robust Personalized Medicine"}, {"text": "Market"}]}, "sentence": " Robust Personalized Medicine Market Offers Potential", "object": {"text": "Potential"}, "action": {"verb": {"text": "Offers", "tense": "present"}, "text": "Offers", "normalized": "Offers"}}], "concepts": [{"text": "Hoffmann\u2013La Roche", "relevance": 0.987331, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Pharmaceutical industry", "relevance": 0.868004, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Genentech", "relevance": 0.604098, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Drug development", "relevance": 0.547055, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Breast cancer", "relevance": 0.533679, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Thermo Fisher Scientific", "relevance": 0.528223, "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Fisher_Scientific"}, {"text": "Bristol-Myers Squibb", "relevance": 0.527524, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Food and Drug Administration", "relevance": 0.513326, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Cancer", "relevance": 0.508833, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Fisher Scientific", "relevance": 0.499764, "dbpedia_resource": "http://dbpedia.org/resource/Fisher_Scientific"}, {"text": "Pharmacology", "relevance": 0.47778, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Hoffmann-La Roche", "relevance": 0.452773, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}, {"text": "Thermo Electron", "relevance": 0.43879, "dbpedia_resource": "http://dbpedia.org/resource/Thermo_Electron"}, {"text": "Drug discovery", "relevance": 0.426937, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Benzodiazepine", "relevance": 0.413875, "dbpedia_resource": "http://dbpedia.org/resource/Benzodiazepine"}, {"text": "Oncology", "relevance": 0.387279, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Research support companies", "relevance": 0.385453, "dbpedia_resource": "http://dbpedia.org/resource/Research_support_companies"}, {"text": "Basel", "relevance": 0.382981, "dbpedia_resource": "http://dbpedia.org/resource/Basel"}, {"text": "Medicine", "relevance": 0.373392, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Assay", "relevance": 0.369535, "dbpedia_resource": "http://dbpedia.org/resource/Assay"}, {"text": "Financial markets", "relevance": 0.363566, "dbpedia_resource": "http://dbpedia.org/resource/Financial_markets"}, {"text": "Laboratory equipment", "relevance": 0.361202, "dbpedia_resource": "http://dbpedia.org/resource/Laboratory_equipment"}, {"text": "Clopidogrel", "relevance": 0.349527, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "GlaxoSmithKline", "relevance": 0.34497, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "United States", "relevance": 0.341157, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Generic drug", "relevance": 0.336008, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "Pharmaceutical drug", "relevance": 0.326772, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Test method", "relevance": 0.324328, "dbpedia_resource": "http://dbpedia.org/resource/Test_method"}], "categories": [{"score": 0.921158, "label": "/health and fitness/disease/cancer"}, {"score": 0.763499, "label": "/science/medicine/oncology"}, {"score": 0.753758, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "employedBy", "sentence": "DUBLIN-( BUSINESS WIRE )-The \"Companion Diagnostics - Global Strategic Business Report\" report has been added to ResearchAndMarkets.com \u02bbs offering.", "score": 0.616046, "arguments": [{"text": "Companion Diagnostics", "location": [30, 51], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Global Strategic Business Report", "location": [54, 86], "entities": [{"type": "Organization", "text": "Global Strategic Business Report", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.789002, "arguments": [{"text": "Scope", "location": [1372, 1377], "entities": [{"type": "Person", "text": "Scope"}]}, {"text": "Wield Great Promise for Streamlined Drug Discovery & Development\nBroader", "location": [1299, 1371], "entities": [{"type": "Organization", "text": "Wield Great Promise for Streamlined Drug Discovery & Development\nBroader"}]}]}, {"type": "employedBy", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.39781, "arguments": [{"text": "Witnesses", "location": [1523, 1532], "entities": [{"type": "Person", "text": "Witnesses"}]}, {"text": "Key Revenue Contributors\nMarket", "location": [1491, 1522], "entities": [{"type": "Organization", "text": "Key Revenue Contributors\nMarket", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.981572, "arguments": [{"text": "Fast Paced Growth", "location": [1533, 1550], "entities": [{"type": "Person", "text": "Fast Paced Growth"}]}, {"text": "Witnesses", "location": [1523, 1532], "entities": [{"type": "Person", "text": "Witnesses"}]}]}, {"type": "partOfMany", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.618396, "arguments": [{"text": "Economic Scenario Favors Funding Pattern\n3", "location": [1652, 1694], "entities": [{"type": "Person", "text": "Economic Scenario Favors Funding Pattern\n3"}]}, {"text": "Witnesses", "location": [1523, 1532], "entities": [{"type": "Person", "text": "Witnesses"}]}]}, {"type": "locatedAt", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.515846, "arguments": [{"text": "Fast Paced Growth", "location": [1533, 1550], "entities": [{"type": "Person", "text": "Fast Paced Growth"}]}, {"text": "Northbound Trajectory", "location": [1573, 1594], "entities": [{"type": "Facility", "text": "Northbound Trajectory"}]}]}, {"type": "locatedAt", "sentence": "INDUSTRY OVERVIEW Companion Diagnostics: An Introductory Prelude Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development Broader Scope and Applications Rev Up Growth Opportunities Healthy Growth Projected over the Next Few Years Developed Regions: Key Revenue Contributors Market Witnesses Fast Paced Growth in Developing Regions Northbound Trajectory in R&D Spending Creates Conducive Environment Prevailing Economic Scenario Favors Funding Pattern 3.", "score": 0.951464, "arguments": [{"text": "Northbound Trajectory", "location": [1573, 1594], "entities": [{"type": "Facility", "text": "Northbound Trajectory"}]}, {"text": "Developing Regions", "location": [1554, 1572], "entities": [{"type": "GeopoliticalEntity", "text": "Developing Regions"}]}]}, {"type": "employedBy", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.564321, "arguments": [{"text": "CDx\nEmphasis", "location": [1947, 1959], "entities": [{"type": "Person", "text": "CDx\nEmphasis"}]}, {"text": "CDx Tests Steers Momentum\nHerceptin Lays", "location": [1997, 2037], "entities": [{"type": "Organization", "text": "CDx Tests Steers Momentum\nHerceptin Lays", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.434281, "arguments": [{"text": "CDx\nEmphasis", "location": [1947, 1959], "entities": [{"type": "Person", "text": "CDx\nEmphasis"}]}, {"text": "Road", "location": [2042, 2046], "entities": [{"type": "Facility", "text": "Road"}]}]}, {"type": "employedBy", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.419741, "arguments": [{"text": "Companion Diagnostics", "location": [2445, 2466], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx", "location": [2467, 2609], "entities": [{"type": "Organization", "text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx"}]}]}, {"type": "locatedAt", "sentence": "MARKET TRENDS, GROWTH DRIVERS & ISSUES Growing Significance of Personalized Medicine Remains a Major Market Driver Companion Diagnostics Lead the Way to Personalized Medicine Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum Herceptin Lays the Road for Companion Diagnostics Oncology - Dominant Therapy Area for CDx Rising Incidence of Cancer Propels the Need for CDx Tests Technology Advancements to Widen CDx Use Case PCR: Dominant Technology Type for CDx Testing QuantaLife ddPCR System: Breakthrough Innovation in the PCR CDx Vertical Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing Significant Role of Biomarkers in Companion Diagnostics Critical Healthcare Needs of Aging Population Underpin CDx Sales Regulatory Scenario Favors CDx Market List of Key Market Requirements for CDx in US, Canada and Europe Resolving Prevailing Challenges:", "score": 0.707006, "arguments": [{"text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx", "location": [2467, 2609], "entities": [{"type": "Organization", "text": "Critical Healthcare Needs of Aging Population Underpin CDx Sales\nRegulatory Scenario Favors CDx Market\nList of Key Market Requirements for CDx"}]}, {"text": "US", "location": [2613, 2615], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "score": 0.903349, "arguments": [{"text": "Pacific", "location": [242, 249], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Latin America", "location": [251, 264], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Critical for Future Growth of CDx Market Key Issues in a Nutshell 4.", "score": 0.544116, "arguments": [{"text": "Critical for Future Growth of CDx Market\nKey Issues", "location": [2668, 2719], "entities": [{"type": "Organization", "text": "Critical for Future Growth of CDx Market\nKey Issues"}]}, {"text": "Nutshell\n4", "location": [2725, 2735], "entities": [{"type": "GeopoliticalEntity", "text": "Nutshell\n4"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.742631, "arguments": [{"text": "Companion Diagnostics\nCompanion Diagnostics", "location": [2805, 2848], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Personalized Medicine\nGenetic Tests", "location": [2769, 2804], "entities": [{"type": "Organization", "text": "Personalized Medicine\nGenetic Tests"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.744955, "arguments": [{"text": "Companion Diagnostics", "location": [3060, 3081], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Drug Development Process", "location": [3035, 3059], "entities": [{"type": "Organization", "text": "Drug Development Process"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.627167, "arguments": [{"text": "Companion Diagnostics", "location": [3101, 3122], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Clinical Trials", "location": [3085, 3100], "entities": [{"type": "Organization", "text": "Clinical Trials", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.314304, "arguments": [{"text": "Select Therapeutic", "location": [3126, 3144], "entities": [{"type": "Organization", "text": "Select Therapeutic"}]}, {"text": "Areas", "location": [3145, 3150], "entities": [{"type": "Location", "text": "Areas"}]}]}, {"type": "locatedAt", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.374683, "arguments": [{"text": "Companion Diagnostics", "location": [3151, 3172], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Areas", "location": [3145, 3150], "entities": [{"type": "Location", "text": "Areas"}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.701942, "arguments": [{"text": "Companion Diagnostics", "location": [3192, 3213], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Oncology\nSelect", "location": [3176, 3191], "entities": [{"type": "Organization", "text": "Oncology\nSelect", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.415113, "arguments": [{"text": "Oncotype DX\nQuantitative Recurrence Score\nOncotype DX Test", "location": [3224, 3282], "entities": [{"type": "Person", "text": "Oncotype DX\nQuantitative Recurrence Score\nOncotype DX Test"}]}, {"text": "Cancer", "location": [3217, 3223], "entities": [{"type": "GeopoliticalEntity", "text": "Cancer"}]}]}, {"type": "hasAttribute", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.624131, "arguments": [{"text": "IndexSM", "location": [3442, 3449], "entities": [{"type": "Person", "text": "IndexSM"}]}, {"text": "Breast Cancer", "location": [3428, 3441], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "hasAttribute", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.699588, "arguments": [{"text": "Assays", "location": [3535, 3541], "entities": [{"type": "Person", "text": "Assays"}]}, {"text": "Breast Cancer", "location": [3521, 3534], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "locatedAt", "sentence": "The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "score": 0.524283, "arguments": [{"text": "Latin America", "location": [251, 264], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}, {"text": "World", "location": [278, 283], "entities": [{"type": "GeopoliticalEntity", "text": "World", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "PRODUCT OVERVIEW Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Companion Diagnostics: What Makes them Work Techniques Used in Companion Diagnostics Biomarkers as Companion Diagnostics Applications of Companion Diagnostics at a Glance Role of Companion Diagnostics in the Drug Development Process Companion Diagnostics in Clinical Trials Companion Diagnostics in Select Therapeutic Areas Companion Diagnostics in Oncology Select Companion Diagnostics in Cancer Oncotype DX Quantitative Recurrence Score Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision Eligibility The Test Procedure Molecular Grade Index (MGISM) (bioTheranostics) Breast Cancer IndexSM (bioTheranostics) KRAS Testing HER2 Testing for Herceptin Treatment in Breast Cancer Assays Used for HER2 Testing MammaPrint The EGFRx Assay to Aid Cancer Treatment c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation) Companion Diagnostics in Inflammatory Diseases PROMETHEUS IBD Serology 7", "score": 0.570184, "arguments": [{"text": "Companion Diagnostics", "location": [3676, 3697], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Inflammatory Diseases\nPROMETHEUS IBD Serology 7", "location": [3701, 3748], "entities": [{"type": "Organization", "text": "Inflammatory Diseases\nPROMETHEUS IBD Serology 7"}]}]}, {"type": "hasAttribute", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.905081, "arguments": [{"text": "Companion Diagnostics", "location": [3777, 3798], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Bowel Disease", "location": [3763, 3776], "entities": [{"type": "HealthCondition", "text": "Breast Cancer"}]}]}, {"type": "employedBy", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.392566, "arguments": [{"text": "Companion Diagnostics", "location": [3777, 3798], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Infectious Diseases\nTrofile Assay", "location": [3802, 3835], "entities": [{"type": "Organization", "text": "Infectious Diseases\nTrofile Assay"}]}]}, {"type": "partOf", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.386574, "arguments": [{"text": "Aid", "location": [3839, 3842], "entities": [{"type": "Organization", "text": "Aid Cancer Treatment\nc-Kit pharmDx Assay"}]}, {"text": "Infectious Diseases\nTrofile Assay", "location": [3802, 3835], "entities": [{"type": "Organization", "text": "Infectious Diseases\nTrofile Assay"}]}]}, {"type": "partOf", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.852005, "arguments": [{"text": "CYP450 Test\nHILOmet PhyzioType System", "location": [3911, 3948], "entities": [{"type": "Organization", "text": "CYP450 Test\nHILOmet PhyzioType System"}]}, {"text": "Drug Metabolism\nAmpliChip", "location": [3885, 3910], "entities": [{"type": "Organization", "text": "Drug Metabolism\nAmpliChip"}]}]}, {"type": "employedBy", "sentence": "for Irritable Bowel Disease Companion Diagnostics in Infectious Diseases Trofile Assay to Aid in HIV Treatment Companion Diagnostics in Drug Metabolism AmpliChip CYP450 Test HILOmet PhyzioType System (Genomas) Warfarin Sensitivity Test Companion Diagnostics: In Stakeholders' Perspective Pharmaceutical Company (Drug Manufacturer) Diagnostic Company (Companion Diagnostic Manufacturer) Patients Physician/Healthcare Professional Payer 5.", "score": 0.570465, "arguments": [{"text": "Companion Diagnostic Manufacturer", "location": [4100, 4133], "entities": [{"type": "Person", "text": "Companion Diagnostic Manufacturer"}]}, {"text": "Diagnostic Company", "location": [4080, 4098], "entities": [{"type": "Organization", "text": "Diagnostic Company"}]}]}, {"type": "partOfMany", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.530278, "arguments": [{"text": "Companion Diagnostics Market\nVendors Rely", "location": [4238, 4279], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Players", "location": [4217, 4224], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "participantIn", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.860623, "arguments": [{"text": "Companion Diagnostics Market\nVendors Rely", "location": [4238, 4279], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "World", "location": [4232, 4237], "entities": [{"type": "SportingEvent", "text": "World"}]}]}, {"type": "agentOf", "sentence": "COMPETITIVE LANDSCAPE Leading Players in the World Companion Diagnostics Market Vendors Rely on Collaborations to Widen Market Footprint Select CDx Collaborative Deals Announced in the Recent Past 5.1.", "score": 0.935809, "arguments": [{"text": "Widen Market Footprint\nSelect CDx Collaborative Deals", "location": [4301, 4354], "entities": [{"type": "Organization", "text": "Widen Market Footprint\nSelect CDx Collaborative Deals"}]}, {"text": "Announced", "location": [4355, 4364], "entities": [{"type": "EventCommunication", "text": "Announced"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.735672, "arguments": [{"text": "Dako PD-L1 IHC 22C3 pharmDx Assay", "location": [4527, 4560], "entities": [{"type": "Person", "text": "Dako PD-L1 IHC 22C3 pharmDx Assay"}]}, {"text": "Launches\nFoundation Medicine Unveils FoundationOne CDx\nAgilent Bags FDA Approval for", "location": [4442, 4526], "entities": [{"type": "Organization", "text": "Launches\nFoundation Medicine Unveils FoundationOne CDx\nAgilent Bags FDA Approval for"}]}]}, {"type": "residesIn", "sentence": "The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "score": 0.280592, "arguments": [{"text": "Rest", "location": [270, 274], "entities": [{"type": "Cardinal", "text": "Rest"}]}, {"text": "World", "location": [278, 283], "entities": [{"type": "GeopoliticalEntity", "text": "World", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.52738, "arguments": [{"text": "Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System", "location": [4684, 4765], "entities": [{"type": "Organization", "text": "Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Urothelial Carcinoma\nRoche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test", "location": [4581, 4680], "entities": [{"type": "Organization", "text": "Urothelial Carcinoma\nRoche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test"}]}]}, {"type": "basedIn", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.91448, "arguments": [{"text": "Roche Wins US", "location": [4775, 4788], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [4769, 4774], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.712751, "arguments": [{"text": "FDA", "location": [4789, 4792], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Roche Wins US", "location": [4775, 4788], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.534595, "arguments": [{"text": "Roche Wins US", "location": [4775, 4788], "entities": [{"type": "Organization", "text": "Roche Wins US", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Approval", "location": [4793, 4801], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.9814, "arguments": [{"text": "FDA", "location": [4789, 4792], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Approval", "location": [4793, 4801], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "agentOf", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.625668, "arguments": [{"text": "Test v2", "location": [4826, 4833], "entities": [{"type": "Person", "text": "Test v2"}]}, {"text": "Approval", "location": [4793, 4801], "entities": [{"type": "EventCommunication", "text": "Approval"}]}]}, {"type": "employedBy", "sentence": "Focus on Select Global Players 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis Diagnostic System in Japan Roche Wins US FDA Approval for cobas EGFR Mutation Test v2 as a CDx with IRESSA Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Qiagen and Freenome to Develop NGS-", "score": 0.427874, "arguments": [{"text": "CDx", "location": [4839, 4842], "entities": [{"type": "Person", "text": "CDx\nEmphasis"}]}, {"text": "IRESSA\nMyriad Genetics Bags US FDA Approval for BRACAnalysis CDx\nMolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug\nThermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments", "location": [4848, 5084], "entities": [{"type": "Organization", "text": "IRESSA\nMyriad Genetics Bags US FDA Approval for BRACAnalysis CDx\nMolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug\nThermo Fisher Scientific Receives US FDA Approval for Oncomine Dx Target Test for Three NSCLC Treatments"}]}]}, {"type": "employedBy", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.257144, "arguments": [{"text": "Companion Diagnostics\nBristol-Myers Squibb", "location": [5281, 5323], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Hands", "location": [5330, 5335], "entities": [{"type": "Organization", "text": "Acquire Foundation Medicine\nThermo Fisher Scientific Joins Hands"}]}]}, {"type": "partOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.455009, "arguments": [{"text": "NeoGenomics\nLabCorp Collaborates", "location": [5410, 5442], "entities": [{"type": "Organization", "text": "NeoGenomics\nLabCorp Collaborates"}]}, {"text": "Dx\nPPD forms Strategic Alliance", "location": [5373, 5404], "entities": [{"type": "Organization", "text": "Dx\nPPD forms Strategic Alliance"}]}]}, {"type": "partOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.509417, "arguments": [{"text": "Unilabs\nQIAGEN Teams Up", "location": [5448, 5471], "entities": [{"type": "Organization", "text": "Unilabs\nQIAGEN Teams Up"}]}, {"text": "NeoGenomics\nLabCorp Collaborates", "location": [5410, 5442], "entities": [{"type": "Organization", "text": "NeoGenomics\nLabCorp Collaborates"}]}]}, {"type": "residesIn", "sentence": "This report analyzes the worldwide markets for Companion Diagnostics in US$ Million.", "score": 0.589667, "arguments": [{"text": "Companion Diagnostics", "location": [551, 572], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "US$ Million", "location": [576, 587], "entities": [{"type": "GeopoliticalEntity", "text": "US$ Million"}]}]}, {"type": "managerOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.420241, "arguments": [{"text": "Bliss", "location": [5510, 5515], "entities": [{"type": "Person", "text": "Bliss"}]}, {"text": "Biopharmaceutical\nFoundation Medicine", "location": [5516, 5553], "entities": [{"type": "Organization", "text": "Biopharmaceutical\nFoundation Medicine"}]}]}, {"type": "employedBy", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.482372, "arguments": [{"text": "Join Thermo Fisher", "location": [5708, 5726], "entities": [{"type": "Person", "text": "Join Thermo Fisher"}]}, {"text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility", "location": [5729, 5806], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility"}]}]}, {"type": "locatedAt", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.480631, "arguments": [{"text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility", "location": [5729, 5806], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility"}]}, {"text": "North Carolina", "location": [5810, 5824], "entities": [{"type": "GeopoliticalEntity", "text": "North Carolina"}]}]}, {"type": "partOf", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.538313, "arguments": [{"text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility", "location": [5729, 5806], "entities": [{"type": "Organization", "text": "CDx Center of Excellence Program\nLabCorp Inaugurates New Covance CDx Facility"}]}, {"text": "Bristol-Myers Squibb Joins Hands", "location": [5825, 5857], "entities": [{"type": "Organization", "text": "Acquire Foundation Medicine\nThermo Fisher Scientific Joins Hands"}]}]}, {"type": "basedIn", "sentence": "based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp Inaugurates New Covance CDx Facility in North Carolina Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6.", "score": 0.834266, "arguments": [{"text": "Bristol-Myers Squibb Joins Hands", "location": [5825, 5857], "entities": [{"type": "Organization", "text": "Acquire Foundation Medicine\nThermo Fisher Scientific Joins Hands"}]}, {"text": "North Carolina", "location": [5810, 5824], "entities": [{"type": "GeopoliticalEntity", "text": "North Carolina"}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.574315, "arguments": [{"text": "Diagnostic Capabilities\nGrowing Cancer Incidence \u2013 An Opportunity Indicator", "location": [6118, 6193], "entities": [{"type": "Organization", "text": "Diagnostic Capabilities\nGrowing Cancer Incidence \u2013 An Opportunity Indicator"}]}, {"text": "Pharmaceutical Companies", "location": [6088, 6112], "entities": [{"type": "Organization", "text": "Pharmaceutical Companies"}]}]}, {"type": "authorOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.542309, "arguments": [{"text": "Companion Diagnostics\nList", "location": [6348, 6374], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "Novel Paradigm", "location": [6330, 6344], "entities": [{"type": "TitleWork", "text": "Novel Paradigm"}]}]}, {"type": "employedBy", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.579496, "arguments": [{"text": "Companion Diagnostics\nList", "location": [6348, 6374], "entities": [{"type": "Person", "text": "Companion Diagnostics\nCompanion Diagnostics Augur"}]}, {"text": "US", "location": [6378, 6380], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.638922, "arguments": [{"text": "FDA", "location": [6381, 6384], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "US", "location": [6378, 6380], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.509984, "arguments": [{"text": "Drug Development Fuel Demand\nList of FDA", "location": [6518, 6558], "entities": [{"type": "Organization", "text": "Drug Development Fuel Demand\nList of FDA"}]}, {"text": "Key Market Driver\nCompetitive Scenario\nRegulatory Overview\nFDA Requirements", "location": [6439, 6514], "entities": [{"type": "Organization", "text": "Key Market Driver\nCompetitive Scenario\nRegulatory Overview\nFDA Requirements"}]}]}, {"type": "locatedAt", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular (USA) Agilent Technologies, Inc. (USA) bioMrieux SA (France) Cepheid (USA) Danaher Corporation (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Foundation Medicine, Inc. (USA) Laboratory Corporation of America Holdings (USA) Leica Biosystems Nussloch GmbH (Germany) Merck & Co. Inc. (USA) Myriad Genetics, Inc. (USA) NeoGenomics, Inc. (USA) QIAGEN N.V. (Netherlands) Quest Diagnostics, Inc. (USA) Thermo Fisher Scientific, Inc. (USA) Key Topics Covered: 1.", "score": 0.521136, "arguments": [{"text": "SA", "location": [733, 735], "entities": [{"type": "GeopoliticalEntity", "text": "SA"}]}, {"text": "France", "location": [737, 743], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.225958, "arguments": [{"text": "Higher R&D Spending", "location": [6616, 6635], "entities": [{"type": "Person", "text": "Higher R&D Spending"}]}, {"text": "Canada", "location": [6609, 6615], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "REGIONAL MARKET PERSPECTIVE 7.1 The United States The United States: Prime Market for Companion Diagnostics Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand List of FDA-Approved Companion Diagnostics: As of H1 2018 7.2 Canada Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada:", "score": 0.614724, "arguments": [{"text": "Underpin CDx Revenues\nCancer Incidence", "location": [6639, 6677], "entities": [{"type": "Organization", "text": "Underpin CDx Revenues\nCancer Incidence"}]}, {"text": "Canada", "location": [6681, 6687], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.621434, "arguments": [{"text": "Growth", "location": [6792, 6798], "entities": [{"type": "Person", "text": "Fast Paced Growth"}]}, {"text": "Spurs", "location": [6786, 6791], "entities": [{"type": "Organization", "text": "Spurs", "disambiguation": {"subtype": ["Sports"]}}]}]}, {"type": "locatedAt", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.518667, "arguments": [{"text": "CDx\nCancer Incidence", "location": [6943, 6963], "entities": [{"type": "Organization", "text": "CDx\nCancer Incidence"}]}, {"text": "Europe", "location": [6967, 6973], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.309327, "arguments": [{"text": "Asia-Pacific", "location": [7066, 7078], "entities": [{"type": "Person", "text": "Asia-Pacific"}]}, {"text": "Growing Market\nUptrend", "location": [7089, 7111], "entities": [{"type": "Organization", "text": "Growing Market\nUptrend"}]}]}, {"type": "basedIn", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.860809, "arguments": [{"text": "Breast Cancer CDx", "location": [7167, 7184], "entities": [{"type": "Organization", "text": "Breast Cancer CDx"}]}, {"text": "China", "location": [7161, 7166], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Opportunity Indicator for Companion Diagnostics Regulatory Scenario 7.3 Japan Graying Population Spurs Growth 7.4 Europe A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Cancer Incidence in Europe: An Opportunity Indicator Ageing Population Drives Demand Regulatory Scenario in Europe 7.5 Asia-Pacific A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth 7.5.1 China Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview 7.6 Latin America 7.7 Rest of World 8.", "score": 0.557161, "arguments": [{"text": "Dominant Category\nLaboratory Equipment & Supplies Sector", "location": [7186, 7242], "entities": [{"type": "Organization", "text": "Dominant Category\nLaboratory Equipment & Supplies Sector"}]}, {"text": "China", "location": [7246, 7251], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular (USA) Agilent Technologies, Inc. (USA) bioMrieux SA (France) Cepheid (USA) Danaher Corporation (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Foundation Medicine, Inc. (USA) Laboratory Corporation of America Holdings (USA) Leica Biosystems Nussloch GmbH (Germany) Merck & Co. Inc. (USA) Myriad Genetics, Inc. (USA) NeoGenomics, Inc. (USA) QIAGEN N.V. (Netherlands) Quest Diagnostics, Inc. (USA) Thermo Fisher Scientific, Inc. (USA) Key Topics Covered: 1.", "score": 0.492357, "arguments": [{"text": "Danaher Corporation", "location": [759, 778], "entities": [{"type": "Organization", "text": "Danaher Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "USA", "location": [754, 757], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular (USA) Agilent Technologies, Inc. (USA) bioMrieux SA (France) Cepheid (USA) Danaher Corporation (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Foundation Medicine, Inc. (USA) Laboratory Corporation of America Holdings (USA) Leica Biosystems Nussloch GmbH (Germany) Merck & Co. Inc. (USA) Myriad Genetics, Inc. (USA) NeoGenomics, Inc. (USA) QIAGEN N.V. (Netherlands) Quest Diagnostics, Inc. (USA) Thermo Fisher Scientific, Inc. (USA) Key Topics Covered: 1.", "score": 0.473406, "arguments": [{"text": "F. Hoffmann-La Roche Ltd.", "location": [785, 810], "entities": [{"type": "Organization", "text": "F. Hoffmann-La Roche Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "USA", "location": [780, 783], "entities": [{"type": "Organization", "text": "Danaher Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "The report profiles 80 companies including many key and niche players such as Abbott Molecular (USA) Agilent Technologies, Inc. (USA) bioMrieux SA (France) Cepheid (USA) Danaher Corporation (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Foundation Medicine, Inc. (USA) Laboratory Corporation of America Holdings (USA) Leica Biosystems Nussloch GmbH (Germany) Merck & Co. Inc. (USA) Myriad Genetics, Inc. (USA) NeoGenomics, Inc. (USA) QIAGEN N.V. (Netherlands) Quest Diagnostics, Inc. (USA) Thermo Fisher Scientific, Inc. (USA) Key Topics Covered: 1.", "score": 0.522437, "arguments": [{"text": "QIAGEN N.V.", "location": [1022, 1033], "entities": [{"type": "Person", "text": "QIAGEN N.V."}]}, {"text": "Netherlands", "location": [1035, 1046], "entities": [{"type": "Organization", "text": "Netherlands"}]}]}], "keywords": [{"text": "Companion Diagnostics", "sentiment": {"score": 0.926953, "label": "positive"}, "relevance": 0.669264, "count": 10}, {"text": "USA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.593993, "count": 11}, {"text": "Global Strategic Business Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578751, "count": 1}, {"text": "Agilent Bags FDA Approval", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.576402, "count": 1}, {"text": "Foundation Medicine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565576, "count": 1}, {"text": "Agilent Technologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564135, "count": 1}, {"text": "Abbott Molecular", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562521, "count": 1}, {"text": "Thermo Fisher Scientific", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562299, "count": 1}, {"text": "Myriad Genetics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553855, "count": 1}, {"text": "F. Hoffmann-La Roche Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551013, "count": 1}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549905, "count": 6}, {"text": "QIAGEN N.V.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543619, "count": 1}, {"text": "report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54334, "count": 4}, {"text": "markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542344, "count": 1}, {"text": "Personalized Medicine", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.542169, "count": 1}, {"text": "Co. Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536979, "count": 1}, {"text": "Leica Biosystems Nussloch GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536214, "count": 1}, {"text": "US", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.535415, "count": 3}, {"text": "Latin America", "sentiment": {"score": 0.977743, "label": "positive"}, "relevance": 0.534244, "count": 2}, {"text": "Broader Scope", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.53352, "count": 1}, {"text": "Laboratory Corporation of America Holdings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532939, "count": 1}, {"text": "Product Approvals", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.532131, "count": 1}, {"text": "Significant Cost Reductions", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.532128, "count": 1}, {"text": "Incidence of Cancer", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.531598, "count": 1}, {"text": "United States", "sentiment": {"score": 0.900573, "label": "positive"}, "relevance": 0.531485, "count": 2}, {"text": "Quest Diagnostics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530426, "count": 1}, {"text": "six-year", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525635, "count": 1}, {"text": "CDx", "sentiment": {"score": 0.913859, "label": "positive"}, "relevance": 0.523356, "count": 5}, {"text": "US FDA Approval", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.523184, "count": 2}, {"text": "Danaher Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522902, "count": 1}, {"text": "BUSINESS WIRE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522629, "count": 1}, {"text": "Strategic Alliance", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.521002, "count": 1}, {"text": "Market data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520496, "count": 1}, {"text": "Myriad Bags Manufacturing", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.520291, "count": 1}, {"text": "Merck", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.520193, "count": 2}, {"text": "Breast Cancer", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.518673, "count": 1}, {"text": "Pharmaceutical Company", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.518149, "count": 1}, {"text": "Biomarkers", "sentiment": {"score": 0.916529, "label": "positive"}, "relevance": 0.517309, "count": 2}, {"text": "Thermo Fisher\u2019s CDx Center", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.516995, "count": 1}, {"text": "Recent Past", "sentiment": {"score": 0.844627, "label": "positive"}, "relevance": 0.51663, "count": 1}, {"text": "Switzerland", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516572, "count": 1}, {"text": "EGFRx Assay", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.516531, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51521, "count": 1}, {"text": "Drug Discovery", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.51501, "count": 1}, {"text": "Generation", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.514949, "count": 1}, {"text": "Great Promise", "sentiment": {"score": 0.99514, "label": "positive"}, "relevance": 0.514645, "count": 1}, {"text": "Germany", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514066, "count": 1}, {"text": "Medicine", "sentiment": {"score": 0.96173, "label": "positive"}, "relevance": 0.513937, "count": 2}, {"text": "PCR CDx Vertical", "sentiment": {"score": 0.931702, "label": "positive"}, "relevance": 0.513824, "count": 1}, {"text": "Cancer Treatment", "sentiment": {"score": 0.94398, "label": "positive"}, "relevance": 0.513758, "count": 1}]}, "extracted_metadata": {"sha1": "3b03ba8e1b588288c1fbad5fcf7691a09f4f4172", "filename": "1542487672438.zip-8c641f1b6b3d48ed9b1e60d1ad79405c.xml", "file_type": "json"}, "external_links": ["https://www.businesswire.com/", "https://www.researchandmarkets.com/research/wq6mtw/companion?w=4", "http://www.businesswire.com/news/home/20181116005158/en/Companion-Diagnostics-Markets-2015-2022-Oncology-Neurology--/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa", "http://www.businesswire.com/news/home/20181116005158/en/Companion-Diagnostics-Markets-2015-2022-Oncology-Neurology&#8211;/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa"], "title": "Companion Diagnostics Markets, 2015-2022: Oncology, Neurology & Others \u2013 Global Strategic Business Report 2018 \u2013 ResearchAndMarkets.com", "forum_title": "Business Wire \u2013 Page 14 \u2013 Stocks News Feed"}, {"id": "lvyFGLVIWeNWTzo6qx2vnNeBABPAygCoEWp6e7XihklcmnQ10w8sOZQIX6gPvx5H", "result_metadata": {"score": 28.346882}, "author": "Kyle Jackson", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zacks Investment Research", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.99902, "label": "/finance/investing"}, {"score": 0.99902, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "memberOf", "sentence": "Ovid Therapeutics (OVID) Rating Increased to Buy at Zacks Investment Research", "score": 0.312843, "arguments": [{"text": "Ovid Therapeutics", "location": [0, 17], "entities": [{"type": "Person", "text": "Ovid Therapeutics"}]}, {"text": "OVID", "location": [19, 23], "entities": [{"type": "Organization", "text": "OVID"}]}]}, {"type": "partOf", "sentence": "Ovid Therapeutics (OVID) Rating Increased to Buy at Zacks Investment Research", "score": 0.641514, "arguments": [{"text": "Buy", "location": [45, 48], "entities": [{"type": "Organization", "text": "Buy"}]}, {"text": "Zacks Investment Research", "location": [52, 77], "entities": [{"type": "Organization", "text": "Zacks Investment Research", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Ovid Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999985, "count": 1}, {"text": "OVID", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.739113, "count": 1}, {"text": "Rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.663134, "count": 1}, {"text": "Zacks Investment Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.003029, "count": 1}]}, "crawl_date": "2018-11-17T18:42:41Z", "url": "https://www.watchlistnews.com/ovid-therapeutics-ovid-rating-increased-to-buy-at-zacks-investment-research/2618484.html", "host": "watchlistnews.com", "text": "It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "main_image_url": "https://www.marketbeat.com/logos/ovid-therapeutics-inc-logo.png", "country": "EU", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-17T18:16:00Z", "enriched_text": {"entities": [{"count": 17, "sentiment": {"score": -0.060972, "label": "negative"}, "text": "Ovid Therapeutics Inc.", "relevance": 0.934323, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "OVID", "relevance": 0.342101, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics Company", "relevance": 0.326531, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Get Ovid Therapeutics", "relevance": 0.326239, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics Daily", "relevance": 0.276236, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics", "relevance": 0.271079, "type": "PrintMedia"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zacks Investment Research", "relevance": 0.161705, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.607986, "label": "negative"}, "text": "Angelman syndrome", "relevance": 0.122556, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Angelman syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Angelman_syndrome"}}, {"count": 1, "sentiment": {"score": 0.396221, "label": "positive"}, "text": "Zacks", "relevance": 0.111448, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.433046, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.107626, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": -0.700724, "label": "negative"}, "text": "Fragile X syndrome", "relevance": 0.104564, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Fragile X syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Fragile_X_syndrome"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Acadian Asset Management LLC", "relevance": 0.0949495, "type": "Company", "disambiguation": {"subtype": [], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}, {"count": 2, "sentiment": {"score": -0.42003, "label": "negative"}, "text": "United States", "relevance": 0.0945325, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "JPMorgan Chase & Co.", "relevance": 0.0903979, "type": "Company", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Piper Jaffray Companies", "relevance": 0.0867909, "type": "Company", "disambiguation": {"subtype": [], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "California", "relevance": 0.079735, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.0779593, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "FilmScreeningVenue", "City"], "name": "New York City", "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cantor Fitzgerald", "relevance": 0.0762397, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ValuEngine", "relevance": 0.075993, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.206115, "label": "positive"}, "text": "BidaskClub", "relevance": 0.0720093, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Millennium Management LLC", "relevance": 0.0716241, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dimensional Fund Advisors LP", "relevance": 0.0711707, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MarketBeat.com", "relevance": 0.0642243, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "12-month", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$112.42 million", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$132,000", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$154,000", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$233,000", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$420,000", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$444,000", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$12.44", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$17.58", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$20.00", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "109.8%", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "165.4%", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "25.27%", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "31.09%", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "482.8%", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.07", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.08", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.53", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.60", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.16", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.59", "relevance": 0.0642243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.75", "relevance": 0.0642243, "type": "Quantity"}], "sentiment": {"document": {"score": 0.240712, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "TweetOvid Therapeutics (NASDAQ:OVID)", "keywords": [{"text": "TweetOvid Therapeutics"}, {"text": "NASDAQ"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": "Tweet Ovid Therapeutics (NASDAQ:OVID) was upgraded by Zacks Investment Research from a \u201chold\u201d rating to a \u201cbuy\u201d rating in a research report issued to clients and investors on Thursday.", "object": {"text": "upgraded by Zacks Investment Research from a \u201chold\u201d rating to a \u201cbuy\u201d rating in a research report issued to clients and investors on Thursday", "keywords": [{"text": "Zacks Investment Research"}, {"text": "research report"}, {"text": "Thursday"}, {"text": "investors"}], "entities": [{"type": "Company", "text": "Zacks Investment Research"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Zacks Investment Research", "keywords": [{"text": "Zacks Investment Research"}], "entities": [{"type": "Company", "text": "Zacks Investment Research"}]}, "sentence": "Tweet Ovid Therapeutics (NASDAQ:OVID) was upgraded by Zacks Investment Research from a \u201chold\u201d rating to a \u201cbuy\u201d rating in a research report issued to clients and investors on Thursday.", "object": {"text": "OVID)"}, "action": {"verb": {"text": "upgrade", "tense": "past"}, "text": "was upgraded", "normalized": "be upgrade"}}, {"subject": {"text": "The brokerage", "keywords": [{"text": "brokerage"}]}, "sentence": " The brokerage presently has a $5.75 price objective on the stock.", "object": {"text": "a $5.75 price objective on the stock", "keywords": [{"text": "price"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$5.75"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Zacks Investment Research", "keywords": [{"text": "Zacks Investment Research"}], "entities": [{"type": "Company", "text": "Zacks Investment Research"}]}, "sentence": " Zacks Investment Research \u2018s price objective indicates a potential upside of 25.27% from the stock\u2019s current price.", "object": {"text": "price objective", "keywords": [{"text": "price objective"}]}, "action": {"verb": {"text": "\u2018s", "tense": "present"}, "text": "\u2018s", "normalized": "\u2018s"}}, {"subject": {"text": "Zacks Investment Research \u2018s price objective", "keywords": [{"text": "Zacks Investment Research"}, {"text": "price"}], "entities": [{"type": "Company", "text": "Zacks Investment Research"}]}, "sentence": " Zacks Investment Research \u2018s price objective indicates a potential upside of 25.27% from the stock\u2019s current price.", "object": {"text": "a potential upside of 25.27% from the stock\u2019s current price", "keywords": [{"text": "potential upside"}, {"text": "current price"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "25.27"}]}, "action": {"verb": {"text": "indicate", "tense": "present"}, "text": "indicates", "normalized": "indicate"}}, {"subject": {"text": "current price", "keywords": [{"text": "current price"}]}, "sentence": " Zacks Investment Research \u2018s price objective indicates a potential upside of 25.27% from the stock\u2019s current price.", "object": {"text": "the stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Ovid Therapeutics Inc.", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " According to Zacks, \u201cOvid Therapeutics Inc. is a biopharmaceutical company.", "object": {"text": "a biopharmaceutical company", "keywords": [{"text": "biopharmaceutical company"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company\u2019s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome.", "object": {"text": "product pipeline", "keywords": [{"text": "product pipeline"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The company\u2019s product pipeline", "keywords": [{"text": "product pipeline"}, {"text": "company"}]}, "sentence": " The company\u2019s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome.", "object": {"text": "of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome", "keywords": [{"text": "Angelman syndrome"}, {"text": "Fragile X syndrome"}, {"text": "development"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Angelman syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Angelman syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Angelman_syndrome"}}, {"type": "HealthCondition", "text": "Fragile X syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Fragile X syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Fragile_X_syndrome"}}]}, "action": {"verb": {"text": "consist", "tense": "present"}, "text": "consists", "normalized": "consist"}}, {"subject": {"text": "The company\u2019s product pipeline consists of OV101,", "keywords": [{"text": "product pipeline"}, {"text": "company"}]}, "sentence": " The company\u2019s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome.", "object": {"text": "in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome", "keywords": [{"text": "Angelman syndrome"}, {"text": "Fragile X syndrome"}, {"text": "development"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Angelman syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Angelman syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Angelman_syndrome"}}, {"type": "HealthCondition", "text": "Fragile X syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Fragile X syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Fragile_X_syndrome"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "object": {"text": "in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies", "keywords": [{"text": "rare epileptic encephalopathies"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "collaboration"}, {"text": "Limited"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "It"}, "sentence": " It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "object": {"text": "OV935", "keywords": [{"text": "OV935"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "Ovid Therapeutics Inc.", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " Ovid Therapeutics Inc. is based in New York, United States.", "object": {"text": "based in New York, United States", "keywords": [{"text": "New York"}, {"text": "United States"}], "entities": [{"type": "Location", "text": "New York", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "City"], "name": "New York City", "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Ovid Therapeutics Inc.", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " Ovid Therapeutics Inc. is based in New York, United States.", "action": {"verb": {"text": "base", "tense": "past"}, "text": "is based", "normalized": "be base"}}, {"subject": {"text": "Several other equities research analysts", "keywords": [{"text": "equities research analysts"}]}, "sentence": " Several other equities research analysts have also recently issued reports on OVID.", "object": {"text": "reports", "keywords": [{"text": "reports"}]}, "action": {"verb": {"text": "issue", "tense": "past"}, "text": "issued", "normalized": "issue"}}, {"subject": {"text": "ValuEngine", "keywords": [{"text": "ValuEngine"}], "entities": [{"type": "Company", "text": "ValuEngine"}]}, "sentence": " ValuEngine cut shares of Ovid Therapeutics from a \u201chold\u201d rating to a \u201csell\u201d rating in a research note on Wednesday, August 8th.", "object": {"text": "shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "cut", "tense": "past"}, "text": "cut", "normalized": "cut"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " ValuEngine cut shares of Ovid Therapeutics from a \u201chold\u201d rating to a \u201csell\u201d rating in a research note on Wednesday, August 8th.", "object": {"text": "to a \u201csell\u201d rating in a research note", "keywords": [{"text": "research note"}, {"text": "sell"}, {"text": "rating"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Cantor Fitzgerald", "keywords": [{"text": "Cantor Fitzgerald"}], "entities": [{"type": "Person", "text": "Cantor Fitzgerald"}]}, "sentence": " Cantor Fitzgerald began coverage on shares of Ovid Therapeutics in a research note on Wednesday.", "object": {"text": "coverage on shares of Ovid Therapeutics in a research note", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "research note"}, {"text": "coverage"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "begin", "tense": "past"}, "text": "began", "normalized": "begin"}}, {"subject": {"text": "They"}, "sentence": " They set an \u201coverweight\u201d rating on the stock.", "object": {"text": "an \u201coverweight\u201d rating on the stock", "keywords": [{"text": "overweight"}, {"text": "rating"}, {"text": "stock"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Piper Jaffray Companies", "keywords": [{"text": "Piper Jaffray Companies"}], "entities": [{"type": "Company", "text": "Piper Jaffray Companies", "disambiguation": {"subtype": ["Company"], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}]}, "sentence": " Piper Jaffray Companies set a $20.00 target price on shares of Ovid Therapeutics and gave the stock a \u201cbuy\u201d rating in a research note on Sunday, August 12th.", "object": {"text": "a $20.00 target price", "keywords": [{"text": "target price"}], "entities": [{"type": "Quantity", "text": "$20.00"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Piper Jaffray Companies", "keywords": [{"text": "Piper Jaffray Companies"}], "entities": [{"type": "Company", "text": "Piper Jaffray Companies", "disambiguation": {"subtype": ["Company"], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}]}, "sentence": " Piper Jaffray Companies set a $20.00 target price on shares of Ovid Therapeutics and gave the stock a \u201cbuy\u201d rating in a research note on Sunday, August 12th.", "object": {"text": "a \u201cbuy\u201d rating in a research note", "keywords": [{"text": "research note"}, {"text": "buy"}, {"text": "rating"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "gave", "normalized": "give"}}, {"subject": {"text": "BidaskClub", "keywords": [{"text": "BidaskClub"}], "entities": [{"type": "Company", "text": "BidaskClub"}]}, "sentence": " Finally, BidaskClub cut shares of Ovid Therapeutics from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research note on Friday, July 27th.", "object": {"text": "shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "cut", "tense": "past"}, "text": "cut", "normalized": "cut"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Finally, BidaskClub cut shares of Ovid Therapeutics from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research note on Friday, July 27th.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Three research analysts", "keywords": [{"text": "research analysts"}]}, "sentence": " Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company\u2019s stock.", "object": {"text": "the stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "rate", "tense": "past"}, "text": "have rated", "normalized": "have rate"}}, {"subject": {"text": "four"}, "sentence": " Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company\u2019s stock.", "object": {"text": "given a buy rating to the company\u2019s stock", "keywords": [{"text": "buy rating"}, {"text": "company"}, {"text": "stock"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company presently has an average rating of \u201cBuy\u201d and an average target price of $17.58.", "object": {"text": "an average rating of \u201cBuy\u201d and an average target price of $17.58", "keywords": [{"text": "average target price"}, {"text": "average rating"}], "entities": [{"type": "Quantity", "text": "$17.58"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "NASDAQ OVID", "keywords": [{"text": "NASDAQ OVID"}], "entities": []}, "sentence": " NASDAQ OVID traded up $0.08 on Thursday, hitting $4.59.", "action": {"verb": {"text": "trade", "tense": "past"}, "text": "traded", "normalized": "trade"}}, {"subject": {"text": "NASDAQ OVID", "keywords": [{"text": "NASDAQ OVID"}], "entities": []}, "sentence": " NASDAQ OVID traded up $0.08 on Thursday, hitting $4.59.", "object": {"text": "$4.59", "entities": [{"type": "Quantity", "text": "$4.59"}]}, "action": {"verb": {"text": "hit", "tense": "present"}, "text": "hitting", "normalized": "hit"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company had a trading volume of 23,911 shares, compared to its average volume of 52,051.", "object": {"text": "a trading volume of 23,911 shares", "keywords": [{"text": "trading volume"}, {"text": "shares"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "a trading volume of 23,911 shares", "keywords": [{"text": "trading volume"}, {"text": "shares"}]}, "sentence": " The company had a trading volume of 23,911 shares, compared to its average volume of 52,051.", "object": {"text": "to its average volume of 52,051", "keywords": [{"text": "average volume"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " Ovid Therapeutics has a 12-month low of $4.16 and a 12-month high of $12.44.", "object": {"text": "a 12-month low of $4.16 and a 12-month high of $12.44", "keywords": [{"text": "12-month high"}], "entities": [{"type": "Quantity", "text": "12-month"}, {"type": "Quantity", "text": "$12.44"}, {"type": "Quantity", "text": "$4.16"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm has a market cap of $112.42 million, a PE ratio of -1.37 and a beta of 1.15.", "object": {"text": "a market cap of $112.42 million, a PE ratio of -1.37 and a beta of 1.15", "keywords": [{"text": "PE ratio"}, {"text": "market cap"}, {"text": "beta"}], "entities": [{"type": "Quantity", "text": "$112.42 million"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ovid Therapeutics (NASDAQ:OVID)", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "NASDAQ"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}, {"type": "Organization", "text": "OVID"}]}, "sentence": " Ovid Therapeutics (NASDAQ:OVID) last announced its earnings results on Thursday, November 8th.", "object": {"text": "its earnings results", "keywords": [{"text": "earnings results"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.07.", "object": {"text": "$0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.07", "keywords": [{"text": "consensus estimate"}, {"text": "earnings"}, {"text": "quarter"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "$0.07"}, {"type": "Quantity", "text": "$0.53"}, {"type": "Quantity", "text": "$0.60"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "research analysts", "keywords": [{"text": "research analysts"}]}, "sentence": " As a group, research analysts predict that Ovid Therapeutics will post -2.1 EPS for the current fiscal year.", "object": {"text": "that Ovid Therapeutics will post -2.1 EPS for the current fiscal year", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "EPS"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "predict", "tense": "present"}, "text": "predict", "normalized": "predict"}}, {"subject": {"text": "A number of institutional investors and hedge funds", "keywords": [{"text": "institutional investors"}, {"text": "number"}, {"text": "funds"}], "entities": []}, "sentence": " A number of institutional investors and hedge funds have recently made changes to their positions in OVID.", "object": {"text": "recently made changes to their positions in OVID", "keywords": [{"text": "OVID"}, {"text": "positions"}, {"text": "changes"}], "entities": [{"type": "Organization", "text": "OVID"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "A number of institutional investors and hedge funds", "keywords": [{"text": "institutional investors"}, {"text": "number"}, {"text": "funds"}], "entities": []}, "sentence": " A number of institutional investors and hedge funds have recently made changes to their positions in OVID.", "object": {"text": "changes", "keywords": [{"text": "changes"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "California State Teachers Retirement System", "keywords": [{"text": "State Teachers Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "sentence": " California State Teachers Retirement System boosted its stake in Ovid Therapeutics by 109.8% during the 1st quarter.", "object": {"text": "its stake in Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "stake"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "boost", "tense": "past"}, "text": "boosted", "normalized": "boost"}}, {"subject": {"text": "California State Teachers Retirement System", "keywords": [{"text": "State Teachers Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "sentence": " California State Teachers Retirement System now owns 18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the last quarter.", "object": {"text": "18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the last quarter", "keywords": [{"text": "shares"}, {"text": "quarter"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$132,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " California State Teachers Retirement System now owns 18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the last quarter.", "object": {"text": "stock worth $132,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$132,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "California State Teachers Retirement System", "keywords": [{"text": "State Teachers Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "sentence": " California State Teachers Retirement System now owns 18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the last quarter.", "object": {"text": "an additional 9,776 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "Acadian Asset Management LLC", "keywords": [{"text": "Acadian Asset Management"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Acadian Asset Management LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}]}, "sentence": " Acadian Asset Management LLC boosted its position in shares of Ovid Therapeutics by 165.4% during the 2nd quarter.", "object": {"text": "its position in shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "position"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "boost", "tense": "past"}, "text": "boosted", "normalized": "boost"}}, {"subject": {"text": "Acadian Asset Management LLC", "keywords": [{"text": "Acadian Asset Management"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Acadian Asset Management LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}]}, "sentence": " Acadian Asset Management LLC now owns 19,729 shares of the company\u2019s stock valued at $154,000 after acquiring an additional 12,294 shares during the last quarter.", "object": {"text": "19,729 shares of the company\u2019s stock valued at $154,000", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$154,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Acadian Asset Management LLC now owns 19,729 shares of the company\u2019s stock valued at $154,000 after acquiring an additional 12,294 shares during the last quarter.", "object": {"text": "stock valued at $154,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$154,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Acadian Asset Management LLC", "keywords": [{"text": "Acadian Asset Management"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Acadian Asset Management LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}]}, "sentence": " Acadian Asset Management LLC now owns 19,729 shares of the company\u2019s stock valued at $154,000 after acquiring an additional 12,294 shares during the last quarter.", "object": {"text": "an additional 12,294 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "acquire", "tense": "present"}, "text": "acquiring", "normalized": "acquire"}}, {"subject": {"text": "JPMorgan Chase & Co.", "keywords": [{"text": "JPMorgan Chase"}], "entities": [{"type": "Company", "text": "JPMorgan Chase & Co.", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}]}, "sentence": " JPMorgan Chase & Co. boosted its position in shares of Ovid Therapeutics by 482.8% during the 1st quarter.", "object": {"text": "its position in shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "position"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "boost", "tense": "past"}, "text": "boosted", "normalized": "boost"}}, {"subject": {"text": "JPMorgan Chase & Co.", "keywords": [{"text": "JPMorgan Chase"}], "entities": [{"type": "Company", "text": "JPMorgan Chase & Co.", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}]}, "sentence": " JPMorgan Chase & Co. now owns 33,006 shares of the company\u2019s stock valued at $233,000 after acquiring an additional 27,343 shares during the last quarter.", "object": {"text": "33,006 shares of the company\u2019s stock valued at $233,000", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$233,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " JPMorgan Chase & Co. now owns 33,006 shares of the company\u2019s stock valued at $233,000 after acquiring an additional 27,343 shares during the last quarter.", "object": {"text": "stock valued at $233,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$233,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "JPMorgan Chase & Co.", "keywords": [{"text": "JPMorgan Chase"}], "entities": [{"type": "Company", "text": "JPMorgan Chase & Co.", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}]}, "sentence": " JPMorgan Chase & Co. now owns 33,006 shares of the company\u2019s stock valued at $233,000 after acquiring an additional 27,343 shares during the last quarter.", "object": {"text": "an additional 27,343 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "acquire", "tense": "present"}, "text": "acquiring", "normalized": "acquire"}}, {"subject": {"text": "Millennium Management LLC", "keywords": [{"text": "Millennium Management LLC"}], "entities": [{"type": "Company", "text": "Millennium Management LLC"}]}, "sentence": " Millennium Management LLC acquired a new position in shares of Ovid Therapeutics during the 1st quarter valued at about $420,000.", "object": {"text": "a new position in shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "new position"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "acquired", "normalized": "acquire"}}], "concepts": [{"text": "Neurological disorders", "relevance": 0.912429, "dbpedia_resource": "http://dbpedia.org/resource/Neurological_disorders"}, {"text": "Syndromes", "relevance": 0.886267, "dbpedia_resource": "http://dbpedia.org/resource/Syndromes"}, {"text": "Financial services", "relevance": 0.826835, "dbpedia_resource": "http://dbpedia.org/resource/Financial_services"}, {"text": "Clinical trial", "relevance": 0.82506, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "JPMorgan Chase", "relevance": 0.793973, "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.723908, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Piper Jaffray", "relevance": 0.718004, "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}, {"text": "Stock", "relevance": 0.692677, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Stock market", "relevance": 0.691342, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}], "categories": [{"score": 0.821961, "label": "/finance/investing"}, {"score": 0.821961, "label": "/finance/investing/beginning investing"}, {"score": 0.702026, "label": "/health and fitness/disease/autism and pdd"}], "relations": [{"type": "hasAttribute", "sentence": "It engaged in developing therapies for patients with rare neurological disorders.", "score": 0.892415, "arguments": [{"text": "patients", "location": [482, 490], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "neurological disorders", "location": [501, 523], "entities": [{"type": "HealthCondition", "text": "neurological disorders"}]}]}, {"type": "partOf", "sentence": "California State Teachers Retirement System boosted its stake in Ovid Therapeutics by 109.8% during the 1st quarter.", "score": 0.972218, "arguments": [{"text": "State Teachers Retirement System", "location": [2536, 2568], "entities": [{"type": "Organization", "text": "State Teachers Retirement System"}]}, {"text": "California", "location": [2525, 2535], "entities": [{"type": "GeopoliticalEntity", "text": "California"}]}]}, {"type": "partOf", "sentence": "California State Teachers Retirement System now owns 18,676 shares of the company's stock worth $132,000 after purchasing an additional 9,776 shares during the last quarter.", "score": 0.99566, "arguments": [{"text": "State Teachers Retirement System", "location": [2653, 2685], "entities": [{"type": "Organization", "text": "State Teachers Retirement System"}]}, {"text": "California", "location": [2642, 2652], "entities": [{"type": "GeopoliticalEntity", "text": "California"}]}]}, {"type": "agentOf", "sentence": "Millennium Management LLC acquired a new position in shares of Ovid Therapeutics during the 1st quarter valued at about $420,000.", "score": 0.888633, "arguments": [{"text": "Millennium Management LLC", "location": [3356, 3381], "entities": [{"type": "Organization", "text": "Millennium Management LLC", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [3382, 3390], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Millennium Management LLC acquired a new position in shares of Ovid Therapeutics during the 1st quarter valued at about $420,000.", "score": 0.923421, "arguments": [{"text": "1st quarter", "location": [3448, 3459], "entities": [{"type": "Date", "text": "1st quarter"}]}, {"text": "acquired", "location": [3382, 3390], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "agentOf", "sentence": "Finally, Dimensional Fund Advisors LP acquired a new position in shares of Ovid Therapeutics during the 3rd quarter valued at about $444,000.", "score": 0.890667, "arguments": [{"text": "Dimensional Fund Advisors LP", "location": [3495, 3523], "entities": [{"type": "Organization", "text": "Dimensional Fund Advisors LP", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [3524, 3532], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Finally, Dimensional Fund Advisors LP acquired a new position in shares of Ovid Therapeutics during the 3rd quarter valued at about $444,000.", "score": 0.923421, "arguments": [{"text": "3rd quarter", "location": [3590, 3601], "entities": [{"type": "Date", "text": "3rd quarter"}]}, {"text": "acquired", "location": [3524, 3532], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "employedBy", "sentence": "Ovid Therapeutics Company Profile Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.", "score": 0.838607, "arguments": [{"text": "Profile\nOvid Therapeutics Inc", "location": [3721, 3750], "entities": [{"type": "Person", "text": "Profile\nOvid Therapeutics Inc"}]}, {"text": "Company", "location": [3713, 3720], "entities": [{"type": "Organization", "text": "Company"}]}]}, {"type": "hasAttribute", "sentence": "Ovid Therapeutics Company Profile Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.", "score": 0.531649, "arguments": [{"text": "families", "location": [3827, 3835], "entities": [{"type": "Person", "text": "families"}]}, {"text": "neurological disorders", "location": [3841, 3863], "entities": [{"type": "HealthCondition", "text": "neurological disorders"}]}]}, {"type": "partOfMany", "sentence": "The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.", "score": 0.458802, "arguments": [{"text": "I", "location": [4025, 4026], "entities": [{"type": "Person", "text": "I"}]}, {"text": "adolescents", "location": [4046, 4057], "entities": [{"type": "Person", "text": "adolescents"}]}]}, {"type": "participantIn", "sentence": "It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "score": 0.915883, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [737, 774], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "collaboration", "location": [718, 731], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}]}, {"type": "locatedAt", "sentence": "Ovid Therapeutics Inc. is based in New York, United States.", "score": 0.305737, "arguments": [{"text": "Ovid Therapeutics Inc.", "location": [829, 851], "entities": [{"type": "Person", "text": "Ovid Therapeutics Inc."}]}, {"text": "New York", "location": [864, 872], "entities": [{"type": "GeopoliticalEntity", "text": "New York"}]}]}, {"type": "hasAttribute", "sentence": "Piper Jaffray Companies set a $20.00 target price on shares of Ovid Therapeutics and gave the stock a \"buy\" rating in a research note on Sunday, August 12th.", "score": 0.521186, "arguments": [{"text": "Piper Jaffray Companies", "location": [1276, 1299], "entities": [{"type": "Organization", "text": "Piper Jaffray Companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$20.00", "location": [1306, 1312], "entities": [{"type": "Money", "text": "$20.00"}]}]}, {"type": "hasAttribute", "sentence": "NASDAQ OVID traded up $0.08 on Thursday, hitting $4.59.", "score": 0.505022, "arguments": [{"text": "OVID", "location": [1786, 1790], "entities": [{"type": "Person", "text": "Ovid Therapeutics Inc."}]}, {"text": "$0.08", "location": [1801, 1806], "entities": [{"type": "Money", "text": "$0.08"}]}]}, {"type": "timeOf", "sentence": "Ovid Therapeutics (NASDAQ:OVID) last announced its earnings results on Thursday, November 8th.", "score": 0.81359, "arguments": [{"text": "NASDAQ:OVID", "location": [2110, 2121], "entities": [{"type": "Time", "text": "NASDAQ:OVID"}]}, {"text": "announced", "location": [2128, 2137], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "timeOf", "sentence": "Ovid Therapeutics (NASDAQ:OVID) last announced its earnings results on Thursday, November 8th.", "score": 0.570726, "arguments": [{"text": "Thursday", "location": [2162, 2170], "entities": [{"type": "Date", "text": "November 8th"}]}, {"text": "announced", "location": [2128, 2137], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.07.", "score": 0.993814, "arguments": [{"text": "company", "location": [2190, 2197], "entities": [{"type": "Organization", "text": "Company"}]}, {"text": "reported", "location": [2198, 2206], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "memberOf", "sentence": "As a group, research analysts predict that Ovid Therapeutics will post -2.1 EPS for the current fiscal year.", "score": 0.382906, "arguments": [{"text": "research analysts", "location": [2321, 2338], "entities": [{"type": "Person", "text": "research analysts"}]}, {"text": "group", "location": [2314, 2319], "entities": [{"type": "Organization", "text": "group"}]}]}], "keywords": [{"text": "Ovid Therapeutics Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.779895, "count": 2}, {"text": "biopharmaceutical company", "sentiment": {"score": -0.574727, "label": "negative"}, "relevance": 0.721961, "count": 2}, {"text": "Zacks Investment Research", "sentiment": {"score": 0.817169, "label": "positive"}, "relevance": 0.688295, "count": 3}, {"text": "ValuEngine cut shares of Ovid Therapeutics", "sentiment": {"score": -0.655534, "label": "negative"}, "relevance": 0.664387, "count": 1}, {"text": "OVID", "sentiment": {"score": 0.55707, "mixed": "1", "label": "positive"}, "relevance": 0.642337, "count": 5}, {"text": "research report", "sentiment": {"score": 0.790135, "label": "positive"}, "relevance": 0.609032, "count": 1}, {"text": "company\u2019s product pipeline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.602996, "count": 1}, {"text": "JPMorgan Chase", "sentiment": {"score": -0.396195, "label": "negative"}, "relevance": 0.596938, "count": 2}, {"text": "Ovid Therapeutics alerts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.592581, "count": 1}, {"text": "Acadian Asset Management LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589617, "count": 2}, {"text": "shares of Ovid Therapeutics", "sentiment": {"score": 0.408476, "mixed": "1", "label": "positive"}, "relevance": 0.576421, "count": 7}, {"text": "Cantor Fitzgerald", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573098, "count": 1}, {"text": "United States", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.564411, "count": 2}, {"text": "California State Teachers Retirement System", "sentiment": {"score": -0.263316, "label": "negative"}, "relevance": 0.559175, "count": 2}, {"text": "hedge funds", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5582, "count": 1}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554476, "count": 1}, {"text": "Piper Jaffray Companies", "sentiment": {"score": 0.59095, "label": "positive"}, "relevance": 0.551136, "count": 1}, {"text": "company", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.546851, "count": 4}, {"text": "equities research analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.545772, "count": 1}, {"text": "clinical trial", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.545306, "count": 2}, {"text": "stock", "sentiment": {"score": 0.420243, "mixed": "1", "label": "positive"}, "relevance": 0.544667, "count": 8}, {"text": "email address", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.54408, "count": 1}, {"text": "average rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541614, "count": 1}, {"text": "related companies", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.540951, "count": 1}, {"text": "hold rating", "sentiment": {"score": 0.521368, "label": "positive"}, "relevance": 0.540509, "count": 1}, {"text": "shares", "sentiment": {"score": -0.330828, "label": "negative"}, "relevance": 0.53706, "count": 4}, {"text": "positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534409, "count": 1}, {"text": "position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534409, "count": 2}, {"text": "share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5309, "count": 1}, {"text": "NASDAQ", "sentiment": {"score": 0.790135, "label": "positive"}, "relevance": 0.530883, "count": 2}, {"text": "com Receive News", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.530378, "count": 1}, {"text": "OV101", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.526794, "count": 2}, {"text": "Fragile X syndrome", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526356, "count": 1}, {"text": "reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523846, "count": 1}, {"text": "institutional investors", "sentiment": {"score": -0.571438, "label": "negative"}, "relevance": 0.522541, "count": 1}, {"text": "Ratings", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.521531, "count": 1}, {"text": "angelman syndrome", "sentiment": {"score": -0.289765, "mixed": "1", "label": "negative"}, "relevance": 0.520356, "count": 2}, {"text": "Co.", "sentiment": {"score": -0.396195, "label": "negative"}, "relevance": 0.520089, "count": 2}, {"text": "free copy of the Zacks research report", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.520002, "count": 1}, {"text": "firm", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519703, "count": 1}, {"text": "information", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.518402, "count": 1}, {"text": "Phase", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.518385, "count": 2}, {"text": "investors", "sentiment": {"score": 0.790135, "label": "positive"}, "relevance": 0.518319, "count": 1}, {"text": "price objective", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518115, "count": 1}, {"text": "collaboration", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51633, "count": 1}, {"text": "group", "sentiment": {"score": -0.377726, "label": "negative"}, "relevance": 0.516224, "count": 1}, {"text": "brokerage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515227, "count": 1}, {"text": "neurological disorders", "sentiment": {"score": -0.574368, "label": "negative"}, "relevance": 0.513783, "count": 1}, {"text": "patients", "sentiment": {"score": -0.574727, "label": "negative"}, "relevance": 0.513595, "count": 2}, {"text": "earnings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513492, "count": 1}]}, "extracted_metadata": {"sha1": "63b3cd93890f08fafd638aed40e6f86dda0a67fe", "filename": "1542480161488.zip-d0fd8c31f7461a67c3ec209f18f958ef.xml", "file_type": "json"}, "external_links": ["http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1", "https://www.marketbeat.com/newsletter/default.aspx", "https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&ADID=AMERBMN_CONTENT_ZER&skip_rpt_name_check=skip_rpt_name_check&t=OVID", "https://twitter.com/share", "http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=OVID", "https://www.marketbeat.com/stocks/NASDAQ/OVID/price-target/"], "title": "Ovid Therapeutics (OVID) Rating Increased to Buy at Zacks Investment Research", "forum_title": "Watch List News"}, {"id": "dOW_MnrwyNNAjr5Jfhu7oBZnOlxrUNwYF5nJ8kr6yFmo3gloam3F3ceZFogphiH2", "result_metadata": {"score": 28.165268}, "author": "Joseph Griffin", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.466943, "label": "positive"}, "text": "Zacks Investment Research", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.998261, "label": "/finance/investing"}, {"score": 0.998261, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "employedBy", "sentence": "Ovid Therapeutics (OVID) Upgraded by Zacks Investment Research to \"Buy\"", "score": 0.306609, "arguments": [{"text": "Ovid Therapeutics", "location": [0, 17], "entities": [{"type": "Person", "text": "Ovid Therapeutics"}]}, {"text": "OVID", "location": [19, 23], "entities": [{"type": "Organization", "text": "OVID"}]}]}], "keywords": [{"text": "Ovid Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999889, "count": 1}, {"text": "OVID", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.223206, "count": 1}, {"text": "Zacks Investment Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.000387, "count": 1}]}, "crawl_date": "2018-11-17T18:31:38Z", "url": "https://www.tickerreport.com/banking-finance/3948806/ovid-therapeutics-ovid-upgraded-by-zacks-investment-research-to-buy.html", "host": "tickerreport.com", "text": "It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "main_image_url": "https://www.marketbeat.com/logos/ovid-therapeutics-inc-logo.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-17T18:16:00Z", "enriched_text": {"entities": [{"count": 17, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics Inc.", "relevance": 0.894999, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics Company", "relevance": 0.322251, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Get Ovid Therapeutics", "relevance": 0.314149, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics Daily", "relevance": 0.265512, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics", "relevance": 0.260385, "type": "PrintMedia"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "OVID", "relevance": 0.223535, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zacks Investment Research", "relevance": 0.154528, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.607986, "label": "negative"}, "text": "Angelman syndrome", "relevance": 0.122574, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Angelman syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Angelman_syndrome"}}, {"count": 1, "sentiment": {"score": 0.396221, "label": "positive"}, "text": "Zacks", "relevance": 0.118762, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.433046, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.116794, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": -0.700724, "label": "negative"}, "text": "Fragile X syndrome", "relevance": 0.1046, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Fragile X syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Fragile_X_syndrome"}}, {"count": 1, "sentiment": {"score": 0.416776, "label": "positive"}, "text": "Zacks", "relevance": 0.102405, "type": "Organization"}, {"count": 2, "sentiment": {"score": -0.42003, "label": "negative"}, "text": "United States", "relevance": 0.0945662, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 2, "sentiment": {"score": 0.501966, "label": "positive"}, "text": "Acadian Asset Management LLC", "relevance": 0.0945281, "type": "Company", "disambiguation": {"subtype": [], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}, {"count": 2, "sentiment": {"score": 0.53066, "label": "positive"}, "text": "JPMorgan Chase & Co.", "relevance": 0.0900508, "type": "Company", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Piper Jaffray Companies", "relevance": 0.0869436, "type": "Company", "disambiguation": {"subtype": [], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "California", "relevance": 0.0800179, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Northern Trust Corp", "relevance": 0.0780714, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.0771303, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "FilmScreeningVenue", "City"], "name": "New York City", "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cantor Fitzgerald", "relevance": 0.0767715, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ValuEngine", "relevance": 0.0755427, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.206115, "label": "positive"}, "text": "BidaskClub", "relevance": 0.072157, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Millennium Management LLC", "relevance": 0.0713278, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MarketBeat.com", "relevance": 0.0642244, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "1-year", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$112.42 million", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,010,000", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$132,000", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$154,000", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$233,000", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$420,000", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$12.44", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$17.58", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$20.00", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "109.8%", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "165.4%", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "25.27%", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "31.09%", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "482.8%", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.07", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.08", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.53", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.60", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.16", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.59", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.75", "relevance": 0.0642244, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "9.3%", "relevance": 0.0642244, "type": "Quantity"}], "sentiment": {"document": {"score": -0.245408, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "TweetOvid Therapeutics (NASDAQ:OVID)", "keywords": [{"text": "TweetOvid Therapeutics"}, {"text": "NASDAQ"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": "Tweet Ovid Therapeutics (NASDAQ:OVID) was upgraded by Zacks Investment Research from a \u201chold\u201d rating to a \u201cbuy\u201d rating in a report issued on Thursday.", "object": {"text": "upgraded by Zacks Investment Research from a \u201chold\u201d rating to a \u201cbuy\u201d rating in a report issued on Thursday", "keywords": [{"text": "Zacks Investment Research"}, {"text": "Thursday"}, {"text": "rating"}, {"text": "buy"}], "entities": [{"type": "Company", "text": "Zacks Investment Research"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Zacks Investment Research", "keywords": [{"text": "Zacks Investment Research"}], "entities": [{"type": "Company", "text": "Zacks Investment Research"}]}, "sentence": "Tweet Ovid Therapeutics (NASDAQ:OVID) was upgraded by Zacks Investment Research from a \u201chold\u201d rating to a \u201cbuy\u201d rating in a report issued on Thursday.", "object": {"text": "OVID)"}, "action": {"verb": {"text": "upgrade", "tense": "past"}, "text": "was upgraded", "normalized": "be upgrade"}}, {"subject": {"text": "The brokerage", "keywords": [{"text": "brokerage"}]}, "sentence": " The brokerage presently has a $5.75 price target on the stock.", "object": {"text": "a $5.75 price target on the stock", "keywords": [{"text": "price target"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$5.75"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Zacks Investment Research", "keywords": [{"text": "Zacks Investment Research"}]}, "sentence": " Zacks Investment Research \u2018s target price points to a potential upside of 25.27% from the company\u2019s current price.", "object": {"text": "target price", "keywords": [{"text": "target price"}]}, "action": {"verb": {"text": "\u2018s", "tense": "present"}, "text": "\u2018s", "normalized": "\u2018s"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Zacks Investment Research \u2018s target price points to a potential upside of 25.27% from the company\u2019s current price.", "object": {"text": "current price", "keywords": [{"text": "current price"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Ovid Therapeutics Inc.", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " According to Zacks, \u201cOvid Therapeutics Inc. is a biopharmaceutical company.", "object": {"text": "a biopharmaceutical company", "keywords": [{"text": "biopharmaceutical company"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company\u2019s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome.", "object": {"text": "product pipeline", "keywords": [{"text": "product pipeline"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The company\u2019s product pipeline", "keywords": [{"text": "product pipeline"}, {"text": "company"}]}, "sentence": " The company\u2019s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome.", "object": {"text": "of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome", "keywords": [{"text": "Angelman syndrome"}, {"text": "Fragile X syndrome"}, {"text": "development"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Angelman syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Angelman syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Angelman_syndrome"}}, {"type": "HealthCondition", "text": "Fragile X syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Fragile X syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Fragile_X_syndrome"}}]}, "action": {"verb": {"text": "consist", "tense": "present"}, "text": "consists", "normalized": "consist"}}, {"subject": {"text": "The company\u2019s product pipeline consists of OV101,", "keywords": [{"text": "product pipeline"}, {"text": "company"}]}, "sentence": " The company\u2019s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome.", "object": {"text": "in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome", "keywords": [{"text": "Angelman syndrome"}, {"text": "Fragile X syndrome"}, {"text": "development"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Angelman syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Angelman syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Angelman_syndrome"}}, {"type": "HealthCondition", "text": "Fragile X syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Fragile X syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Fragile_X_syndrome"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "object": {"text": "in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies", "keywords": [{"text": "rare epileptic encephalopathies"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "collaboration"}, {"text": "Limited"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "It"}, "sentence": " It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "object": {"text": "OV935", "keywords": [{"text": "OV935"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "Ovid Therapeutics Inc.", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " Ovid Therapeutics Inc. is based in New York, United States.", "object": {"text": "based in New York, United States", "keywords": [{"text": "New York"}, {"text": "United States"}], "entities": [{"type": "Location", "text": "New York", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "City"], "name": "New York City", "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Ovid Therapeutics Inc.", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " Ovid Therapeutics Inc. is based in New York, United States.", "action": {"verb": {"text": "base", "tense": "past"}, "text": "is based", "normalized": "be base"}}, {"subject": {"text": "A number of other research analysts", "keywords": [{"text": "research analysts"}, {"text": "number"}]}, "sentence": " A number of other research analysts have also recently commented on the stock.", "object": {"text": "on the stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "comment", "tense": "past"}, "text": "commented", "normalized": "comment"}}, {"subject": {"text": "Cantor Fitzgerald", "keywords": [{"text": "Cantor Fitzgerald"}], "entities": [{"type": "Person", "text": "Cantor Fitzgerald"}]}, "sentence": " Cantor Fitzgerald assumed coverage on shares of Ovid Therapeutics in a research report on Wednesday.", "object": {"text": "coverage on shares of Ovid Therapeutics in a research report on Wednesday", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "research report"}, {"text": "Wednesday"}, {"text": "coverage"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "assume", "tense": "past"}, "text": "assumed", "normalized": "assume"}}, {"subject": {"text": "They"}, "sentence": " They issued an \u201coverweight\u201d rating on the stock.", "object": {"text": "an \u201coverweight\u201d rating on the stock", "keywords": [{"text": "overweight"}, {"text": "rating"}, {"text": "stock"}]}, "action": {"verb": {"text": "issue", "tense": "past"}, "text": "issued", "normalized": "issue"}}, {"subject": {"text": "ValuEngine", "keywords": [{"text": "ValuEngine"}], "entities": [{"type": "Company", "text": "ValuEngine"}]}, "sentence": " ValuEngine raised shares of Ovid Therapeutics from a \u201csell\u201d rating to a \u201chold\u201d rating in a research report on Tuesday, September 4th.", "object": {"text": "shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " ValuEngine raised shares of Ovid Therapeutics from a \u201csell\u201d rating to a \u201chold\u201d rating in a research report on Tuesday, September 4th.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Piper Jaffray Companies", "keywords": [{"text": "Piper Jaffray Companies"}], "entities": [{"type": "Company", "text": "Piper Jaffray Companies", "disambiguation": {"subtype": ["Company"], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}]}, "sentence": " Piper Jaffray Companies set a $20.00 target price on shares of Ovid Therapeutics and gave the company a \u201cbuy\u201d rating in a research report on Sunday, August 12th.", "object": {"text": "a $20.00 target price", "keywords": [{"text": "target price"}], "entities": [{"type": "Quantity", "text": "$20.00"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Piper Jaffray Companies", "keywords": [{"text": "Piper Jaffray Companies"}], "entities": [{"type": "Company", "text": "Piper Jaffray Companies", "disambiguation": {"subtype": ["Company"], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}]}, "sentence": " Piper Jaffray Companies set a $20.00 target price on shares of Ovid Therapeutics and gave the company a \u201cbuy\u201d rating in a research report on Sunday, August 12th.", "object": {"text": "a \u201cbuy\u201d rating in a research report", "keywords": [{"text": "research report"}, {"text": "buy"}, {"text": "rating"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "gave", "normalized": "give"}}, {"subject": {"text": "BidaskClub", "keywords": [{"text": "BidaskClub"}], "entities": [{"type": "Company", "text": "BidaskClub"}]}, "sentence": " Finally, BidaskClub cut shares of Ovid Therapeutics from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research report on Friday, July 27th.", "object": {"text": "shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "cut", "tense": "past"}, "text": "cut", "normalized": "cut"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Finally, BidaskClub cut shares of Ovid Therapeutics from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research report on Friday, July 27th.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Three analysts", "keywords": [{"text": "analysts"}]}, "sentence": " Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company\u2019s stock.", "object": {"text": "rated the stock with a hold rating and four", "keywords": [{"text": "hold rating"}, {"text": "stock"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Three analysts", "keywords": [{"text": "analysts"}]}, "sentence": " Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company\u2019s stock.", "object": {"text": "the stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "rate", "tense": "past"}, "text": "have rated", "normalized": "have rate"}}, {"subject": {"text": "four"}, "sentence": " Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company\u2019s stock.", "object": {"text": "assigned a buy rating to the company\u2019s stock", "keywords": [{"text": "buy rating"}, {"text": "company"}, {"text": "stock"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company currently has an average rating of \u201cBuy\u201d and a consensus target price of $17.58.", "object": {"text": "an average rating of \u201cBuy\u201d and a consensus target price of $17.58", "keywords": [{"text": "consensus target price"}, {"text": "average rating"}], "entities": [{"type": "Quantity", "text": "$17.58"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "NASDAQ OVID", "keywords": [{"text": "NASDAQ OVID"}], "entities": []}, "sentence": " NASDAQ OVID traded up $0.08 during trading hours on Thursday, reaching $4.59.", "action": {"verb": {"text": "trade", "tense": "past"}, "text": "traded", "normalized": "trade"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company had a trading volume of 23,911 shares, compared to its average volume of 52,051.", "object": {"text": "a trading volume of 23,911 shares", "keywords": [{"text": "trading volume"}, {"text": "shares"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "a trading volume of 23,911 shares", "keywords": [{"text": "trading volume"}, {"text": "shares"}]}, "sentence": " The company had a trading volume of 23,911 shares, compared to its average volume of 52,051.", "object": {"text": "to its average volume of 52,051", "keywords": [{"text": "average volume"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " Ovid Therapeutics has a 1-year low of $4.16 and a 1-year high of $12.44.", "object": {"text": "a 1-year low of $4.16 and a 1-year high of $12.44", "keywords": [{"text": "1-year high"}], "entities": [{"type": "Quantity", "text": "1-year"}, {"type": "Quantity", "text": "$12.44"}, {"type": "Quantity", "text": "$4.16"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock has a market capitalization of $112.42 million, a P/E ratio of -1.37 and a beta of 1.15.", "object": {"text": "a market capitalization of $112.42 million, a P/E ratio of -1.37 and a beta of 1.15", "keywords": [{"text": "market capitalization"}, {"text": "P/E ratio"}, {"text": "beta"}], "entities": [{"type": "Quantity", "text": "$112.42 million"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "its earnings results", "keywords": [{"text": "earnings results"}]}, "sentence": " Ovid Therapeutics (NASDAQ:OVID) last posted its earnings results on Thursday, November 8th.", "action": {"verb": {"text": "post", "tense": "past"}, "text": "posted", "normalized": "post"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company reported ($0.53) EPS for the quarter, beating the Zacks\u2019 consensus estimate of ($0.60) by $0.07.", "object": {"text": "$0.53) EPS for the quarter", "keywords": [{"text": "EPS"}, {"text": "quarter"}], "entities": [{"type": "Quantity", "text": "$0.53"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "equities research analysts", "keywords": [{"text": "equities research analysts"}]}, "sentence": " On average, equities research analysts anticipate that Ovid Therapeutics will post -2.1 EPS for the current fiscal year.", "object": {"text": "that Ovid Therapeutics will post -2.1 EPS for the current fiscal year", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "EPS"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "anticipate", "tense": "present"}, "text": "anticipate", "normalized": "anticipate"}}, {"subject": {"text": "A number of large investors", "keywords": [{"text": "large investors"}, {"text": "number"}]}, "sentence": " A number of large investors have recently modified their holdings of the business.", "object": {"text": "recently modified their holdings of the business", "keywords": [{"text": "holdings"}, {"text": "business"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "A number of large investors", "keywords": [{"text": "large investors"}, {"text": "number"}]}, "sentence": " A number of large investors have recently modified their holdings of the business.", "object": {"text": "their holdings of the business", "keywords": [{"text": "holdings"}, {"text": "business"}]}, "action": {"verb": {"text": "modify", "tense": "past"}, "text": "modified", "normalized": "modify"}}, {"subject": {"text": "California State Teachers Retirement System", "keywords": [{"text": "State Teachers Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "sentence": " California State Teachers Retirement System increased its stake in Ovid Therapeutics by 109.8% during the first quarter.", "object": {"text": "its stake in Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "stake"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "increased", "normalized": "increase"}}, {"subject": {"text": "California State Teachers Retirement System", "keywords": [{"text": "State Teachers Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "sentence": " California State Teachers Retirement System now owns 18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the period.", "object": {"text": "18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the period", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}, {"text": "period"}], "entities": [{"type": "Quantity", "text": "$132,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " California State Teachers Retirement System now owns 18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the period.", "object": {"text": "stock worth $132,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$132,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "California State Teachers Retirement System", "keywords": [{"text": "State Teachers Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "sentence": " California State Teachers Retirement System now owns 18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the period.", "object": {"text": "an additional 9,776 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "Northern Trust Corp", "keywords": [{"text": "Northern Trust Corp"}], "entities": [{"type": "Company", "text": "Northern Trust Corp"}]}, "sentence": " Northern Trust Corp increased its stake in Ovid Therapeutics by 9.3% during the second quarter.", "object": {"text": "its stake in Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "stake"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "increased", "normalized": "increase"}}, {"subject": {"text": "Northern Trust Corp", "keywords": [{"text": "Northern Trust Corp"}], "entities": [{"type": "Company", "text": "Northern Trust Corp"}]}, "sentence": " Northern Trust Corp now owns 129,497 shares of the company\u2019s stock worth $1,010,000 after purchasing an additional 11,067 shares during the period.", "object": {"text": "129,497 shares of the company\u2019s stock worth $1,010,000", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$1,010,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Northern Trust Corp now owns 129,497 shares of the company\u2019s stock worth $1,010,000 after purchasing an additional 11,067 shares during the period.", "object": {"text": "stock worth $1,010,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$1,010,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Northern Trust Corp", "keywords": [{"text": "Northern Trust Corp"}], "entities": [{"type": "Company", "text": "Northern Trust Corp"}]}, "sentence": " Northern Trust Corp now owns 129,497 shares of the company\u2019s stock worth $1,010,000 after purchasing an additional 11,067 shares during the period.", "object": {"text": "an additional 11,067 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "Acadian Asset Management LLC", "keywords": [{"text": "Acadian Asset Management"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Acadian Asset Management LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}]}, "sentence": " Acadian Asset Management LLC increased its stake in Ovid Therapeutics by 165.4% during the second quarter.", "object": {"text": "its stake in Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "stake"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "increased", "normalized": "increase"}}, {"subject": {"text": "Acadian Asset Management LLC", "keywords": [{"text": "Acadian Asset Management"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Acadian Asset Management LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}]}, "sentence": " Acadian Asset Management LLC now owns 19,729 shares of the company\u2019s stock worth $154,000 after purchasing an additional 12,294 shares during the period.", "object": {"text": "19,729 shares of the company\u2019s stock worth $154,000 after purchasing an additional 12,294 shares during the period", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}, {"text": "period"}], "entities": [{"type": "Quantity", "text": "$154,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Acadian Asset Management LLC now owns 19,729 shares of the company\u2019s stock worth $154,000 after purchasing an additional 12,294 shares during the period.", "object": {"text": "stock worth $154,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$154,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Acadian Asset Management LLC", "keywords": [{"text": "Acadian Asset Management"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Acadian Asset Management LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}]}, "sentence": " Acadian Asset Management LLC now owns 19,729 shares of the company\u2019s stock worth $154,000 after purchasing an additional 12,294 shares during the period.", "object": {"text": "an additional 12,294 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "JPMorgan Chase & Co.", "keywords": [{"text": "JPMorgan Chase"}], "entities": [{"type": "Company", "text": "JPMorgan Chase & Co.", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}]}, "sentence": " JPMorgan Chase & Co. increased its stake in Ovid Therapeutics by 482.8% during the first quarter.", "object": {"text": "its stake in Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "stake"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "increased", "normalized": "increase"}}, {"subject": {"text": "JPMorgan Chase & Co.", "keywords": [{"text": "JPMorgan Chase"}], "entities": [{"type": "Company", "text": "JPMorgan Chase & Co.", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}]}, "sentence": " JPMorgan Chase & Co. now owns 33,006 shares of the company\u2019s stock worth $233,000 after purchasing an additional 27,343 shares during the period.", "object": {"text": "33,006 shares of the company\u2019s stock worth $233,000", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$233,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}], "concepts": [{"text": "Neurological disorders", "relevance": 0.911501, "dbpedia_resource": "http://dbpedia.org/resource/Neurological_disorders"}, {"text": "Syndromes", "relevance": 0.885337, "dbpedia_resource": "http://dbpedia.org/resource/Syndromes"}, {"text": "Clinical trial", "relevance": 0.852284, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "JPMorgan Chase", "relevance": 0.793343, "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}, {"text": "Financial services", "relevance": 0.739758, "dbpedia_resource": "http://dbpedia.org/resource/Financial_services"}, {"text": "Stock market", "relevance": 0.731548, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.722988, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Piper Jaffray", "relevance": 0.717601, "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}, {"text": "Stock", "relevance": 0.692521, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Minneapolis", "relevance": 0.657221, "dbpedia_resource": "http://dbpedia.org/resource/Minneapolis"}], "categories": [{"score": 0.777105, "label": "/finance/investing"}, {"score": 0.777105, "label": "/finance/investing/beginning investing"}, {"score": 0.7231, "label": "/finance/investing/day trading"}], "relations": [{"type": "hasAttribute", "sentence": "It engaged in developing therapies for patients with rare neurological disorders.", "score": 0.892415, "arguments": [{"text": "patients", "location": [444, 452], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "neurological disorders", "location": [463, 485], "entities": [{"type": "HealthCondition", "text": "neurological disorders"}]}]}, {"type": "employedBy", "sentence": "Ovid Therapeutics Company Profile Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.", "score": 0.838607, "arguments": [{"text": "Profile\nOvid Therapeutics Inc", "location": [3746, 3775], "entities": [{"type": "Person", "text": "Profile\nOvid Therapeutics Inc"}]}, {"text": "Company", "location": [3738, 3745], "entities": [{"type": "Organization", "text": "Company"}]}]}, {"type": "hasAttribute", "sentence": "Ovid Therapeutics Company Profile Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.", "score": 0.531649, "arguments": [{"text": "families", "location": [3852, 3860], "entities": [{"type": "Person", "text": "families"}]}, {"text": "neurological disorders", "location": [3866, 3888], "entities": [{"type": "HealthCondition", "text": "neurological disorders"}]}]}, {"type": "partOfMany", "sentence": "The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.", "score": 0.458802, "arguments": [{"text": "I", "location": [4050, 4051], "entities": [{"type": "Person", "text": "I"}]}, {"text": "adolescents", "location": [4071, 4082], "entities": [{"type": "Person", "text": "adolescents"}]}]}, {"type": "partOf", "sentence": "Get a free copy of the Zacks research report on Ovid Therapeutics (OVID) For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .", "score": 0.495019, "arguments": [{"text": "OVID", "location": [4196, 4200], "entities": [{"type": "Organization", "text": "OVID"}]}, {"text": "Zacks", "location": [4152, 4157], "entities": [{"type": "Organization", "text": "Zacks Investment Research", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Get a free copy of the Zacks research report on Ovid Therapeutics (OVID) For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .", "score": 0.327083, "arguments": [{"text": "Ovid Therapeutics", "location": [4177, 4194], "entities": [{"type": "Person", "text": "Tweet\nOvid Therapeutics"}]}, {"text": "OVID", "location": [4196, 4200], "entities": [{"type": "Organization", "text": "OVID"}]}]}, {"type": "participantIn", "sentence": "It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "score": 0.915883, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [699, 736], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "collaboration", "location": [680, 693], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}]}, {"type": "locatedAt", "sentence": "Ovid Therapeutics Inc. is based in New York, United States.", "score": 0.305737, "arguments": [{"text": "Ovid Therapeutics Inc.", "location": [791, 813], "entities": [{"type": "Person", "text": "Ovid Therapeutics Inc."}]}, {"text": "New York", "location": [826, 834], "entities": [{"type": "GeopoliticalEntity", "text": "New York"}]}]}, {"type": "agentOf", "sentence": "\" Get Ovid Therapeutics alerts: A number of other research analysts have also recently commented on the stock.", "score": 0.49928, "arguments": [{"text": "research analysts", "location": [901, 918], "entities": [{"type": "Person", "text": "research analysts"}]}, {"text": "commented", "location": [938, 947], "entities": [{"type": "EventCommunication", "text": "commented"}]}]}, {"type": "agentOf", "sentence": "They issued an \"overweight\" rating on the stock.", "score": 0.991161, "arguments": [{"text": "They", "location": [1063, 1067], "entities": [{"type": "Person", "text": "research analysts"}]}, {"text": "issued", "location": [1068, 1074], "entities": [{"type": "EventCommunication", "text": "issued"}]}]}, {"type": "affectedBy", "sentence": "Piper Jaffray Companies set a $20.00 target price on shares of Ovid Therapeutics and gave the company a \"buy\" rating in a research report on Sunday, August 12th.", "score": 0.659654, "arguments": [{"text": "company", "location": [1340, 1347], "entities": [{"type": "Organization", "text": "Company"}]}, {"text": "gave", "location": [1331, 1335], "entities": [{"type": "EventCommunication", "text": "gave"}]}]}, {"type": "timeOf", "sentence": "Piper Jaffray Companies set a $20.00 target price on shares of Ovid Therapeutics and gave the company a \"buy\" rating in a research report on Sunday, August 12th.", "score": 0.621275, "arguments": [{"text": "Sunday", "location": [1387, 1393], "entities": [{"type": "Date", "text": "August 12th"}]}, {"text": "gave", "location": [1331, 1335], "entities": [{"type": "EventCommunication", "text": "gave"}]}]}, {"type": "agentOf", "sentence": "The company reported ($0.53) EPS for the quarter, beating the Zacks' consensus estimate of ($0.60) by $0.07.", "score": 0.993287, "arguments": [{"text": "company", "location": [2189, 2196], "entities": [{"type": "Organization", "text": "Company"}]}, {"text": "reported", "location": [2197, 2205], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "partOf", "sentence": "California State Teachers Retirement System increased its stake in Ovid Therapeutics by 109.8% during the first quarter.", "score": 0.971946, "arguments": [{"text": "State Teachers Retirement System", "location": [2509, 2541], "entities": [{"type": "Organization", "text": "State Teachers Retirement System"}]}, {"text": "California", "location": [2498, 2508], "entities": [{"type": "GeopoliticalEntity", "text": "California"}]}]}, {"type": "partOf", "sentence": "California State Teachers Retirement System now owns 18,676 shares of the company's stock worth $132,000 after purchasing an additional 9,776 shares during the period.", "score": 0.99566, "arguments": [{"text": "State Teachers Retirement System", "location": [2630, 2662], "entities": [{"type": "Organization", "text": "State Teachers Retirement System"}]}, {"text": "California", "location": [2619, 2629], "entities": [{"type": "GeopoliticalEntity", "text": "California"}]}]}], "keywords": [{"text": "Ovid Therapeutics Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.787455, "count": 2}, {"text": "company\u2019s current price", "sentiment": {"score": 0.296113, "label": "positive"}, "relevance": 0.736942, "count": 1}, {"text": "Zacks Investment Research", "sentiment": {"score": 0.594798, "label": "positive"}, "relevance": 0.668956, "count": 3}, {"text": "OVID", "sentiment": {"score": 0.718598, "label": "positive"}, "relevance": 0.650484, "count": 3}, {"text": "shares of Ovid Therapeutics", "sentiment": {"score": 0.401523, "mixed": "1", "label": "positive"}, "relevance": 0.632467, "count": 4}, {"text": "biopharmaceutical company", "sentiment": {"score": -0.574727, "label": "negative"}, "relevance": 0.607898, "count": 2}, {"text": "JPMorgan Chase", "sentiment": {"score": -0.346696, "label": "negative"}, "relevance": 0.597991, "count": 2}, {"text": "Ovid Therapeutics alerts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.596512, "count": 1}, {"text": "Acadian Asset Management LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.590331, "count": 2}, {"text": "Cantor Fitzgerald", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575623, "count": 1}, {"text": "number of other research analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575465, "count": 1}, {"text": "average rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.572643, "count": 1}, {"text": "company\u2019s product pipeline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.56668, "count": 1}, {"text": "United States", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.560865, "count": 2}, {"text": "Northern Trust Corp", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558246, "count": 2}, {"text": "research report", "sentiment": {"score": 0.401523, "mixed": "1", "label": "positive"}, "relevance": 0.556737, "count": 4}, {"text": "company", "sentiment": {"score": 0, "mixed": "1", "label": "neutral"}, "relevance": 0.550715, "count": 5}, {"text": "California State Teachers Retirement System", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550507, "count": 2}, {"text": "email address", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.54774, "count": 1}, {"text": "stock", "sentiment": {"score": -0.346696, "label": "negative"}, "relevance": 0.546067, "count": 9}, {"text": "clinical trial", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.545683, "count": 2}, {"text": "related companies", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.53819, "count": 1}, {"text": "stake", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537555, "count": 4}, {"text": "report", "sentiment": {"score": 0.547525, "label": "positive"}, "relevance": 0.536807, "count": 1}, {"text": "hold rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536128, "count": 1}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535836, "count": 1}, {"text": "NASDAQ", "sentiment": {"score": 0.547525, "label": "positive"}, "relevance": 0.535613, "count": 2}, {"text": "com Receive News", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.534574, "count": 1}, {"text": "market capitalization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534205, "count": 1}, {"text": "Institutional investors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53399, "count": 1}, {"text": "analysts", "sentiment": {"score": 0.344084, "label": "positive"}, "relevance": 0.533726, "count": 2}, {"text": "Piper Jaffray Companies", "sentiment": {"score": 0.62797, "label": "positive"}, "relevance": 0.532985, "count": 1}, {"text": "shares", "sentiment": {"score": 0.619207, "label": "positive"}, "relevance": 0.529091, "count": 5}, {"text": "Fragile X syndrome", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526576, "count": 1}, {"text": "OV101", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.522461, "count": 2}, {"text": "concise daily summary of the latest news", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.522203, "count": 1}, {"text": "Ratings", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.520849, "count": 1}, {"text": "angelman syndrome", "sentiment": {"score": -0.289765, "mixed": "1", "label": "negative"}, "relevance": 0.520526, "count": 2}, {"text": "Co.", "sentiment": {"score": -0.346696, "label": "negative"}, "relevance": 0.520292, "count": 2}, {"text": "price target", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520176, "count": 1}, {"text": "Phase", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.518539, "count": 2}, {"text": "information", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.517354, "count": 1}, {"text": "Ovid Therapeutics Daily", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.516935, "count": 1}, {"text": "equities", "sentiment": {"score": 0.344084, "label": "positive"}, "relevance": 0.51571, "count": 1}, {"text": "collaboration", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515199, "count": 1}, {"text": "brokerage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51489, "count": 1}, {"text": "second quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514836, "count": 2}, {"text": "free copy of the Zacks research report", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.514522, "count": 1}, {"text": "neurological disorders", "sentiment": {"score": -0.574368, "label": "negative"}, "relevance": 0.513562, "count": 1}, {"text": "patients", "sentiment": {"score": -0.574727, "label": "negative"}, "relevance": 0.513509, "count": 2}]}, "extracted_metadata": {"sha1": "9c331f242cd7917756294453fa057601ca2d3f02", "filename": "1542479498948.zip-894bba0eb9a197ccd12afdf9545655d0.xml", "file_type": "json"}, "external_links": ["http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1", "https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&ADID=AMERBMN_CONTENT_ZER&skip_rpt_name_check=skip_rpt_name_check&t=OVID", "http://twitter.com/share", "http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=OVID", "https://www.marketbeat.com/newsletter/default.aspx", "https://www.marketbeat.com/stocks/NASDAQ/OVID/price-target/"], "title": "Ovid Therapeutics (OVID) Upgraded by Zacks Investment Research to \u201cBuy\u201d", "forum_title": "Ticker Report"}, {"id": "godYnWYIoziPmqOmgokXdawA2-8Lxfu3P65V9zNBWgnXDS-LQhX0tFQNb49AW1oT", "result_metadata": {"score": 26.021297}, "author": "Dennis Huang", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.729147, "label": "negative"}, "text": "Takeda Pharmaceuticals Buys", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.729147, "label": "negative"}, "text": "Ariad Pharmaceuticals", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "ARIAD Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/ARIAD_Pharmaceuticals"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.83333, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.761059, "label": "/health and fitness/drugs"}], "relations": [{"type": "employedBy", "sentence": "Takeda Pharmaceuticals Buys out Ariad Pharmaceuticals", "score": 0.743138, "arguments": [{"text": "Takeda Pharmaceuticals Buys", "location": [0, 27], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals Buys"}]}, {"text": "Ariad Pharmaceuticals", "location": [32, 53], "entities": [{"type": "Organization", "text": "Ariad Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Ariad Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998502, "count": 1}, {"text": "Takeda Pharmaceuticals Buys", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.984798, "count": 1}]}, "crawl_date": "2018-11-17T20:47:52Z", "url": "https://www.financialbuzz.com/takeda-pharmaceuticals-buys-out-ariad-pharmaceuticals-657075/", "host": "financialbuzz.com", "text": "ARIAD Pharmaceuticals, Inc.", "main_image_url": "https://www.financialbuzz.com/wp-content/uploads/2018/08/1483987559_buyout27.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2017-01-09T13:45:00-06:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0.119668, "label": "positive"}, "text": "Takeda", "relevance": 0.915739, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.376854, "label": "negative"}, "text": "Takeda Pharmaceuticals", "relevance": 0.708629, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.540338, "type": "Person"}, {"count": 5, "sentiment": {"score": 0.29989, "label": "positive"}, "text": "Ariad", "relevance": 0.430468, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.534357, "label": "negative"}, "text": "ARIAD Pharmaceuticals, Inc.", "relevance": 0.342804, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alexander Denner", "relevance": 0.217096, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ariad", "relevance": 0.213646, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Christophe Weber", "relevance": 0.209402, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "president and CEO", "relevance": 0.202033, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5.2 billion", "relevance": 0.202033, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "72 percent", "relevance": 0.202033, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$24", "relevance": 0.202033, "type": "Quantity"}], "sentiment": {"document": {"score": 0.755664, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)", "keywords": [{"text": "ARIAD Pharmaceuticals"}, {"text": "Inc."}, {"text": "NASDAQ"}], "entities": [{"type": "Company", "text": "ARIAD Pharmaceuticals, Inc."}]}, "sentence": "ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is up over 72 percent after the oncology company announced its being bought out by Takeda Pharmaceuticals.", "object": {"text": "up over 72 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "72 percent"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the oncology company", "keywords": [{"text": "oncology company"}]}, "sentence": "ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is up over 72 percent after the oncology company announced its being bought out by Takeda Pharmaceuticals.", "object": {"text": "its being bought out by Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "by Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is up over 72 percent after the oncology company announced its being bought out by Takeda Pharmaceuticals.", "object": {"text": "its"}, "action": {"verb": {"text": "buy", "tense": "past"}, "text": "being bought", "normalized": "be buy"}}, {"subject": {"text": "Takeda buying Ariad for $24 per share in cash", "keywords": [{"text": "Takeda buying Ariad"}, {"text": "cash"}, {"text": "share"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Company", "text": "Ariad"}, {"type": "Quantity", "text": "$24"}]}, "sentence": " The deal involved Takeda buying Ariad for $24 per share in cash.", "object": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " The deal involved Takeda buying Ariad for $24 per share in cash.", "object": {"text": "Ariad", "keywords": [{"text": "Ariad"}], "entities": [{"type": "Company", "text": "Ariad"}]}, "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}, {"subject": {"text": "The $5.2 billion deal", "keywords": [{"text": "deal"}], "entities": [{"type": "Quantity", "text": "$5.2 billion"}]}, "sentence": " The $5.2 billion deal is expected to close before the end of the month as both boards have signed the deal.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is expected to close", "normalized": "be expect to close"}}, {"subject": {"text": "The $5.2 billion deal", "keywords": [{"text": "deal"}], "entities": [{"type": "Quantity", "text": "$5.2 billion"}]}, "sentence": " The $5.2 billion deal is expected to close before the end of the month as both boards have signed the deal.", "action": {"verb": {"text": "close", "tense": "future"}, "text": "is expected to close", "normalized": "be expect to close"}}, {"subject": {"text": "both boards", "keywords": [{"text": "boards"}]}, "sentence": " The $5.2 billion deal is expected to close before the end of the month as both boards have signed the deal.", "object": {"text": "signed the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "both boards", "keywords": [{"text": "boards"}]}, "sentence": " The $5.2 billion deal is expected to close before the end of the month as both boards have signed the deal.", "object": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "sign", "tense": "past"}, "text": "have signed", "normalized": "have sign"}}, {"subject": {"text": "This transaction", "keywords": [{"text": "transaction"}]}, "sentence": " \u201cThis transaction is a great outcome for shareholders of Ariad and Takeda.", "object": {"text": "a great outcome for shareholders of Ariad and Takeda", "keywords": [{"text": "great outcome"}, {"text": "Takeda"}, {"text": "shareholders"}, {"text": "Ariad"}], "entities": [{"type": "Company", "text": "Ariad"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Both Ariad and Takeda", "keywords": [{"text": "Takeda"}, {"text": "Ariad"}], "entities": [{"type": "Person", "text": "Ariad"}, {"type": "Person", "text": "Takeda"}]}, "sentence": " Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad\u2019s pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "object": {"text": "passionate about helping cancer patients", "keywords": [{"text": "cancer patients"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Both Ariad and Takeda", "keywords": [{"text": "Takeda"}, {"text": "Ariad"}], "entities": [{"type": "Person", "text": "Ariad"}, {"type": "Person", "text": "Takeda"}]}, "sentence": " Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad\u2019s pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "object": {"text": "cancer patients", "keywords": [{"text": "cancer patients"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helping", "normalized": "help"}}, {"subject": {"text": "I"}, "sentence": " Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad\u2019s pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "object": {"text": "the talent and resources of Takeda coupled with Ariad\u2019s pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement", "keywords": [{"text": "Alexander Denner"}, {"text": "Ariad\u2019s pipeline"}, {"text": "cancer treatments"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Company", "text": "Ariad"}, {"type": "Company", "text": "Ariad"}, {"type": "Person", "text": "Alexander Denner"}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believe", "normalized": "believe"}}, {"subject": {"text": "Alexander Denner", "keywords": [{"text": "Alexander Denner"}], "entities": [{"type": "Person", "text": "Alexander Denner"}]}, "sentence": " Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad\u2019s pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "action": {"verb": {"text": "state", "tense": "past"}, "text": "stated", "normalized": "state"}}, {"subject": {"text": "The acquisition of Ariad", "keywords": [{"text": "acquisition"}, {"text": "Ariad"}], "entities": [{"type": "Company", "text": "Ariad"}]}, "sentence": " \u201cThe acquisition of Ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders,\u201d Takeda\u2019s president and CEO, Christophe Weber said.", "object": {"text": "a unique opportunity that will enable us to positively impact the lives of more patients worldwide", "keywords": [{"text": "unique opportunity"}, {"text": "lives"}, {"text": "patients"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a unique opportunity", "keywords": [{"text": "unique opportunity"}]}, "sentence": " \u201cThe acquisition of Ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders,\u201d Takeda\u2019s president and CEO, Christophe Weber said.", "object": {"text": "us to positively impact the lives of more patients worldwide", "keywords": [{"text": "lives"}, {"text": "patients"}]}, "action": {"verb": {"text": "enable", "tense": "future"}, "text": "will enable", "normalized": "will enable"}}, {"subject": {"text": "us"}, "sentence": " \u201cThe acquisition of Ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders,\u201d Takeda\u2019s president and CEO, Christophe Weber said.", "object": {"text": "the lives of more patients worldwide", "keywords": [{"text": "lives"}, {"text": "patients"}]}, "action": {"verb": {"text": "impact", "tense": "future"}, "text": "impact", "normalized": "impact"}}, {"subject": {"text": "Takeda\u2019s president and CEO, Christophe Weber", "keywords": [{"text": "Christophe Weber"}, {"text": "Takeda"}, {"text": "CEO"}, {"text": "president"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "president and CEO"}, {"type": "Person", "text": "Christophe Weber"}]}, "sentence": " \u201cThe acquisition of Ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders,\u201d Takeda\u2019s president and CEO, Christophe Weber said.", "object": {"text": "The acquisition of Ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders", "keywords": [{"text": "attractive returns"}, {"text": "strategic priorities"}, {"text": "unique opportunity"}, {"text": "shareholders"}], "entities": [{"type": "Company", "text": "Ariad"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}], "concepts": [{"text": "Oncology", "relevance": 0.933714, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.6764, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Economics", "relevance": 0.650339, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Cancer", "relevance": 0.644832, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Share", "relevance": 0.644036, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}, {"text": "English-language films", "relevance": 0.60935, "dbpedia_resource": "http://dbpedia.org/resource/English-language_films"}], "categories": [{"score": 0.906853, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.678294, "label": "/finance/financial news"}, {"score": 0.67482, "label": "/real estate/buying and selling homes"}], "relations": [{"type": "hasAttribute", "sentence": "ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is up over 72 percent after the oncology company announced its being bought out by Takeda Pharmaceuticals.", "score": 0.929963, "arguments": [{"text": "ARIAD Pharmaceuticals, Inc.", "location": [0, 27], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "ARIA", "location": [37, 41], "entities": [{"type": "Ticker", "text": "ARIA"}]}]}, {"type": "ownerOf", "sentence": "Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad's pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "score": 0.420292, "arguments": [{"text": "Ariad", "location": [528, 533], "entities": [{"type": "Organization", "text": "Ariad"}]}, {"text": "pipeline", "location": [536, 544], "entities": [{"type": "Vehicle", "text": "pipeline"}]}]}, {"type": "locatedAt", "sentence": "Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad's pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "score": 0.689273, "arguments": [{"text": "people", "location": [549, 555], "entities": [{"type": "Person", "text": "people"}]}, {"text": "pipeline", "location": [536, 544], "entities": [{"type": "Vehicle", "text": "pipeline"}]}]}, {"type": "employedBy", "sentence": "Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad's pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "score": 0.543534, "arguments": [{"text": "Chairmain", "location": [610, 619], "entities": [{"type": "Person", "text": "Chairmain"}]}, {"text": "Ariad", "location": [623, 628], "entities": [{"type": "Organization", "text": "Ariad"}]}]}, {"type": "agentOf", "sentence": "Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad's pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "score": 0.538743, "arguments": [{"text": "Chairmain", "location": [610, 619], "entities": [{"type": "Person", "text": "Chairmain"}]}, {"text": "stated", "location": [647, 653], "entities": [{"type": "EventCommunication", "text": "stated"}]}]}, {"type": "employedBy", "sentence": "Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad's pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "score": 0.482631, "arguments": [{"text": "Alexander Denner", "location": [630, 646], "entities": [{"type": "Person", "text": "Alexander Denner"}]}, {"text": "Ariad", "location": [623, 628], "entities": [{"type": "Organization", "text": "Ariad"}]}]}, {"type": "agentOf", "sentence": "Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad's pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "score": 0.523218, "arguments": [{"text": "Alexander Denner", "location": [630, 646], "entities": [{"type": "Person", "text": "Alexander Denner"}]}, {"text": "stated", "location": [647, 653], "entities": [{"type": "EventCommunication", "text": "stated"}]}]}, {"type": "affectedBy", "sentence": "\"The acquisition of Ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders,\" Takeda's president and CEO, Christophe Weber said.", "score": 0.674998, "arguments": [{"text": "Ariad", "location": [695, 700], "entities": [{"type": "Organization", "text": "Ariad"}]}, {"text": "acquisition", "location": [680, 691], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOfMany", "sentence": "\"The acquisition of Ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders,\" Takeda's president and CEO, Christophe Weber said.", "score": 0.254031, "arguments": [{"text": "shareholders", "location": [877, 889], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "our", "location": [873, 876], "entities": [{"type": "Person", "text": "our"}]}]}, {"type": "colleague", "sentence": "\"The acquisition of Ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders,\" Takeda's president and CEO, Christophe Weber said.", "score": 0.459163, "arguments": [{"text": "Takeda", "location": [892, 898], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "president", "location": [901, 910], "entities": [{"type": "Person", "text": "president"}]}]}, {"type": "agentOf", "sentence": "\"The acquisition of Ariad is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders,\" Takeda's president and CEO, Christophe Weber said.", "score": 0.990089, "arguments": [{"text": "Christophe Weber", "location": [920, 936], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [937, 941], "entities": [{"type": "EventCommunication", "text": "stated"}]}]}, {"type": "agentOf", "sentence": "ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is up over 72 percent after the oncology company announced its being bought out by Takeda Pharmaceuticals.", "score": 0.966046, "arguments": [{"text": "oncology company", "location": [75, 91], "entities": [{"type": "Organization", "text": "Ariad"}]}, {"text": "announced", "location": [92, 101], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "The deal involved Takeda buying Ariad for $24 per share in cash.", "score": 0.422154, "arguments": [{"text": "Takeda", "location": [168, 174], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "Ariad", "location": [182, 187], "entities": [{"type": "Organization", "text": "Ariad"}]}]}, {"type": "employedBy", "sentence": "Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad's pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "score": 0.352806, "arguments": [{"text": "Takeda", "location": [508, 514], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "Ariad", "location": [528, 533], "entities": [{"type": "Organization", "text": "Ariad"}]}]}, {"type": "affectedBy", "sentence": "The deal involved Takeda buying Ariad for $24 per share in cash.", "score": 0.896906, "arguments": [{"text": "Ariad", "location": [182, 187], "entities": [{"type": "Organization", "text": "Ariad"}]}, {"text": "buying", "location": [175, 181], "entities": [{"type": "EventBusiness", "text": "buying"}]}]}, {"type": "employedBy", "sentence": "\"This transaction is a great outcome for shareholders of Ariad and Takeda.", "score": 0.481651, "arguments": [{"text": "shareholders", "location": [364, 376], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Ariad", "location": [380, 385], "entities": [{"type": "Organization", "text": "Ariad"}]}]}, {"type": "partOfMany", "sentence": "\"This transaction is a great outcome for shareholders of Ariad and Takeda.", "score": 0.494516, "arguments": [{"text": "Takeda", "location": [390, 396], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "shareholders", "location": [364, 376], "entities": [{"type": "Person", "text": "shareholders"}]}]}, {"type": "hasAttribute", "sentence": "Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad's pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "score": 0.723969, "arguments": [{"text": "Takeda", "location": [413, 419], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "cancer", "location": [449, 455], "entities": [{"type": "HealthCondition", "text": "cancer"}]}]}, {"type": "hasAttribute", "sentence": "Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad's pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "score": 0.804121, "arguments": [{"text": "patients", "location": [456, 464], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [449, 455], "entities": [{"type": "HealthCondition", "text": "cancer"}]}]}, {"type": "locatedAt", "sentence": "Both Ariad and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with Ariad's pipeline and people will accelerate the development of cancer treatments, Chairmain of Ariad, Alexander Denner stated in the announcement.", "score": 0.858966, "arguments": [{"text": "Takeda", "location": [508, 514], "entities": [{"type": "Person", "text": "Takeda Pharmaceuticals"}]}, {"text": "pipeline", "location": [536, 544], "entities": [{"type": "Vehicle", "text": "pipeline"}]}]}], "keywords": [{"text": "ARIAD Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.897832, "count": 1}, {"text": "deal", "sentiment": {"score": 0.515591, "label": "positive"}, "relevance": 0.76777, "count": 3}, {"text": "cancer patients", "sentiment": {"score": 0.739408, "label": "positive"}, "relevance": 0.738479, "count": 1}, {"text": "Takeda Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.699374, "count": 1}, {"text": "end of the month", "sentiment": {"score": 0.369962, "label": "positive"}, "relevance": 0.697228, "count": 1}, {"text": "unique opportunity", "sentiment": {"score": 0.997306, "label": "positive"}, "relevance": 0.660793, "count": 1}, {"text": "Ariad", "sentiment": {"score": 0.739408, "label": "positive"}, "relevance": 0.621701, "count": 2}, {"text": "Takeda", "sentiment": {"score": 0.741027, "label": "positive"}, "relevance": 0.612424, "count": 2}, {"text": "transaction", "sentiment": {"score": 0.744612, "label": "positive"}, "relevance": 0.593917, "count": 1}, {"text": "boards", "sentiment": {"score": 0.369962, "label": "positive"}, "relevance": 0.590132, "count": 1}, {"text": "shareholders of Ariad", "sentiment": {"score": 0.744612, "label": "positive"}, "relevance": 0.566252, "count": 1}, {"text": "talent", "sentiment": {"score": 0.739408, "label": "positive"}, "relevance": 0.556251, "count": 1}, {"text": "shareholders", "sentiment": {"score": 0.997306, "label": "positive"}, "relevance": 0.553327, "count": 1}, {"text": "involved Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551614, "count": 1}, {"text": "people", "sentiment": {"score": 0.739408, "label": "positive"}, "relevance": 0.550739, "count": 1}, {"text": "NASDAQ", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549515, "count": 1}, {"text": "ARIA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547301, "count": 1}, {"text": "acquisition of Ariad", "sentiment": {"score": 0.997306, "label": "positive"}, "relevance": 0.535137, "count": 1}, {"text": "lives of more patients", "sentiment": {"score": 0.997306, "label": "positive"}, "relevance": 0.532815, "count": 1}, {"text": "CEO", "sentiment": {"score": 0.997306, "label": "positive"}, "relevance": 0.520736, "count": 1}, {"text": "development of cancer treatments", "sentiment": {"score": 0.739408, "label": "positive"}, "relevance": 0.519551, "count": 1}, {"text": "share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514109, "count": 1}, {"text": "announcement", "sentiment": {"score": 0.895349, "label": "positive"}, "relevance": 0.511637, "count": 1}, {"text": "cash", "sentiment": {"score": 0.369962, "label": "positive"}, "relevance": 0.511637, "count": 1}, {"text": "Ariad\u2019s pipeline", "sentiment": {"score": 0.739408, "label": "positive"}, "relevance": 0.510756, "count": 1}, {"text": "great outcome", "sentiment": {"score": 0.744612, "label": "positive"}, "relevance": 0.496891, "count": 1}, {"text": "resources of Takeda", "sentiment": {"score": 0.739408, "label": "positive"}, "relevance": 0.492416, "count": 1}, {"text": "strategic priorities", "sentiment": {"score": 0.997306, "label": "positive"}, "relevance": 0.485909, "count": 1}, {"text": "oncology company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484964, "count": 1}, {"text": "Chairmain of Ariad", "sentiment": {"score": 0.739408, "label": "positive"}, "relevance": 0.474472, "count": 1}, {"text": "attractive returns", "sentiment": {"score": 0.997306, "label": "positive"}, "relevance": 0.466434, "count": 1}, {"text": "Takeda\u2019s president", "sentiment": {"score": 0.997306, "label": "positive"}, "relevance": 0.437724, "count": 1}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416263, "count": 1}, {"text": "Alexander Denner", "sentiment": {"score": 0.739408, "label": "positive"}, "relevance": 0.415824, "count": 1}, {"text": "Christophe Weber", "sentiment": {"score": 0.997306, "label": "positive"}, "relevance": 0.406694, "count": 1}]}, "extracted_metadata": {"sha1": "0028dd4ff3c72ea5312237acc7382f7acf8cdc01", "filename": "1542487672438.zip-4564b1a303fabe53148fc75a8735e4d3.xml", "file_type": "json"}, "title": "Takeda Pharmaceuticals Buys out Ariad Pharmaceuticals", "forum_title": "Market News | Financial Buzz - Part 290"}, {"id": "oalfVahT9jUDaUm8Ru1T6z-JsYSMfn3pgSTs-ffhsP7KLSYZPB6_6J5OVJKiWuow", "result_metadata": {"score": 24.846142}, "author": "ann.castro", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biocon", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Biocon", "dbpedia_resource": "http://dbpedia.org/resource/Biocon"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sunpharma", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.33, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Exenatide", "relevance": 0.957867, "dbpedia_resource": "http://dbpedia.org/resource/Exenatide"}, {"text": "Anti-diabetic drug", "relevance": 0.934192, "dbpedia_resource": "http://dbpedia.org/resource/Anti-diabetic_drug"}, {"text": "InnoMed PredTox", "relevance": 0.753482, "dbpedia_resource": "http://dbpedia.org/resource/InnoMed_PredTox"}, {"text": "Sitagliptin", "relevance": 0.745051, "dbpedia_resource": "http://dbpedia.org/resource/Sitagliptin"}, {"text": "Biotechnology companies", "relevance": 0.695412, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Multinational companies", "relevance": 0.690438, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}], "categories": [{"score": 0.922788, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.838438, "label": "/health and fitness"}, {"score": 0.748814, "label": "/health and fitness/drugs"}], "relations": [{"type": "locatedAt", "sentence": "Global Oral Antidiabetic Drugs Market Insights 2018-2025: Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis", "score": 0.603478, "arguments": [{"text": "Abbott", "location": [84, 90], "entities": [{"type": "Organization", "text": "Abbott", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Biocon", "location": [92, 98], "entities": [{"type": "GeopoliticalEntity", "text": "Biocon"}]}]}, {"type": "locatedAt", "sentence": "Global Oral Antidiabetic Drugs Market Insights 2018-2025: Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis", "score": 0.556838, "arguments": [{"text": "Biocon", "location": [92, 98], "entities": [{"type": "GeopoliticalEntity", "text": "Biocon"}]}, {"text": "Sanofi", "location": [100, 106], "entities": [{"type": "GeopoliticalEntity", "text": "Sanofi"}]}]}, {"type": "locatedAt", "sentence": "Global Oral Antidiabetic Drugs Market Insights 2018-2025: Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis", "score": 0.592284, "arguments": [{"text": "Sanofi", "location": [100, 106], "entities": [{"type": "GeopoliticalEntity", "text": "Sanofi"}]}, {"text": "Sunpharma", "location": [108, 117], "entities": [{"type": "GeopoliticalEntity", "text": "Sunpharma"}]}]}, {"type": "basedIn", "sentence": "Global Oral Antidiabetic Drugs Market Insights 2018-2025: Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis", "score": 0.524669, "arguments": [{"text": "Novartis", "location": [119, 127], "entities": [{"type": "Organization", "text": "Novartis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Sunpharma", "location": [108, 117], "entities": [{"type": "GeopoliticalEntity", "text": "Sunpharma"}]}]}], "keywords": [{"text": "Eli Lilly", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.856937, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.69617, "count": 1}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.679178, "count": 1}, {"text": "Abbott", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.662205, "count": 1}, {"text": "Global Oral Antidiabetic Drugs Market Insights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612944, "count": 1}, {"text": "Sanofi", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612508, "count": 1}, {"text": "Novartis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577236, "count": 1}, {"text": "Biocon", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417963, "count": 1}, {"text": "Sunpharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.375502, "count": 1}]}, "crawl_date": "2018-11-17T23:36:38Z", "url": "http://blamfluie.com/global-oral-antidiabetic-drugs-market-insights-2018-2025-eli-lilly-merck-pfizer-abbott-biocon-sanofi-sunpharma-novartis/", "host": "blamfluie.com", "text": "The well-established players in the market are Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Boehringer Ingelheim, Takeda Pharmaceuticals, Oramed Pharmaceuticals, Jiangsu Wanbang, Nanjing Xinbai.", "main_image_url": "http://blamfluie.com/wp-content/uploads/2018/11/Global-Oral-Antidiabetic-Drugs-Market.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-17T23:30:00Z", "enriched_text": {"entities": [{"count": 8, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Oral Antidiabetic Drugs", "relevance": 0.89409, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Technical Data and Manufacturing Plants Analysis of Oral Antidiabetic Drugs", "relevance": 0.429331, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Analysis of Oral Antidiabetic Drugs", "relevance": 0.409337, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Classification of Oral Antidiabetic Drugs", "relevance": 0.377366, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oral Antidiabetic Drugs", "relevance": 0.364918, "type": "PrintMedia"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.206656, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.162286, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.161036, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck", "relevance": 0.156619, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biocon", "relevance": 0.150221, "type": "Company", "disambiguation": {"subtype": [], "name": "Biocon", "dbpedia_resource": "http://dbpedia.org/resource/Biocon"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott", "relevance": 0.146709, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sunpharma", "relevance": 0.141029, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.461414, "label": "negative"}, "text": "Takeda Pharmaceuticals", "relevance": 0.139744, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim", "relevance": 0.139487, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novo Nordisk", "relevance": 0.133021, "type": "Company", "disambiguation": {"subtype": [], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"count": 2, "sentiment": {"score": -0.517898, "label": "negative"}, "text": "Oramed Pharmaceuticals", "relevance": 0.123614, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nanjing Xinbai", "relevance": 0.121666, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jiangsu Wanbang", "relevance": 0.116901, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "segmentations Sulfonylureas", "relevance": 0.113388, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "product development", "relevance": 0.0967295, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.0932044, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.0927819, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.0851184, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Taiwan", "relevance": 0.0811491, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.348856, "label": "positive"}, "text": "China", "relevance": 0.0805039, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Korea", "relevance": 0.0771033, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0.625179, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The global \u201c Oral Antidiabetic Drugs market \u201d research report", "keywords": [{"text": "Oral Antidiabetic Drugs"}, {"text": "research report"}, {"text": "market"}]}, "sentence": " The global \u201c Oral Antidiabetic Drugs market \u201d research report enlists and explains all the minute details about the Oral Antidiabetic Drugs market.", "object": {"text": "all the minute details about the Oral Antidiabetic Drugs market", "keywords": [{"text": "Oral Antidiabetic Drugs"}]}, "action": {"verb": {"text": "explain", "tense": "present"}, "text": "explains", "normalized": "explain"}}, {"subject": {"text": "It"}, "sentence": " It also sheds light on the significant features and aspects of the market and explains it with appropriate statistics.In addition, it also highlights the dominating players in the market joined with their market share.", "object": {"text": "light", "keywords": [{"text": "light"}]}, "action": {"verb": {"text": "shed", "tense": "present"}, "text": "sheds", "normalized": "shed"}}, {"subject": {"text": "It"}, "sentence": " It also sheds light on the significant features and aspects of the market and explains it with appropriate statistics.In addition, it also highlights the dominating players in the market joined with their market share.", "object": {"text": "it"}, "action": {"verb": {"text": "explain", "tense": "present"}, "text": "explains", "normalized": "explain"}}, {"subject": {"text": "it"}, "sentence": " It also sheds light on the significant features and aspects of the market and explains it with appropriate statistics.In addition, it also highlights the dominating players in the market joined with their market share.", "object": {"text": "the dominating players", "keywords": [{"text": "dominating players"}]}, "action": {"verb": {"text": "highlight", "tense": "present"}, "text": "highlights", "normalized": "highlight"}}, {"subject": {"text": "The well-established players in the market", "keywords": [{"text": "well-established players"}, {"text": "market"}], "entities": [{"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}]}, "sentence": " The well-established players in the market are Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Boehringer Ingelheim, Takeda Pharmaceuticals, Oramed Pharmaceuticals, Jiangsu Wanbang, Nanjing Xinbai.", "object": {"text": "Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Boehringer Ingelheim, Takeda Pharmaceuticals, Oramed Pharmaceuticals, Jiangsu Wanbang, Nanjing Xinbai", "keywords": [{"text": "Boehringer Ingelheim"}, {"text": "Takeda Pharmaceuticals"}, {"text": "Novo Nordisk"}, {"text": "Jiangsu Wanbang"}], "entities": [{"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"type": "Company", "text": "Merck"}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Abbott"}, {"type": "Company", "text": "Biocon", "disambiguation": {"subtype": ["Company"], "name": "Biocon", "dbpedia_resource": "http://dbpedia.org/resource/Biocon"}}, {"type": "Company", "text": "Sunpharma"}, {"type": "Company", "text": "Novartis", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Novo Nordisk", "disambiguation": {"subtype": ["Company"], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"type": "Company", "text": "Boehringer Ingelheim", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Oramed Pharmaceuticals"}, {"type": "Company", "text": "Jiangsu Wanbang"}, {"type": "Company", "text": "Nanjing Xinbai"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "its functionality", "keywords": [{"text": "functionality"}]}, "sentence": " The global Oral Antidiabetic Drugs market research report starts with the Oral Antidiabetic Drugs market overview where the market is defined and its functionality are explained.", "object": {"text": "explained"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It explains how the market is classified with respect to the types of the product, end users, applications Hospitals, Clinics, Others, features, type of raw material used, and so on.", "object": {"text": "how the market is classified with respect to the types of the product, end users, applications Hospitals, Clinics, Others, features, type of raw material used, and so on", "keywords": [{"text": "applications Hospitals"}, {"text": "end users"}, {"text": "raw material"}, {"text": "respect"}]}, "action": {"verb": {"text": "explain", "tense": "present"}, "text": "explains", "normalized": "explain"}}, {"subject": {"text": "These segments", "keywords": [{"text": "segments"}]}, "sentence": " These segments are further classified into the sub-segments for in-depth analysis and understanding of the particular market.", "object": {"text": "further classified into the sub-segments for in-depth analysis and understanding of the particular market", "keywords": [{"text": "in-depth analysis"}, {"text": "particular market"}, {"text": "sub-segments"}, {"text": "understanding"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "These segments", "keywords": [{"text": "segments"}]}, "sentence": " These segments are further classified into the sub-segments for in-depth analysis and understanding of the particular market.", "object": {"text": "into the sub-segments for in-depth analysis and understanding of the particular market", "keywords": [{"text": "in-depth analysis"}, {"text": "particular market"}, {"text": "sub-segments"}, {"text": "understanding"}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "classified", "normalized": "classify"}}, {"subject": {"text": "the report", "keywords": [{"text": "report"}]}, "sentence": " Along with the segmentation, the report covers the most trending facts of the global Oral Antidiabetic Drugs market, most prominent market, market that accounts the maximum revenue, manufacture analysis, market share, market size, market forecast trends, market sales, production, supply, demand, and so on.", "object": {"text": "the most trending facts of the global Oral Antidiabetic Drugs market, most prominent market, market that accounts the maximum revenue, manufacture analysis, market share, market size, market forecast trends, market sales, production, supply, demand, and so on", "keywords": [{"text": "Oral Antidiabetic Drugs"}, {"text": "market forecast trends"}, {"text": "trending facts"}, {"text": "maximum revenue"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "most prominent market, market", "keywords": [{"text": "prominent market"}]}, "sentence": " Along with the segmentation, the report covers the most trending facts of the global Oral Antidiabetic Drugs market, most prominent market, market that accounts the maximum revenue, manufacture analysis, market share, market size, market forecast trends, market sales, production, supply, demand, and so on.", "object": {"text": "the maximum revenue, manufacture analysis, market share, market size, market forecast trends, market sales, production, supply, demand, and so on", "keywords": [{"text": "market forecast trends"}, {"text": "maximum revenue"}, {"text": "manufacture analysis"}, {"text": "market share"}]}, "action": {"verb": {"text": "account", "tense": "present"}, "text": "accounts", "normalized": "account"}}, {"subject": {"text": "This"}, "sentence": " This can help to understand the position of market in detail.", "object": {"text": "to understand the position of market in detail", "keywords": [{"text": "position"}, {"text": "market"}]}, "action": {"verb": {"text": "help", "tense": "future"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "This"}, "sentence": " This can help to understand the position of market in detail.", "object": {"text": "the position of market", "keywords": [{"text": "position"}, {"text": "market"}]}, "action": {"verb": {"text": "understand", "tense": "future"}, "text": "can help to understand", "normalized": "can help to understand"}}, {"subject": {"text": "Additional Information", "keywords": [{"text": "Additional Information"}]}, "sentence": " Additional Information Provided In The Global Oral Antidiabetic Drugs Market Research Report", "action": {"verb": {"text": "Provided", "tense": "past"}, "text": "Provided", "normalized": "Provided"}}, {"subject": {"text": "The global Oral Antidiabetic Drugs market research report", "keywords": [{"text": "Oral Antidiabetic Drugs"}, {"text": "market research report"}], "entities": [{"type": "PrintMedia", "text": "Global Oral Antidiabetic Drugs"}]}, "sentence": " The global Oral Antidiabetic Drugs market research report highlights the factors that influence the Oral Antidiabetic Drugs market growth and product development along with technological upgradations that can boost the Oral Antidiabetic Drugs market.", "object": {"text": "the factors that influence the Oral Antidiabetic Drugs market growth and product development along with technological upgradations that can boost the Oral Antidiabetic Drugs market", "keywords": [{"text": "Oral Antidiabetic Drugs"}, {"text": "Antidiabetic Drugs market"}, {"text": "Drugs market growth"}, {"text": "technological upgradations"}], "entities": [{"type": "JobTitle", "text": "product development"}]}, "action": {"verb": {"text": "highlight", "tense": "present"}, "text": "highlights", "normalized": "highlight"}}, {"subject": {"text": "the factors", "keywords": [{"text": "factors"}]}, "sentence": " The global Oral Antidiabetic Drugs market research report highlights the factors that influence the Oral Antidiabetic Drugs market growth and product development along with technological upgradations that can boost the Oral Antidiabetic Drugs market.", "object": {"text": "the Oral Antidiabetic Drugs market growth and product development", "keywords": [{"text": "Oral Antidiabetic Drugs"}, {"text": "market growth"}, {"text": "product development"}], "entities": [{"type": "JobTitle", "text": "product development"}]}, "action": {"verb": {"text": "influence", "tense": "present"}, "text": "influence", "normalized": "influence"}}, {"subject": {"text": "technological upgradations", "keywords": [{"text": "technological upgradations"}]}, "sentence": " The global Oral Antidiabetic Drugs market research report highlights the factors that influence the Oral Antidiabetic Drugs market growth and product development along with technological upgradations that can boost the Oral Antidiabetic Drugs market.", "object": {"text": "the Oral Antidiabetic Drugs market", "keywords": [{"text": "Oral Antidiabetic Drugs"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "can boost", "normalized": "can boost"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report also covers the restraining factors that hinder the Oral Antidiabetic Drugs market growth.", "object": {"text": "the restraining factors that hinder the Oral Antidiabetic Drugs market growth", "keywords": [{"text": "Oral Antidiabetic Drugs"}, {"text": "restraining factors"}, {"text": "market growth"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "the restraining factors", "keywords": [{"text": "restraining factors"}]}, "sentence": " The report also covers the restraining factors that hinder the Oral Antidiabetic Drugs market growth.", "object": {"text": "the Oral Antidiabetic Drugs market growth", "keywords": [{"text": "Oral Antidiabetic Drugs"}, {"text": "market growth"}]}, "action": {"verb": {"text": "hinder", "tense": "present"}, "text": "hinder", "normalized": "hinder"}}, {"subject": {"text": "The global Oral Antidiabetic Drugs market research report", "keywords": [{"text": "Oral Antidiabetic Drugs"}, {"text": "market research report"}], "entities": [{"type": "PrintMedia", "text": "Global Oral Antidiabetic Drugs"}]}, "sentence": " The global Oral Antidiabetic Drugs market research report also discusses the competitive market players, their recent developments and advancements, their sales strategies which have helped them to achieve the prominent players position in the Oral Antidiabetic Drugs market.", "object": {"text": "the competitive market players, their recent developments and advancements, their sales strategies which have helped them to achieve the prominent players position in the Oral Antidiabetic Drugs market", "keywords": [{"text": "prominent players position"}, {"text": "Oral Antidiabetic Drugs"}, {"text": "competitive market players"}, {"text": "recent developments"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discusses", "normalized": "discuss"}}, {"subject": {"text": "their sales strategies", "keywords": [{"text": "sales strategies"}]}, "sentence": " The global Oral Antidiabetic Drugs market research report also discusses the competitive market players, their recent developments and advancements, their sales strategies which have helped them to achieve the prominent players position in the Oral Antidiabetic Drugs market.", "object": {"text": "to achieve the prominent players position in the Oral Antidiabetic Drugs market", "keywords": [{"text": "prominent players position"}, {"text": "Oral Antidiabetic Drugs"}]}, "action": {"verb": {"text": "help", "tense": "past"}, "text": "have helped", "normalized": "have help"}}, {"subject": {"text": "15 Chapters", "keywords": [{"text": "Chapters"}]}, "sentence": " There are 15 Chapters to display the Global Oral Antidiabetic Drugs market", "object": {"text": "the Global Oral Antidiabetic Drugs market", "keywords": [{"text": "Oral Antidiabetic Drugs"}], "entities": [{"type": "PrintMedia", "text": "Global Oral Antidiabetic Drugs"}]}, "action": {"verb": {"text": "display", "tense": "future"}, "text": "to display", "normalized": "to display"}}], "concepts": [{"text": "Anti-diabetic drug", "relevance": 0.945817, "dbpedia_resource": "http://dbpedia.org/resource/Anti-diabetic_drug"}, {"text": "Marketing", "relevance": 0.941353, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Bankruptcy in the United States", "relevance": 0.930553, "dbpedia_resource": "http://dbpedia.org/resource/Bankruptcy_in_the_United_States"}, {"text": "Exenatide", "relevance": 0.78075, "dbpedia_resource": "http://dbpedia.org/resource/Exenatide"}, {"text": "United States bankruptcy law", "relevance": 0.742002, "dbpedia_resource": "http://dbpedia.org/resource/United_States_bankruptcy_law"}, {"text": "Economics", "relevance": 0.71333, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Metformin", "relevance": 0.687866, "dbpedia_resource": "http://dbpedia.org/resource/Metformin"}, {"text": "Alpha-glucosidase inhibitor", "relevance": 0.675577, "dbpedia_resource": "http://dbpedia.org/resource/Alpha-glucosidase_inhibitor"}, {"text": "InnoMed PredTox", "relevance": 0.639417, "dbpedia_resource": "http://dbpedia.org/resource/InnoMed_PredTox"}, {"text": "Growth hormone", "relevance": 0.632243, "dbpedia_resource": "http://dbpedia.org/resource/Growth_hormone"}, {"text": "Miglitol", "relevance": 0.609957, "dbpedia_resource": "http://dbpedia.org/resource/Miglitol"}, {"text": "Novo Nordisk", "relevance": 0.591022, "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}, {"text": "Anti-diabetic drugs", "relevance": 0.58675, "dbpedia_resource": "http://dbpedia.org/resource/Anti-diabetic_drugs"}, {"text": "Boehringer Ingelheim", "relevance": 0.569146, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Pioglitazone", "relevance": 0.5589, "dbpedia_resource": "http://dbpedia.org/resource/Pioglitazone"}, {"text": "Sitagliptin", "relevance": 0.542608, "dbpedia_resource": "http://dbpedia.org/resource/Sitagliptin"}, {"text": "Phenformin", "relevance": 0.539607, "dbpedia_resource": "http://dbpedia.org/resource/Phenformin"}, {"text": "Diabetes mellitus", "relevance": 0.522902, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}, {"text": "Buformin", "relevance": 0.514696, "dbpedia_resource": "http://dbpedia.org/resource/Buformin"}], "categories": [{"score": 0.854624, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.811445, "label": "/health and fitness"}, {"score": 0.768843, "label": "/business and industrial/manufacturing"}], "relations": [{"type": "locatedAt", "sentence": "Global Oral Antidiabetic Drugs Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis The global \" Oral Antidiabetic Drugs market \" research report enlists and explains all the minute details about the Oral Antidiabetic Drugs market.", "score": 0.592288, "arguments": [{"text": "Abbott", "location": [57, 63], "entities": [{"type": "Organization", "text": "Abbott", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Biocon", "location": [65, 71], "entities": [{"type": "GeopoliticalEntity", "text": "Biocon"}]}]}, {"type": "locatedAt", "sentence": "The well-established players in the market are Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Boehringer Ingelheim, Takeda Pharmaceuticals, Oramed Pharmaceuticals, Jiangsu Wanbang, Nanjing Xinbai.", "score": 0.603478, "arguments": [{"text": "Abbott", "location": [541, 547], "entities": [{"type": "Organization", "text": "Abbott", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Biocon", "location": [549, 555], "entities": [{"type": "GeopoliticalEntity", "text": "Biocon"}]}]}, {"type": "partOf", "sentence": "There are 15 Chapters to display the Global Oral Antidiabetic Drugs market Chapter 1 , Definition, Specifications and Classification of Oral Antidiabetic Drugs , Applications of Oral Antidiabetic Drugs , Market Segment by Regions; Chapter 2 , Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3 , Technical Data and Manufacturing Plants Analysis of Oral Antidiabetic Drugs , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4 , Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5 and 6 , Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Oral Antidiabetic Drugs Segment Market Analysis (", "score": 0.528932, "arguments": [{"text": "Oral Antidiabetic Drugs", "location": [3346, 3369], "entities": [{"type": "Organization", "text": "The Oral Antidiabetic Drugs Segment Market Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Market Segment", "location": [3372, 3386], "entities": [{"type": "Organization", "text": "Market Segment", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "There are 15 Chapters to display the Global Oral Antidiabetic Drugs market Chapter 1 , Definition, Specifications and Classification of Oral Antidiabetic Drugs , Applications of Oral Antidiabetic Drugs , Market Segment by Regions; Chapter 2 , Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3 , Technical Data and Manufacturing Plants Analysis of Oral Antidiabetic Drugs , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4 , Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5 and 6 , Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Oral Antidiabetic Drugs Segment Market Analysis (", "score": 0.683997, "arguments": [{"text": "Manufacturing Plants Analysis", "location": [3549, 3578], "entities": [{"type": "Organization", "text": "Manufacturing Plants Distribution", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Oral Antidiabetic Drugs", "location": [3582, 3605], "entities": [{"type": "Organization", "text": "The Oral Antidiabetic Drugs Segment Market Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "There are 15 Chapters to display the Global Oral Antidiabetic Drugs market Chapter 1 , Definition, Specifications and Classification of Oral Antidiabetic Drugs , Applications of Oral Antidiabetic Drugs , Market Segment by Regions; Chapter 2 , Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3 , Technical Data and Manufacturing Plants Analysis of Oral Antidiabetic Drugs , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4 , Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5 and 6 , Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Oral Antidiabetic Drugs Segment Market Analysis (", "score": 0.372643, "arguments": [{"text": "Price Analysis", "location": [3864, 3878], "entities": [{"type": "Person", "text": "Price Analysis"}]}, {"text": "Company", "location": [3880, 3887], "entities": [{"type": "Organization", "text": "Segment"}]}]}, {"type": "partOf", "sentence": "by Type); Chapter 7 and 8 , The Oral Antidiabetic Drugs Segment Market Analysis (by Application) Major Manufacturers Analysis of Oral Antidiabetic Drugs ; Chapter 9 , Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Sulfonylureas, Biguanides, Meglitinides, Alpha-glucosidase Inhibitors, Others, Market Trend by Application Hospitals, Clinics, Others; Chapter 10 , Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11 , The Consumers Analysis of Global Oral Antidiabetic Drugs ; Chapter 12 , Oral Antidiabetic Drugs Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15 , Oral Antidiabetic Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.", "score": 0.628697, "arguments": [{"text": "Market Trend", "location": [4378, 4390], "entities": [{"type": "Organization", "text": "Market Trend Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Application Hospitals", "location": [4394, 4415], "entities": [{"type": "Organization", "text": "Application Hospitals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "by Type); Chapter 7 and 8 , The Oral Antidiabetic Drugs Segment Market Analysis (by Application) Major Manufacturers Analysis of Oral Antidiabetic Drugs ; Chapter 9 , Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Sulfonylureas, Biguanides, Meglitinides, Alpha-glucosidase Inhibitors, Others, Market Trend by Application Hospitals, Clinics, Others; Chapter 10 , Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11 , The Consumers Analysis of Global Oral Antidiabetic Drugs ; Chapter 12 , Oral Antidiabetic Drugs Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15 , Oral Antidiabetic Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.", "score": 0.489066, "arguments": [{"text": "distributors", "location": [4784, 4796], "entities": [{"type": "Organization", "text": "distributors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Oral Antidiabetic Drugs", "location": [4745, 4768], "entities": [{"type": "Organization", "text": "The Oral Antidiabetic Drugs Segment Market Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Global Oral Antidiabetic Drugs Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis The global \" Oral Antidiabetic Drugs market \" research report enlists and explains all the minute details about the Oral Antidiabetic Drugs market.", "score": 0.516863, "arguments": [{"text": "Biocon", "location": [65, 71], "entities": [{"type": "GeopoliticalEntity", "text": "Biocon"}]}, {"text": "Sanofi", "location": [73, 79], "entities": [{"type": "GeopoliticalEntity", "text": "Sanofi"}]}]}, {"type": "locatedAt", "sentence": "The well-established players in the market are Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Boehringer Ingelheim, Takeda Pharmaceuticals, Oramed Pharmaceuticals, Jiangsu Wanbang, Nanjing Xinbai.", "score": 0.556838, "arguments": [{"text": "Biocon", "location": [549, 555], "entities": [{"type": "GeopoliticalEntity", "text": "Biocon"}]}, {"text": "Sanofi", "location": [557, 563], "entities": [{"type": "GeopoliticalEntity", "text": "Sanofi"}]}]}, {"type": "locatedAt", "sentence": "The global Oral Antidiabetic Drugs market research report also brings to the lime light the leading market players Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Boehringer Ingelheim, Takeda Pharmaceuticals, Oramed Pharmaceuticals, Jiangsu Wanbang, Nanjing Xinbai] which contribute in both aspects, value and volume of sales and the regions that have moderate and slow growth.", "score": 0.96825, "arguments": [{"text": "Biocon", "location": [2626, 2632], "entities": [{"type": "GeopoliticalEntity", "text": "Biocon"}]}, {"text": "Sanofi", "location": [2634, 2640], "entities": [{"type": "GeopoliticalEntity", "text": "Sanofi"}]}]}, {"type": "locatedAt", "sentence": "Global Oral Antidiabetic Drugs Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis The global \" Oral Antidiabetic Drugs market \" research report enlists and explains all the minute details about the Oral Antidiabetic Drugs market.", "score": 0.55088, "arguments": [{"text": "Sanofi", "location": [73, 79], "entities": [{"type": "GeopoliticalEntity", "text": "Sanofi"}]}, {"text": "Sunpharma", "location": [81, 90], "entities": [{"type": "GeopoliticalEntity", "text": "Sunpharma"}]}]}, {"type": "locatedAt", "sentence": "The well-established players in the market are Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Boehringer Ingelheim, Takeda Pharmaceuticals, Oramed Pharmaceuticals, Jiangsu Wanbang, Nanjing Xinbai.", "score": 0.591215, "arguments": [{"text": "Sanofi", "location": [557, 563], "entities": [{"type": "GeopoliticalEntity", "text": "Sanofi"}]}, {"text": "Sunpharma", "location": [565, 574], "entities": [{"type": "GeopoliticalEntity", "text": "Sunpharma"}]}]}, {"type": "locatedAt", "sentence": "The global Oral Antidiabetic Drugs market research report also brings to the lime light the leading market players Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Boehringer Ingelheim, Takeda Pharmaceuticals, Oramed Pharmaceuticals, Jiangsu Wanbang, Nanjing Xinbai] which contribute in both aspects, value and volume of sales and the regions that have moderate and slow growth.", "score": 0.972025, "arguments": [{"text": "Sanofi", "location": [2634, 2640], "entities": [{"type": "GeopoliticalEntity", "text": "Sanofi"}]}, {"text": "Sunpharma", "location": [2642, 2651], "entities": [{"type": "GeopoliticalEntity", "text": "Sunpharma"}]}]}, {"type": "agentOf", "sentence": "sample.html?repid=65997 The Global Oral Antidiabetic Drugs Market Research Report Overview The global Oral Antidiabetic Drugs market research report starts with the Oral Antidiabetic Drugs market overview where the market is defined and its functionality are explained.", "score": 0.523969, "arguments": [{"text": "its", "location": [941, 944], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "explained", "location": [963, 972], "entities": [{"type": "EventCommunication", "text": "explained"}]}]}, {"type": "locatedAt", "sentence": "The second part of the report brings to the light the detailed study of segmentations Sulfonylureas, Biguanides, Meglitinides, Alpha-glucosidase Inhibitors, Others of the Oral Antidiabetic Drugs market.", "score": 0.600865, "arguments": [{"text": "Biguanides", "location": [1075, 1085], "entities": [{"type": "GeopoliticalEntity", "text": "Biguanides"}]}, {"text": "Meglitinides", "location": [1087, 1099], "entities": [{"type": "GeopoliticalEntity", "text": "Meglitinides"}]}]}, {"type": "locatedAt", "sentence": "by Type); Chapter 7 and 8 , The Oral Antidiabetic Drugs Segment Market Analysis (by Application) Major Manufacturers Analysis of Oral Antidiabetic Drugs ; Chapter 9 , Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Sulfonylureas, Biguanides, Meglitinides, Alpha-glucosidase Inhibitors, Others, Market Trend by Application Hospitals, Clinics, Others; Chapter 10 , Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11 , The Consumers Analysis of Global Oral Antidiabetic Drugs ; Chapter 12 , Oral Antidiabetic Drugs Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15 , Oral Antidiabetic Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.", "score": 0.603913, "arguments": [{"text": "Biguanides", "location": [4314, 4324], "entities": [{"type": "GeopoliticalEntity", "text": "Biguanides"}]}, {"text": "Meglitinides", "location": [4326, 4338], "entities": [{"type": "GeopoliticalEntity", "text": "Meglitinides"}]}]}, {"type": "locatedAt", "sentence": "The second part of the report brings to the light the detailed study of segmentations Sulfonylureas, Biguanides, Meglitinides, Alpha-glucosidase Inhibitors, Others of the Oral Antidiabetic Drugs market.", "score": 0.642774, "arguments": [{"text": "Meglitinides", "location": [1087, 1099], "entities": [{"type": "GeopoliticalEntity", "text": "Meglitinides"}]}, {"text": "Alpha", "location": [1101, 1106], "entities": [{"type": "GeopoliticalEntity", "text": "Alpha"}]}]}, {"type": "locatedAt", "sentence": "by Type); Chapter 7 and 8 , The Oral Antidiabetic Drugs Segment Market Analysis (by Application) Major Manufacturers Analysis of Oral Antidiabetic Drugs ; Chapter 9 , Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Sulfonylureas, Biguanides, Meglitinides, Alpha-glucosidase Inhibitors, Others, Market Trend by Application Hospitals, Clinics, Others; Chapter 10 , Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11 , The Consumers Analysis of Global Oral Antidiabetic Drugs ; Chapter 12 , Oral Antidiabetic Drugs Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15 , Oral Antidiabetic Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.", "score": 0.640975, "arguments": [{"text": "Meglitinides", "location": [4326, 4338], "entities": [{"type": "GeopoliticalEntity", "text": "Meglitinides"}]}, {"text": "Alpha", "location": [4340, 4345], "entities": [{"type": "GeopoliticalEntity", "text": "Alpha"}]}]}, {"type": "employedBy", "sentence": "The second part of the report brings to the light the detailed study of segmentations Sulfonylureas, Biguanides, Meglitinides, Alpha-glucosidase Inhibitors, Others of the Oral Antidiabetic Drugs market.", "score": 0.368087, "arguments": [{"text": "Others", "location": [1131, 1137], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "Oral Antidiabetic Drugs", "location": [1145, 1168], "entities": [{"type": "Organization", "text": "The Oral Antidiabetic Drugs Segment Market Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "The global Oral Antidiabetic Drugs market research report also brings to the lime light the leading market players Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Boehringer Ingelheim, Takeda Pharmaceuticals, Oramed Pharmaceuticals, Jiangsu Wanbang, Nanjing Xinbai] which contribute in both aspects, value and volume of sales and the regions that have moderate and slow growth.", "score": 0.931305, "arguments": [{"text": "Eli Lilly", "location": [2592, 2601], "entities": [{"type": "Person", "text": "Eli Lilly"}]}, {"text": "players", "location": [2584, 2591], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "employedBy", "sentence": "The global Oral Antidiabetic Drugs market research report also brings to the lime light the leading market players Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Boehringer Ingelheim, Takeda Pharmaceuticals, Oramed Pharmaceuticals, Jiangsu Wanbang, Nanjing Xinbai] which contribute in both aspects, value and volume of sales and the regions that have moderate and slow growth.", "score": 0.506347, "arguments": [{"text": "Eli Lilly", "location": [2592, 2601], "entities": [{"type": "Person", "text": "Eli Lilly"}]}, {"text": "Merck", "location": [2603, 2608], "entities": [{"type": "Organization", "text": "Merck", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Oral Antidiabetic Drugs market", "sentiment": {"score": 0.371174, "mixed": "1", "label": "positive"}, "relevance": 0.887744, "count": 4}, {"text": "research report", "sentiment": {"score": -0.866416, "label": "negative"}, "relevance": 0.709015, "count": 1}, {"text": "depth analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.70023, "count": 1}, {"text": "aspects of the market", "sentiment": {"score": 0.70437, "label": "positive"}, "relevance": 0.624702, "count": 1}, {"text": "market", "sentiment": {"score": 0.587508, "label": "positive"}, "relevance": 0.623513, "count": 6}, {"text": "market share", "sentiment": {"score": 0.616474, "label": "positive"}, "relevance": 0.602124, "count": 2}, {"text": "Chapter", "sentiment": {"score": 0.669141, "label": "positive"}, "relevance": 0.585899, "count": 6}, {"text": "Chapters", "sentiment": {"score": 0.566736, "label": "positive"}, "relevance": 0.585899, "count": 1}, {"text": "segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5858, "count": 1}, {"text": "Additional Information", "sentiment": {"score": 0.933641, "label": "positive"}, "relevance": 0.571039, "count": 1}, {"text": "manufacture analysis", "sentiment": {"score": 0.510331, "label": "positive"}, "relevance": 0.560999, "count": 1}, {"text": "product development", "sentiment": {"score": 0.933641, "label": "positive"}, "relevance": 0.560056, "count": 1}, {"text": "Market Segment", "sentiment": {"score": 0.566736, "label": "positive"}, "relevance": 0.559365, "count": 1}, {"text": "Manufacturing Cost Structure", "sentiment": {"score": 0.566736, "label": "positive"}, "relevance": 0.556999, "count": 1}, {"text": "Oral Antidiabetic Drugs market overview", "sentiment": {"score": 0.606699, "label": "positive"}, "relevance": 0.554717, "count": 1}, {"text": "minute details", "sentiment": {"score": -0.866416, "label": "negative"}, "relevance": 0.554067, "count": 1}, {"text": "Manufacturing Process", "sentiment": {"score": 0.566736, "label": "positive"}, "relevance": 0.55392, "count": 1}, {"text": "Novo Nordisk", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553391, "count": 2}, {"text": "Boehringer Ingelheim", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550666, "count": 2}, {"text": "market sales", "sentiment": {"score": 0.510331, "label": "positive"}, "relevance": 0.548963, "count": 1}, {"text": "significant features", "sentiment": {"score": 0.70437, "label": "positive"}, "relevance": 0.546366, "count": 1}, {"text": "Others of the Oral Antidiabetic Drugs market", "sentiment": {"score": 0.580832, "label": "positive"}, "relevance": 0.545805, "count": 1}, {"text": "market size", "sentiment": {"score": 0.510331, "label": "positive"}, "relevance": 0.544917, "count": 1}, {"text": "sub-segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543736, "count": 1}, {"text": "recent developments", "sentiment": {"score": 0.82775, "label": "positive"}, "relevance": 0.542692, "count": 1}, {"text": "United States", "sentiment": {"score": 0.716707, "label": "positive"}, "relevance": 0.54222, "count": 1}, {"text": "players", "sentiment": {"score": 0.70437, "label": "positive"}, "relevance": 0.541386, "count": 2}, {"text": "Global Oral Antidiabetic Drugs Eli Lilly", "sentiment": {"score": -0.866416, "label": "negative"}, "relevance": 0.540857, "count": 1}, {"text": "detailed study of segmentations Sulfonylureas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538746, "count": 1}, {"text": "report", "sentiment": {"score": 0.510331, "label": "positive"}, "relevance": 0.537675, "count": 2}, {"text": "light", "sentiment": {"score": 0.70437, "label": "positive"}, "relevance": 0.537085, "count": 2}, {"text": "Technical Data", "sentiment": {"score": 0.566736, "label": "positive"}, "relevance": 0.535616, "count": 1}, {"text": "type of raw material", "sentiment": {"score": 0.580832, "label": "positive"}, "relevance": 0.5322, "count": 1}, {"text": "Company Segment", "sentiment": {"score": 0.716707, "label": "positive"}, "relevance": 0.53191, "count": 3}, {"text": "second part of the report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531469, "count": 1}, {"text": "segmentation", "sentiment": {"score": 0.510331, "label": "positive"}, "relevance": 0.529772, "count": 1}, {"text": "market position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527616, "count": 1}, {"text": "types of the product", "sentiment": {"score": 0.580832, "label": "positive"}, "relevance": 0.52522, "count": 1}, {"text": "Takeda Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522986, "count": 2}, {"text": "Capacity", "sentiment": {"score": 0.566736, "label": "positive"}, "relevance": 0.522905, "count": 1}, {"text": "Merck", "sentiment": {"score": -0.866416, "label": "negative"}, "relevance": 0.522041, "count": 3}, {"text": "Pfizer", "sentiment": {"score": -0.866416, "label": "negative"}, "relevance": 0.521713, "count": 3}, {"text": "aspects", "sentiment": {"score": 0.752574, "label": "positive"}, "relevance": 0.521451, "count": 1}, {"text": "Abbott", "sentiment": {"score": -0.866416, "label": "negative"}, "relevance": 0.521366, "count": 3}, {"text": "trends", "sentiment": {"score": 0.510331, "label": "positive"}, "relevance": 0.520963, "count": 1}, {"text": "Sanofi", "sentiment": {"score": -0.866416, "label": "negative"}, "relevance": 0.520577, "count": 3}, {"text": "regions", "sentiment": {"score": 0.752574, "label": "positive"}, "relevance": 0.519774, "count": 1}, {"text": "Novartis", "sentiment": {"score": -0.866416, "label": "negative"}, "relevance": 0.519733, "count": 3}, {"text": "Application", "sentiment": {"score": 0.716707, "label": "positive"}, "relevance": 0.518297, "count": 1}, {"text": "advancements", "sentiment": {"score": 0.82775, "label": "positive"}, "relevance": 0.51804, "count": 1}]}, "extracted_metadata": {"sha1": "6ee33cec9729f2754ae314ab718edf3d211099ea", "filename": "1542497798254.zip-b265a5125c977d5afc0075362e5231eb.xml", "file_type": "json"}, "external_links": ["http://www.reportsbuzz.com/65997/global-oral-antidiabetic-drugs-market-outlook-2018-2025/", "http://www.reportsbuzz.com/request-for-sample.html?repid=65997", "http://www.reportsbuzz.com/inquiry-for-buying.html?repid=65997"], "title": "Global Oral Antidiabetic Drugs Market Insights 2018-2025: Eli Lilly, Merck, Pfizer, Abbott, Biocon, Sanofi, Sunpharma, Novartis", "forum_title": "Blamfluie"}, {"id": "8hPdLih1snohLQUps0ELW1jZM5XDoG1lp_YBjbkZhszI9PYa21h87ri59FVEe2NP", "result_metadata": {"score": 23.31398}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ACAAI Annual Scientific Meeting", "relevance": 0.33, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Organization"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Scientific journal", "relevance": 0.856286, "dbpedia_resource": "http://dbpedia.org/resource/Scientific_journal"}], "categories": [{"score": 0.681043, "label": "/technology and computing/enterprise technology/data management"}, {"score": 0.677949, "label": "/science"}, {"score": 0.626644, "label": "/education/homework and study tips"}], "relations": [{"type": "locatedAt", "sentence": "Shire Announces New HELP Study(TM) Data for Lanadelumab in HAE at 2018 ACAAI Annual Scientific Meeting", "score": 0.545526, "arguments": [{"text": "Data for Lanadelumab", "location": [35, 55], "entities": [{"type": "Organization", "text": "Data for Lanadelumab"}]}, {"text": "HAE", "location": [59, 62], "entities": [{"type": "GeopoliticalEntity", "text": "HAE"}]}]}], "keywords": [{"text": "Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.961093, "count": 1}, {"text": "New HELP Study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.931414, "count": 1}, {"text": "TM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.75324, "count": 1}, {"text": "Data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.734779, "count": 1}, {"text": "HAE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.695781, "count": 1}, {"text": "ACAAI Annual Scientific Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54143, "count": 1}, {"text": "Lanadelumab", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.258962, "count": 1}]}, "crawl_date": "2018-11-18T06:14:28Z", "url": "https://globenewswire.com/news-release/2018/11/16/1652822/0/en/Shire-Announces-New-HELP-Study-TM-Data-for-Lanadelumab-in-HAE-at-2018-ACAAI-Annual-Scientific-Meeting.html", "host": "globenewswire.com", "text": "Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the UK Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire\u2019s most recent Annual Report on Form 10-K and in Shire\u2019s subsequent Quarterly Reports on Form", "main_image_url": "http://globenewswire.com/Attachment/LogoDisplay/556715?filename=556715.jpg&size=1", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T07:00:00Z", "enriched_text": {"entities": [{"count": 12, "sentiment": {"score": -0.326261, "label": "negative"}, "text": "Shire", "relevance": 0.817889, "type": "Organization"}, {"count": 7, "sentiment": {"score": -0.384545, "label": "negative"}, "text": "Shire", "relevance": 0.812927, "type": "Person"}, {"count": 6, "sentiment": {"score": -0.487456, "label": "negative"}, "text": "Shire", "relevance": 0.623558, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.589505, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 3, "sentiment": {"score": -0.590764, "label": "negative"}, "text": "Shire", "relevance": 0.528555, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ophthalmics", "relevance": 0.210072, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0.213166, "label": "positive"}, "text": "United Kingdom", "relevance": 0.192479, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.182216, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities and Exchange Commission", "relevance": 0.181211, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Union", "relevance": 0.17527, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Baxalta", "relevance": 0.160628, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10-K", "relevance": 0.159941, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "8-K", "relevance": 0.159941, "type": "Quantity"}], "sentiment": {"document": {"score": 0.396387, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions.", "object": {"text": "the global biotechnology leader serving patients", "keywords": [{"text": "global biotechnology leader"}, {"text": "patients"}], "entities": [{"type": "Person", "text": "Shire"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions.", "object": {"text": "to push boundaries", "keywords": [{"text": "boundaries"}]}, "action": {"verb": {"text": "seek", "tense": "present"}, "text": "seek", "normalized": "seek"}}, {"subject": {"text": "We"}, "sentence": " We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions.", "object": {"text": "boundaries", "keywords": [{"text": "boundaries"}]}, "action": {"verb": {"text": "push", "tense": "future"}, "text": "seek to push", "normalized": "seek to push"}}, {"subject": {"text": "We"}, "sentence": " We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions.", "object": {"text": "new possibilities for patient communities who often have few or no other champions", "keywords": [{"text": "new possibilities"}, {"text": "patient communities"}, {"text": "champions"}]}, "action": {"verb": {"text": "discover", "tense": "present"}, "text": "discovering", "normalized": "discover"}}, {"subject": {"text": "We"}, "sentence": " We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions.", "object": {"text": "new possibilities", "keywords": [{"text": "new possibilities"}]}, "action": {"verb": {"text": "deliver", "tense": "present"}, "text": "delivering", "normalized": "deliver"}}, {"subject": {"text": "patient communities", "keywords": [{"text": "patient communities"}]}, "sentence": " We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions.", "object": {"text": "few or no other champions", "keywords": [{"text": "champions"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "we"}, "sentence": " Relentlessly on the edge of what\u2019s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope.", "object": {"text": "serial innovators", "keywords": [{"text": "serial innovators"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "a diverse pipeline", "keywords": [{"text": "diverse pipeline"}]}, "sentence": " Relentlessly on the edge of what\u2019s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope.", "object": {"text": "fresh thinking and new hope", "keywords": [{"text": "fresh thinking"}, {"text": "new hope"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offering", "normalized": "offer"}}, {"subject": {"text": "we"}, "sentence": " Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients.", "object": {"text": "with healthcare communities in over 100 countries", "keywords": [{"text": "healthcare communities"}, {"text": "countries"}]}, "action": {"verb": {"text": "Serving", "tense": "present"}, "text": "Serving", "normalized": "Serving"}}, {"subject": {"text": "we"}, "sentence": " Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients.", "object": {"text": "with healthcare communities", "keywords": [{"text": "healthcare communities"}]}, "action": {"verb": {"text": "partner", "tense": "present"}, "text": "partnering", "normalized": "partner"}}, {"subject": {"text": "we"}, "sentence": " Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients.", "object": {"text": "to be part of the entire patient journey to enable earlier diagnosis", "keywords": [{"text": "entire patient journey"}, {"text": "earlier diagnosis"}]}, "action": {"verb": {"text": "strive", "tense": "present"}, "text": "strive", "normalized": "strive"}}, {"subject": {"text": "we"}, "sentence": " Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients.", "object": {"text": "part of the entire patient journey", "keywords": [{"text": "entire patient journey"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "strive to be", "normalized": "strive to be"}}, {"subject": {"text": "Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine and Ophthalmics", "keywords": [{"text": "Genetic Diseases"}, {"text": "Internal Medicine"}, {"text": "Hematology"}, {"text": "Immunology"}], "entities": [{"type": "Location", "text": "Ophthalmics", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine and Ophthalmics.", "object": {"text": "Our diverse portfolio of therapeutic areas", "keywords": [{"text": "diverse portfolio"}, {"text": "therapeutic areas"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "it"}, "sentence": " Championing patients is our call to action - it brings the opportunity - and responsibility - to change people\u2019s lives.", "object": {"text": "the opportunity - and responsibility - to change people\u2019s lives", "keywords": [{"text": "responsibility"}, {"text": "opportunity"}, {"text": "people"}, {"text": "lives"}]}, "action": {"verb": {"text": "bring", "tense": "present"}, "text": "brings", "normalized": "bring"}}, {"subject": {"text": "it"}, "sentence": " Championing patients is our call to action - it brings the opportunity - and responsibility - to change people\u2019s lives.", "object": {"text": "people\u2019s lives", "keywords": [{"text": "people"}, {"text": "lives"}]}, "action": {"verb": {"text": "change", "tense": "future"}, "text": "to change", "normalized": "to change"}}, {"subject": {"text": "herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, projected revenues, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements", "keywords": [{"text": "anticipated timing"}, {"text": "limitation statements"}, {"text": "forward-looking statements"}, {"text": "pipeline products"}]}, "sentence": " www.shire.com Forward-Looking Statements Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, projected revenues, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements.", "object": {"text": "www.shire.com Forward-Looking Statements Statements", "keywords": [{"text": "www.shire.com Forward-Looking Statements"}]}, "action": {"verb": {"text": "include", "tense": "past"}, "text": "included", "normalized": "include"}}, {"subject": {"text": "statements", "keywords": [{"text": "statements"}]}, "sentence": " www.shire.com Forward-Looking Statements Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, projected revenues, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements.", "object": {"text": "future strategy", "keywords": [{"text": "future strategy"}]}, "action": {"verb": {"text": "concern", "tense": "present"}, "text": "concerning", "normalized": "concern"}}, {"subject": {"text": "a number of risks and uncertainties", "keywords": [{"text": "uncertainties"}, {"text": "risks"}, {"text": "number"}]}, "sentence": " Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time.", "object": {"text": "Such forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "action": {"verb": {"text": "involve", "tense": "present"}, "text": "involve", "normalized": "involve"}}, {"subject": {"text": "subject to change"}, "sentence": " Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " In the event such risks or uncertainties materialize, Shire\u2019s results could be materially adversely affected.", "object": {"text": "results could be materially adversely affected", "keywords": [{"text": "results"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Shire\u2019s results", "keywords": [{"text": "Shire"}, {"text": "results"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " In the event such risks or uncertainties materialize, Shire\u2019s results could be materially adversely affected.", "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Shire\u2019s results", "keywords": [{"text": "Shire"}, {"text": "results"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " In the event such risks or uncertainties materialize, Shire\u2019s results could be materially adversely affected.", "action": {"verb": {"text": "affect", "tense": "future"}, "text": "affected", "normalized": "affect"}}, {"subject": {"text": "Shire\u2019s products", "keywords": [{"text": "Shire"}, {"text": "products"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " The risks and uncertainties include, but are not limited to, the following: Shire\u2019s products may not be a commercial success; increased pricing pressures and limits on patient access as a result of governmental regulations and market developments may affect Shire\u2019s future revenues, financial condition and results of operations; Shire depends on third parties to supply certain inputs and services critical to its operations including certain inputs, services and ingredients critical to its manufacturing processes.", "object": {"text": "a commercial success", "keywords": [{"text": "commercial success"}]}, "action": {"verb": {"text": "be", "tense": "future", "negated": true}, "text": "be", "normalized": "be"}}, {"subject": {"text": "governmental regulations and market developments", "keywords": [{"text": "governmental regulations"}, {"text": "market developments"}]}, "sentence": " The risks and uncertainties include, but are not limited to, the following: Shire\u2019s products may not be a commercial success; increased pricing pressures and limits on patient access as a result of governmental regulations and market developments may affect Shire\u2019s future revenues, financial condition and results of operations; Shire depends on third parties to supply certain inputs and services critical to its operations including certain inputs, services and ingredients critical to its manufacturing processes.", "object": {"text": "Shire\u2019s future revenues, financial condition and results of operations", "keywords": [{"text": "future revenues"}, {"text": "financial condition"}, {"text": "Shire"}, {"text": "results"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "affect", "tense": "future"}, "text": "may affect", "normalized": "may affect"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " The risks and uncertainties include, but are not limited to, the following: Shire\u2019s products may not be a commercial success; increased pricing pressures and limits on patient access as a result of governmental regulations and market developments may affect Shire\u2019s future revenues, financial condition and results of operations; Shire depends on third parties to supply certain inputs and services critical to its operations including certain inputs, services and ingredients critical to its manufacturing processes.", "object": {"text": "to supply certain inputs and services critical to its operations including certain inputs, services and ingredients critical to its manufacturing processes", "keywords": [{"text": "certain inputs"}, {"text": "manufacturing processes"}, {"text": "ingredients"}, {"text": "services"}]}, "action": {"verb": {"text": "depend", "tense": "present"}, "text": "depends", "normalized": "depend"}}, {"subject": {"text": "third parties", "keywords": [{"text": "parties"}]}, "sentence": " The risks and uncertainties include, but are not limited to, the following: Shire\u2019s products may not be a commercial success; increased pricing pressures and limits on patient access as a result of governmental regulations and market developments may affect Shire\u2019s future revenues, financial condition and results of operations; Shire depends on third parties to supply certain inputs and services critical to its operations including certain inputs, services and ingredients critical to its manufacturing processes.", "object": {"text": "certain inputs and services critical to its operations including certain inputs, services and ingredients critical to its manufacturing processes", "keywords": [{"text": "certain inputs"}, {"text": "manufacturing processes"}, {"text": "ingredients"}, {"text": "services"}]}, "action": {"verb": {"text": "supply", "tense": "future"}, "text": "to supply", "normalized": "to supply"}}, {"subject": {"text": "Any disruption to the supply chain for any of Shire\u2019s products", "keywords": [{"text": "disruption"}, {"text": "Shire"}, {"text": "supply chain"}, {"text": "products"}], "entities": []}, "sentence": " Any disruption to the supply chain for any of Shire\u2019s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time; the manufacture of Shire\u2019s products is subject to extensive oversight by various regulatory agencies.", "object": {"text": "in Shire being unable to continue marketing", "keywords": [{"text": "Shire"}, {"text": "marketing"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "result", "tense": "future"}, "text": "may result", "normalized": "may result"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "sentence": " Any disruption to the supply chain for any of Shire\u2019s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time; the manufacture of Shire\u2019s products is subject to extensive oversight by various regulatory agencies.", "object": {"text": "so"}, "action": {"verb": {"text": "do", "tense": "future"}, "text": "to do", "normalized": "to do"}}, {"subject": {"text": "the manufacture of Shire", "keywords": [{"text": "Shire"}, {"text": "manufacture"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Any disruption to the supply chain for any of Shire\u2019s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time; the manufacture of Shire\u2019s products is subject to extensive oversight by various regulatory agencies.", "object": {"text": "products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the manufacture of Shire\u2019s products", "keywords": [{"text": "Shire"}, {"text": "manufacture"}, {"text": "products"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Any disruption to the supply chain for any of Shire\u2019s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time; the manufacture of Shire\u2019s products is subject to extensive oversight by various regulatory agencies.", "object": {"text": "subject to extensive oversight by various regulatory agencies", "keywords": [{"text": "various regulatory agencies"}, {"text": "extensive oversight"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Regulatory approvals or interventions", "keywords": [{"text": "Regulatory approvals"}, {"text": "interventions"}]}, "sentence": " Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to, among other things, significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches; the nature of producing plasma-based therapies may prevent Shire from timely responding to market forces and effectively managing its production capacity; Shire has a portfolio of products in various stages of research and development.", "object": {"text": "with changes to manufacturing sites, ingredients or manufacturing processes", "keywords": [{"text": "ingredients"}, {"text": "changes"}, {"text": "sites"}, {"text": "processes"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "plasma-based therapies", "keywords": [{"text": "plasma-based therapies"}]}, "sentence": " Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to, among other things, significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches; the nature of producing plasma-based therapies may prevent Shire from timely responding to market forces and effectively managing its production capacity; Shire has a portfolio of products in various stages of research and development.", "object": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "action": {"verb": {"text": "prevent", "tense": "future"}, "text": "may prevent", "normalized": "may prevent"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to, among other things, significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches; the nature of producing plasma-based therapies may prevent Shire from timely responding to market forces and effectively managing its production capacity; Shire has a portfolio of products in various stages of research and development.", "object": {"text": "to market forces", "keywords": [{"text": "market forces"}]}, "action": {"verb": {"text": "respond", "tense": "future"}, "text": "responding", "normalized": "respond"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to, among other things, significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches; the nature of producing plasma-based therapies may prevent Shire from timely responding to market forces and effectively managing its production capacity; Shire has a portfolio of products in various stages of research and development.", "object": {"text": "its production capacity", "keywords": [{"text": "production capacity"}]}, "action": {"verb": {"text": "manage", "tense": "present"}, "text": "effectively managing", "normalized": "effectively manage"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to, among other things, significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches; the nature of producing plasma-based therapies may prevent Shire from timely responding to market forces and effectively managing its production capacity; Shire has a portfolio of products in various stages of research and development.", "object": {"text": "a portfolio of products in various stages of research and development", "keywords": [{"text": "various stages"}, {"text": "portfolio"}, {"text": "products"}, {"text": "research"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The successful development of these products", "keywords": [{"text": "successful development"}, {"text": "products"}]}, "sentence": " The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval; the actions of certain customers could affect Shire\u2019s ability to sell or market products profitably.", "object": {"text": "highly uncertain"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The successful development of these products", "keywords": [{"text": "successful development"}, {"text": "products"}]}, "sentence": " The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval; the actions of certain customers could affect Shire\u2019s ability to sell or market products profitably.", "object": {"text": "significant expenditures", "keywords": [{"text": "significant expenditures"}]}, "action": {"verb": {"text": "require", "tense": "present"}, "text": "requires", "normalized": "require"}}, {"subject": {"text": "these products", "keywords": [{"text": "products"}]}, "sentence": " The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval; the actions of certain customers could affect Shire\u2019s ability to sell or market products profitably.", "object": {"text": "regulatory approval", "keywords": [{"text": "regulatory approval"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "the actions of certain customers", "keywords": [{"text": "certain customers"}, {"text": "actions"}]}, "sentence": " The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval; the actions of certain customers could affect Shire\u2019s ability to sell or market products profitably.", "object": {"text": "Shire\u2019s ability to sell or market products profitably", "keywords": [{"text": "Shire"}, {"text": "ability"}, {"text": "products"}]}, "action": {"verb": {"text": "affect", "tense": "future"}, "text": "could affect", "normalized": "could affect"}}, {"subject": {"text": "certain customers", "keywords": [{"text": "certain customers"}]}, "sentence": " The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval; the actions of certain customers could affect Shire\u2019s ability to sell or market products profitably.", "object": {"text": "products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "to sell or market", "normalized": "to sell or market"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement.", "object": {"text": "on our behalf", "keywords": [{"text": "behalf"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "All forward-looking statements attributable to us or any person acting on our behalf", "keywords": [{"text": "forward-looking statements"}, {"text": "behalf"}, {"text": "person"}]}, "sentence": " All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement.", "object": {"text": "expressly qualified in their entirety by this cautionary statement", "keywords": [{"text": "cautionary statement"}, {"text": "entirety"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Readers", "keywords": [{"text": "Readers"}]}, "sentence": " Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "object": {"text": "to place undue reliance on these forward-looking statements that speak only as of the date hereof", "keywords": [{"text": "undue reliance"}, {"text": "forward-looking statements"}, {"text": "date"}]}, "action": {"verb": {"text": "caution", "tense": "past", "negated": true}, "text": "are cautioned", "normalized": "be caution"}}, {"subject": {"text": "undue reliance", "keywords": [{"text": "undue reliance"}]}, "sentence": " Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "object": {"text": "on these forward-looking statements that speak only as of the date hereof", "keywords": [{"text": "forward-looking statements"}, {"text": "date"}]}, "action": {"verb": {"text": "place", "tense": "future", "negated": true}, "text": "to place", "normalized": "to place"}}, {"subject": {"text": "these forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "action": {"verb": {"text": "speak", "tense": "present"}, "text": "speak", "normalized": "speak"}}, {"subject": {"text": "by applicable law", "keywords": [{"text": "applicable law"}]}, "sentence": " Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.", "object": {"text": "the extent", "keywords": [{"text": "extent"}]}, "action": {"verb": {"text": "require", "tense": "past"}, "text": "otherwise required", "normalized": "otherwise require"}}, {"subject": {"text": "we"}, "sentence": " Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.", "object": {"text": "not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise", "keywords": [{"text": "forward-looking statements"}, {"text": "new information"}, {"text": "future events"}, {"text": "obligation"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "we"}, "sentence": " Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.", "object": {"text": "any obligation to update or revise forward-looking statements", "keywords": [{"text": "forward-looking statements"}, {"text": "obligation"}]}, "action": {"verb": {"text": "undertake", "tense": "present", "negated": true}, "text": "undertake", "normalized": "undertake"}}, {"subject": {"text": "we"}, "sentence": " Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.", "object": {"text": "forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "action": {"verb": {"text": "update", "tense": "future"}, "text": "to update or revise", "normalized": "to update or revise"}}, {"subject": {"text": "we"}, "sentence": " Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.", "object": {"text": "forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "action": {"verb": {"text": "revise", "tense": "present"}, "text": "to update or revise", "normalized": "to update or revise"}}], "concepts": [{"text": "Form 10-K", "relevance": 0.985388, "dbpedia_resource": "http://dbpedia.org/resource/Form_10-K"}, {"text": "Product marketing", "relevance": 0.756867, "dbpedia_resource": "http://dbpedia.org/resource/Product_marketing"}, {"text": "Uncertainty", "relevance": 0.740033, "dbpedia_resource": "http://dbpedia.org/resource/Uncertainty"}, {"text": "Form 10-Q", "relevance": 0.616943, "dbpedia_resource": "http://dbpedia.org/resource/Form_10-Q"}, {"text": "Economic growth", "relevance": 0.594112, "dbpedia_resource": "http://dbpedia.org/resource/Economic_growth"}, {"text": "Risk", "relevance": 0.5414, "dbpedia_resource": "http://dbpedia.org/resource/Risk"}, {"text": "Adverse drug reaction", "relevance": 0.527835, "dbpedia_resource": "http://dbpedia.org/resource/Adverse_drug_reaction"}, {"text": "Intellectual property", "relevance": 0.526394, "dbpedia_resource": "http://dbpedia.org/resource/Intellectual_property"}], "categories": [{"score": 0.942536, "label": "/finance/financial news"}, {"score": 0.8862, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.842313, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "partOfMany", "sentence": "NOTES TO EDITORS About Shire Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions.", "score": 0.814366, "arguments": [{"text": "Shire\nShire", "location": [23, 34], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "EDITORS", "location": [9, 16], "entities": [{"type": "Person", "text": "EDITORS"}]}]}, {"type": "agentOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the UK Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \"ITEM1A: Risk Factors\", and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.626351, "arguments": [{"text": "partners", "location": [6113, 6121], "entities": [{"type": "Organization", "text": "partners"}]}, {"text": "announcement", "location": [6141, 6153], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the UK Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \"ITEM1A: Risk Factors\", and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.907391, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [6157, 6194], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announcement", "location": [6141, 6153], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "timeOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the UK Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \"ITEM1A: Risk Factors\", and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.58352, "arguments": [{"text": "May 8, 2018", "location": [6198, 6209], "entities": [{"type": "Date", "text": "May 8, 2018"}]}, {"text": "announcement", "location": [6141, 6153], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "basedIn", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the UK Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \"ITEM1A: Risk Factors\", and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.555296, "arguments": [{"text": "Takeover Code", "location": [6256, 6269], "entities": [{"type": "Organization", "text": "Takeover Code"}]}, {"text": "UK", "location": [6253, 6255], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the UK Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \"ITEM1A: Risk Factors\", and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.992537, "arguments": [{"text": "Shire", "location": [6364, 6369], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "Report", "location": [6391, 6397], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "timeOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the UK Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \"ITEM1A: Risk Factors\", and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.8525, "arguments": [{"text": "10-K", "location": [6406, 6410], "entities": [{"type": "Date", "text": "10-K"}]}, {"text": "Report", "location": [6391, 6397], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the UK Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in \"ITEM1A: Risk Factors\", and in Shire's subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.988878, "arguments": [{"text": "Shire", "location": [6418, 6423], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "Reports", "location": [6447, 6454], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "agentOf", "sentence": "Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "score": 0.834273, "arguments": [{"text": "Readers", "location": [6844, 6851], "entities": [{"type": "Person", "text": "Readers"}]}, {"text": "cautioned", "location": [6856, 6865], "entities": [{"type": "EventCommunication", "text": "cautioned"}]}]}, {"type": "memberOf", "sentence": "NOTES TO EDITORS About Shire Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions.", "score": 0.38214, "arguments": [{"text": "patients", "location": [78, 86], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "biotechnology leader", "location": [49, 69], "entities": [{"type": "Organization", "text": "biotechnology leader"}]}]}, {"type": "hasAttribute", "sentence": "NOTES TO EDITORS About Shire Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions.", "score": 0.9008, "arguments": [{"text": "patients", "location": [78, 86], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diseases", "location": [97, 105], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "residesIn", "sentence": "Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients.", "score": 0.538306, "arguments": [{"text": "patients", "location": [416, 424], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "communities", "location": [456, 467], "entities": [{"type": "Location", "text": "communities"}]}]}, {"type": "locatedAt", "sentence": "Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients.", "score": 0.952632, "arguments": [{"text": "communities", "location": [456, 467], "entities": [{"type": "Location", "text": "communities"}]}, {"text": "countries", "location": [480, 489], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine and Ophthalmics.", "score": 0.396177, "arguments": [{"text": "Our", "location": [650, 653], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "areas", "location": [687, 692], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "employedBy", "sentence": "enforce or defend the intellectual property rights required to conduct its business; Shire faces intense competition for highly qualified personnel from other companies and organizations; failure to successfully execute or attain strategic objectives from Shire's acquisitions and growth strategy may adversely affect Shire's financial condition and results of operations; Shire's growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products; a slowdown of global economic growth, or economic instability of countries in which Shire does business, could have negative consequences for Shire's business and increase the risk of non-payment by Shire's customers; changes in foreign currency exchange rates and interest rates could have a material adverse effect on Shire's operating results and liquidity;", "score": 0.412236, "arguments": [{"text": "personnel", "location": [4233, 4242], "entities": [{"type": "Person", "text": "personnel"}]}, {"text": "organizations", "location": [4268, 4281], "entities": [{"type": "Organization", "text": "organizations"}]}]}, {"type": "agentOf", "sentence": "enforce or defend the intellectual property rights required to conduct its business; Shire faces intense competition for highly qualified personnel from other companies and organizations; failure to successfully execute or attain strategic objectives from Shire's acquisitions and growth strategy may adversely affect Shire's financial condition and results of operations; Shire's growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products; a slowdown of global economic growth, or economic instability of countries in which Shire does business, could have negative consequences for Shire's business and increase the risk of non-payment by Shire's customers; changes in foreign currency exchange rates and interest rates could have a material adverse effect on Shire's operating results and liquidity;", "score": 0.448309, "arguments": [{"text": "Shire", "location": [4351, 4356], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "acquisitions", "location": [4359, 4371], "entities": [{"type": "EventBusiness", "text": "acquisitions"}]}]}, {"type": "partOfMany", "sentence": "enforce or defend the intellectual property rights required to conduct its business; Shire faces intense competition for highly qualified personnel from other companies and organizations; failure to successfully execute or attain strategic objectives from Shire's acquisitions and growth strategy may adversely affect Shire's financial condition and results of operations; Shire's growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products; a slowdown of global economic growth, or economic instability of countries in which Shire does business, could have negative consequences for Shire's business and increase the risk of non-payment by Shire's customers; changes in foreign currency exchange rates and interest rates could have a material adverse effect on Shire's operating results and liquidity;", "score": 0.214474, "arguments": [{"text": "Shire", "location": [4876, 4881], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "customers", "location": [4884, 4893], "entities": [{"type": "Person", "text": "customers"}]}]}], "keywords": [{"text": "Shire\u2019s results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.689497, "count": 1}, {"text": "pipeline products", "sentiment": {"score": 0.552925, "label": "positive"}, "relevance": 0.687513, "count": 1}, {"text": "shire", "sentiment": {"score": 0.552925, "label": "positive"}, "relevance": 0.686315, "count": 1}, {"text": "Shire\u2019s products", "sentiment": {"score": 0.525796, "label": "positive"}, "relevance": 0.636736, "count": 3}, {"text": "Statements Statements", "sentiment": {"score": 0.552925, "label": "positive"}, "relevance": 0.593126, "count": 1}, {"text": "Shire", "sentiment": {"score": -0.316619, "mixed": "1", "label": "negative"}, "relevance": 0.577661, "count": 7}, {"text": "Shire\u2019s future revenues", "sentiment": {"score": 0.735621, "label": "positive"}, "relevance": 0.574544, "count": 1}, {"text": "intellectual property rights", "sentiment": {"score": 0.251019, "label": "positive"}, "relevance": 0.567062, "count": 2}, {"text": "product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557383, "count": 1}, {"text": "financial condition", "sentiment": {"score": 0.525796, "label": "positive"}, "relevance": 0.557095, "count": 2}, {"text": "patients", "sentiment": {"score": 0.479471, "mixed": "1", "label": "positive"}, "relevance": 0.554076, "count": 3}, {"text": "results of operations", "sentiment": {"score": 0.44098, "label": "positive"}, "relevance": 0.551299, "count": 3}, {"text": "products", "sentiment": {"score": 0.369597, "label": "positive"}, "relevance": 0.54598, "count": 4}, {"text": "commercial potential", "sentiment": {"score": 0.552925, "label": "positive"}, "relevance": 0.542809, "count": 1}, {"text": "supply chain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542163, "count": 1}, {"text": "revenues", "sentiment": {"score": 0.552925, "label": "positive"}, "relevance": 0.54121, "count": 1}, {"text": "result of governmental regulations", "sentiment": {"score": 0.735621, "label": "positive"}, "relevance": 0.540738, "count": 1}, {"text": "market forces", "sentiment": {"score": -0.664943, "label": "negative"}, "relevance": 0.538012, "count": 1}, {"text": "operations", "sentiment": {"score": 0.735621, "label": "positive"}, "relevance": 0.536966, "count": 1}, {"text": "significant delays", "sentiment": {"score": -0.664943, "label": "negative"}, "relevance": 0.535224, "count": 1}, {"text": "patient communities", "sentiment": {"score": 0.92262, "label": "positive"}, "relevance": 0.534804, "count": 1}, {"text": "market developments", "sentiment": {"score": 0.735621, "label": "positive"}, "relevance": 0.534777, "count": 1}, {"text": "Fluctuations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53371, "count": 1}, {"text": "production capacity", "sentiment": {"score": -0.664943, "label": "negative"}, "relevance": 0.533544, "count": 1}, {"text": "Regulatory approvals", "sentiment": {"score": -0.664943, "label": "negative"}, "relevance": 0.533107, "count": 1}, {"text": "historical facts", "sentiment": {"score": 0.552925, "label": "positive"}, "relevance": 0.531983, "count": 1}, {"text": "legal matters", "sentiment": {"score": 0.251019, "label": "positive"}, "relevance": 0.531918, "count": 1}, {"text": "edge", "sentiment": {"score": 0.916985, "label": "positive"}, "relevance": 0.531011, "count": 1}, {"text": "commercial success", "sentiment": {"score": 0.735621, "label": "positive"}, "relevance": 0.530145, "count": 1}, {"text": "manufacture of Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529947, "count": 1}, {"text": "Readers", "sentiment": {"score": -0.790305, "label": "negative"}, "relevance": 0.52889, "count": 1}, {"text": "such risks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528762, "count": 1}, {"text": "statements", "sentiment": {"score": -0.348513, "mixed": "1", "label": "negative"}, "relevance": 0.528598, "count": 5}, {"text": "adverse effect", "sentiment": {"score": 0.251019, "label": "positive"}, "relevance": 0.528462, "count": 1}, {"text": "conditions", "sentiment": {"score": -0.841481, "label": "negative"}, "relevance": 0.527996, "count": 1}, {"text": "new possibilities", "sentiment": {"score": 0.92262, "label": "positive"}, "relevance": 0.527314, "count": 1}, {"text": "competition", "sentiment": {"score": 0.251019, "label": "positive"}, "relevance": 0.526452, "count": 1}, {"text": "approvals", "sentiment": {"score": 0.552925, "label": "positive"}, "relevance": 0.525774, "count": 1}, {"text": "Articles", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525572, "count": 1}, {"text": "articles", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525572, "count": 2}, {"text": "manufacturing processes", "sentiment": {"score": 0.735621, "label": "positive"}, "relevance": 0.523684, "count": 1}, {"text": "substantial competition", "sentiment": {"score": 0.251019, "label": "positive"}, "relevance": 0.522315, "count": 1}, {"text": "future events", "sentiment": {"score": 0.407857, "label": "positive"}, "relevance": 0.522131, "count": 1}, {"text": "regulatory approval", "sentiment": {"score": 0.566006, "label": "positive"}, "relevance": 0.52209, "count": 1}, {"text": "future strategy", "sentiment": {"score": 0.552925, "label": "positive"}, "relevance": 0.521648, "count": 1}, {"text": "uncertainties", "sentiment": {"score": -0.654234, "label": "negative"}, "relevance": 0.521583, "count": 3}, {"text": "actions of certain customers", "sentiment": {"score": 0.566006, "label": "positive"}, "relevance": 0.521387, "count": 1}, {"text": "rare diseases", "sentiment": {"score": -0.841481, "label": "negative"}, "relevance": 0.521238, "count": 1}, {"text": "number of risks", "sentiment": {"score": -0.639226, "label": "negative"}, "relevance": 0.520959, "count": 1}, {"text": "product sales", "sentiment": {"score": -0.664943, "label": "negative"}, "relevance": 0.519999, "count": 1}]}, "extracted_metadata": {"sha1": "a2469e13366fb10bf0d10955e8bb887b423c6766", "filename": "1542521668717.zip-637790e75161e683ff2f5e113912fe8a.xml", "file_type": "json"}, "title": "Shire Announces New HELP Study(TM) Data for Lanadelumab in HAE at 2018 ACAAI Annual Scientific Meeting", "forum_title": "GlobeNewswire RSS Feed"}]}